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Resistance to therapeutic drugs is detrimental to treatment efficacy in chronic myeloid 
leukaemia (CML). CML is driven by the constitutive activity of the tyrosine kinase, Bcr-Abl, and 
has been treated effectively, in the majority of patients, using tyrosine kinase inhibitor (TKI) 
therapy. However, therapeutic TKI resistance often results in suboptimal treatment response. 
The molecular mechanisms of TKI resistance include: overexpression of Bcr-Abl; perturbed 
activity of cell membrane influx/efflux transporters; amino acid substitutions in the Bcr-Abl 
kinase domain precluding TKI binding (known as kinase domain mutations); and loss of 
dependence on Bcr-Abl kinase activity, via the gain of alternate driver function (known as Bcr-
Abl independence). There is a temporal order to the acquisition of resistance mechanisms, 
with shifts in clonal architecture over time and treatment altering therapy sensitivity. This 
thesis explores the emergence of resistance to the TKIs dasatinib and ponatinib with regard 
to CML, investigating the molecular mechanisms of TKI resistance, to identify novel 
therapeutic strategies for circumventing resistance and improving treatment outcomes. 
 
The initial experiments described development of a leukaemic cell model of TKI resistance. 
Using gradually increasing concentrations of the TKI dasatinib, TKI resistance was induced. A 
dasatinib resistant K562 cell line was established by culture in increasing concentrations of 
dasatinib over several months. Intermediate cell line samples were harvested over the course 
of TKI dose escalation and were interrogated for TKI sensitivity by TKI-induced cell death assay 
and phospho-CrkL IC50. Results indicated the loss of dasatinib and ponatinib sensitivity and 
efficacy with prolonged dasatinib exposure. The expression of BCR-ABL1 gene transcript and 
protein levels were analysed, demonstrating BCR-ABL1 overexpression as an early occurring 
resistance mechanism. The Bcr-Abl kinase domain mutation, T315I, was observed emerging 
late in dasatinib dose escalation, conferring complete dasatinib resistance. Dose escalation 
intermediates were further examined by transcriptome sequencing. By interrogating global 
gene expression perturbation and genetic structural rearrangements, putative resistance 
mechanisms were identified: a) overexpression of the drug transporter ABCG2, and b) 
expression of the rare BCR-ABL1 transcript isoform, e6a2.  
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The identification of ABCG2 expression in mRNAseq experiments was validated by assays to 
demonstrate ABCG2 function and involvement in TKI resistance, confirming ABCG2 
overexpression as a critical early resistance mechanism. Cell death and IC50 assays were 
performed in the presence of the ABCG2 inhibitor, Ko143, which sensitised ABCG2 
overexpressing cells to TKI-based inhibition. It was demonstrated, for the first time, that 
ABCG2 is able to confer decreased ponatinib sensitivity. Interestingly, the loss of ABCG2 
expression coincided with the gain of T315I, demonstrating the competitive advantage of 
T315I-positive cells. 
 
The role of the e6a2 BCR-ABL1 fusion transcript in TKI resistance was investigated. BCR-ABL1 
e6a2 gene expression was quantified in dasatinib resistant cells using RT-qPCR and DNA qPCR, 
demonstrating a transient peak in expression, followed by a distinct reduction. Intriguingly, 
this reduction in BCR-ABL1 expression coincided with the gain of ABCG2. To determine 
whether e6a2 was less sensitive to TKI than the typical e14a2 (p210) or e1a2 (p190) Bcr-Abl 
fusions, these were cloned into a Ba/F3 pro-B cell line. All isoforms were able to transform 
cells to IL-3 independence, demonstrating the leukaemia driving activity of Bcr-Abl. TKI-
induced cell death experiments determined that e6a2 expressing cells were less sensitive to 
dasatinib than Ba/F3 cells harbouring the e14a2 isoform. Overall, several resistance 
mechanisms were identified and explored, however more may remain undetected. Results 
suggest a model of selective pressure in drug resistance, whereby leukaemic cells expressing 
the most efficient drug resistance mechanisms are selected for, eventually becoming the 
predominant cell population. These data and conclusions have bearing on the treatment of 
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1.1 Chronic Myeloid Leukaemia 
The first recorded case of chronic myeloid leukaemia (CML) was described in 1845 by 
physician and pathologist, John Hughes Bennett (1). Though the cause was unknown, Bennett 
described symptoms of spleen, liver and lymph node enlargement, and material resembling 
thick pus exuded from cut veins (2). The patient, treated with purgatives, potassium iodide, 
and the application of leeches, died from the disease three months following diagnosis. Death 
was attributed to “the presence of purulent matter in the blood” (3). Today, the World Health 
Organization describes CML as “a myeloproliferative disorder affecting the hematopoietic 
stem cell compartment” (4). As its name suggests, chronic myeloid leukaemia is a cancer of 
the granulocytic lineage cells, including neutrophils, eosinophils, basophils, and their stem cell 
precursors. The overproduction of these cells in the bone marrow and peripheral blood 
results in disease (5, 6), and can be seen in Figure 1.1. Affecting around 1-2 per 100,000 adults, 
CML accounts for ~15% of newly diagnosed leukaemia in adults, and there are approximately 
340 new patients diagnosed in Australia each year (7, 8). Little is known of CML risk factors, 
although exposure to ionising radiation increases rates of CML (9). 
 
In patients with CML, anaemia, thrombocytosis and neutrophilia can result in patient fatigue, 
immunosuppression, and propensity to bleed and bruise easily. However, ~50% of CML cases 
are asymptomatic, and disease diagnosis occurs following routine physical examination or 
blood tests (7). As the disease progresses, splenomegaly can lead to abdominal discomfort as 
the excess leukocytes overflow to lymphatic tissue (8). The disease is often indolent. 
However, without effective treatment, CML is almost universally fatal. CML is typically 
identified in its less aggressive chronic phase, progressing over 5-8 years through an 
accelerated phase and ultimately to blast crisis (7). Blast crisis is characterised by a block in 
cellular differentiation, resulting in an increase in the proportion of immature blast cells in 
the bone marrow and peripheral blood. As genetic abnormalities accumulate in the leukaemic 
cell, symptoms worsen, and patients typically succumb to the disease (10). 
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1.2 The molecular biology of CML 
1.2.1 The Philadelphia chromosome and Bcr-Abl 
Much is now known about the genetic and molecular basis of the disease. There is a 
consistent genetic abnormality underlying the malignant transformation in patients with 
CML. Nowell and Hungerford identified the Philadelphia (Ph) chromosome in patient 
leukaemic cells; a genetic hallmark associated of CML, named for the place of its discovery 
(11). Using improved cytogenetic Giemsa banding techniques, Janet Rowley expanded on 
their research, elucidating the origins of the Ph chromosome: a translocation between 
chromosomes 9 and 22 (t(9;22)(q34;q11) (Figure 1.2) (12). The translocation is thought to 
arise due to a double strand break of the two DNA molecules, followed by aberrant DNA 
repair joining the chromosomes, and sequencing of the Ph breakpoint location has identified 
Alu repeat sequences which could facilitate DNA strand end joining (13). The Ph chromosome 
is consistently observed in the leukaemic cells of CML and ALL patients, providing a genetic 
identifier for CML cells as determined by FISH or other cytogenetic analysis (5). 
 
As a result of the translocation event, two genes are fused together: the breakpoint cluster 
region (BCR) gene on chromosome 22, with the Abelson murine leukaemia viral oncogene 
homolog 1 (ABL1) gene on chromosome 9, giving rise to the BCR-ABL1 fusion gene. BCR-ABL1 
is an oncogene; enforced expression in the murine haematopoietic cell line, Ba/F3, results in 
a rapid malignant transformation (14, 15), and the introduction of BCR-ABL1 into 
haematopoietic cells in murine models induces a myeloproliferative disease (16-18). Such a 
specific marker of disease allowed for development of molecular assays that measure BCR-
ABL1 gene transcript expression using RT-qPCR, for disease diagnosis and monitoring (19). 
The fusion of BCR to ABL1 removes the 5’ regulatory elements of the ABL1 gene, relegating 
transcriptional control to the constitutive BCR promoter region (20, 21). Thus, the fusion gene 
is transcribed and translated as a fusion protein, with both ABL1 and BCR sequences 
contributing important functional elements to its oncogenic activity. In the majority of 
patients, a fusion from intron 13 or 14 of BCR, to a region within the ~300 kb breakpoint 
region in intron 1 of ABL1, gives rise to a 210 kD protein product known as Bcr-Abl p210 (5). 
However, several transcript and protein isoforms have been identified in CML: genomic BCR 
breakpoints are found in introns 1 to 19, and genomic ABL1 breakpoints are available within 
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introns 1 and 2 (Figure 1.3) (22). These are transcribed as a number of different BCR-ABL1 
transcripts. The Ph chromosome and BCR-ABL1 transcript is also associated with other 
leukaemias; a breakpoint fusing BCR exon 1 to ABL1 exon 2 (e1a2 transcript, giving rise to the 
p190 protein) is associated with ~30% of adult acute lymphoblastic leukaemia (ALL) cases, 
known as Ph+ ALL (23, 24). 
 
The different BCR and ABL1 breakpoints can result in translation of a range of protein isoforms 
which harbour varying functional domains. However, regardless of the isoform present, it is 
the tyrosine kinase activity of the translated Bcr-Abl protein, derived from the Abl kinase 
domain region, which is the primary driver of the disease phenotype (25). The physiological 
properties of both Abl and Bcr are relevant for understanding the oncogenic properties of the 
fused Bcr-Abl variant isoforms, and will be discussed below. 
 
1.2.2 Structure and function of Abelson kinase 
The highly conserved and ubiquitously expressed wildtype ABL1 proto-oncogene encodes a 
non-receptor tyrosine kinase, Abl, which phosphorylates specific tyrosine residues on protein 
cofactors and is an important mediator of proliferative growth factor signalling. Abl kinase 
activation has been demonstrated following stimulation by platelet derived growth factor 
(PDGF), members of the epidermal growth factor (EGF) family, and transforming growth 
factor-ß (TGF-ß) cytokines (26). Canonical signal transduction downstream of Abl kinase 
occurs through induction of extracellular signal regulated kinase 5 (ERK5), Janus kinase/signal 
transduction and activation of transcription (Jak2/STAT5), and c-Jun N-terminal kinase (JNK) 
proteins, which permit activation of downstream effector, the proto-oncogenic transcription 
factor Myc (26). 
 
The Abl protein contains three nuclear localisation domains and one nuclear export signalling 
domain, which shuttle the protein between the nucleus and cytosol. Abl contains protein 
binding SH2 and SH3 domains, as well as a catalytic tyrosine kinase domain (27). Proline rich 
regions of Abl bind and interact with the SH3 domains of protein scaffolding cofactors, such 
as Crk (28). Physiologically, Abl plays an important role in leukocyte, cardiomyocyte and 
osteoblast development, acting as mediators of growth factor signal transduction. Disruption 
of the ABL1 gene transcript in C57BL/6J murine models results in a ~50% loss of neonate 
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viability, with gene knockout resulting in splenic and thymic atrophy, impaired lymphoid 
development, cardiac abnormality, and defective osteoblast proliferation (26, 29). 
 
In addition to CML, the dysregulated and aberrant activity of Abl kinase has been implicated 
in several malignancies, including breast, lung, ovarian, skin, bladder, colorectal, and renal 
cell carcinomas (30). Aberrant Abl kinase activation has also been identified in other blood 
cancers, including acute myeloid leukaemia, and both B- and T-cell ALL (30). In addition to 
acting as a proliferative driver, Abl activity is known to regulate epithelial cell polarity and 
tumour epithelial-mesenchymal transition, leading to increased cell invasion and metastasis 
(30). 
 
The kinase activity of native Abl is tightly regulated through multiple mechanisms. Principle 
kinase activity moderation occurs via an autoinhibitory mechanism, mediated by its N-
terminal cap (31). Crystallographic studies of Abl have demonstrated the presence of a 
hydrophobic pocket within the catalytic kinase domain, which, when bound to the 
myristoylated N-terminal region of Abl, results in an inhibitory conformational change 
whereby the SH2 and SH3 domains bind distal regions in the kinase domain, losing an 
activating phosphorylated tyrosine residue at position 245 (27, 32). Thus, native Abl is 
typically not kinase active. In CML, the 5’ fusion of BCR replaces the N-terminal cap region, 
resulting in Bcr-Abl autophosphorylation, constitutive kinase activity, and disease. 
 
1.2.3 Structure and function of the Bcr protein 
The BCR gene also encodes a protein kinase, alternatively spliced to yield a 130 or 160 kDa 
serine-threonine kinase (33, 34). Native Bcr harbours three major functional domains: a 
serine/threonine kinase domain, a Dbl-homologous (DH) guanidine exchange factor (GEF) 
domain, and a C-terminal Rac GTPase activating protein (GAP) domain (Figure 1.4) (34). A 
central pleckstrin homology (PH) domain is able to bind PIP2 and PIP3 molecules, localising 
Bcr to plasma membranes. Additionally, an N-terminal coiled-coil oligomerisation domain 
mediates protein homodimerisation and kinase-activating autophosphorylation. 
Immunoprecipitation of Bcr and its interacting proteins recovers a 650 kDa protein complex, 
demonstrating the protein’s extensive scaffolding and cofactor recruitment (33). It is likely 
that signalling through the Bcr protein complex is involved in haematopoiesis and cell 
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differentiation. Through protein-protein interactions of its DH domain, Bcr has been 
demonstrated to stimulate GTP binding to RhoA, Rac1, Rac2, and Cdc42 (35). The members 
of the Rho/Rac family of GTPases coordinate diverse cellular functions, and importantly, are 
central to the development and differentiation of haematopoietic cells (36). It is possible that 
Bcr activity is involved with mitogenesis and cell cycle control, through interactions with Myc 
(37), and the tumour suppressor Bap-1 (38). Recently, Bcr was demonstrated to play a role in 
activation of inflammatory NF-kB signalling, through interactions with casein kinase II (39). 
The diverse cell signalling roles and extensive protein scaffolding interactions of Bcr are 
important for the oncogenic signalling profile of the Bcr-Abl fusion protein. 
 
1.2.4 Oncogenic kinase signalling of p210 Bcr-Abl 
With both Abl and Bcr independently regulating several aspects of cellular signalling and 
haematopoiesis, the fusion of the two proteins produces a potent oncogenic entity, which is 
independently capable of driving the CML phenotype. The phosphorylation cascade of signal 
activation induced by the aberrant, constitutive kinase activity of Bcr-Abl impacts several 
proliferative pathways (Figure 1.5). Tyrosine kinase activity is performed by the Abl kinase 
domain, however the signalling pathway activation profile of Bcr-Abl is more complex than 
that of Abl alone. Bcr-Abl tetramerisation, mediated by the Bcr oligomerisation domain, is 
critical for full tyrosine kinase activation (40-42). Canonical Abl signalling occurs through 
activation of the mitogen activated protein kinase (MAPK) and Jak/STAT pathways. These 
pathways are also activated by Bcr-Abl, however, the kinase interactions are more diverse 
than that of native Abl. Within Bcr, the phosphorylated tyrosine 177 forms critical interactions 
with the Grb2 adaptor protein, which in turn recruits the Son of Sevenless homolog 1 (SOS1) 
protein via its SH3 domain. The Bcr-Abl/Grb2/SOS1 complex is able to stimulate conversion 
of GDP to GTP on the Ras protein, potently activating the proliferative MAPK signalling 
pathway (43, 44). Grb2 also mediates Bcr-Abl activation of the Src family kinases Hck and Lyn, 
which are important transducers of growth factor signalling (45). Src kinase activation can in 
turn mediate the downstream activation of STAT5 (46). 
 
In addition to canonical pathway activation through Jak proteins, the direct phosphorylation 
of STAT1 and STAT5 proteins by Bcr-Abl has been described, independent of Jak 
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phosphorylation (47). Often upregulated in several cancer types, the dimerization and nuclear 
translocation of phosphorylated STAT5 results in activation of Myc, D-type cyclins, Bcl-2, Bcl-
xL, and several other genes involved in cell cycle, chromatin remodelling, and protection from 
apoptosis (48, 49). Each signalling pathway activated contributes to CML oncogenesis; it has 
been demonstrated that functional cooperation of STAT, PI3K/Akt and MAPK pathway 
activation is required for the full oncogenic transformation potential of Bcr-Abl (50). 
 
Additionally, Bcr-Abl p210 is a potent activator of the PI3K/Akt signalling pathway (51), 
promoting cell survival through activation of mammalian target of rapamycin (mTOR) 
signalling and downstream gene expression changes (43, 44). Bcr-Abl kinase activity results in 
the repression of apoptotic signalling, through inhibitory phosphorylation of the pro-
apoptotic Bad protein (52). Bcr-Abl is also known to be a potent activator of Myc signalling, 
through multiple overlapping pathways. Expression of Myc is regulated by PI3K/Akt signalling, 
and phosphorylation of Myc by Jak2 is associated with the loss of proteasomal Myc 
degradation, resulting in increased Myc activation (53-55). Interestingly, it has been 
demonstrated that BCR and BCR-ABL1 gene expression is upregulated by Myc activation, 
leading to a positive feedback loop of proliferative and oncogenic signalling. Bcr-Abl activity 
has been also demonstrated to increase genomic instability (10, 56). This occurs both directly, 
with Bcr-Abl increasing reactive oxygen species and DNA mutation(s) (57), but also indirectly 
with downstream signalling pathway activation protecting leukaemic cells from apoptosis, 
allowing DNA damage to accrue (58, 59). CML progression to blast crisis coincides with the 
gain of multiple genetic abnormalities, and the increased mutation rate caused by Bcr-Abl 
signalling may be central to disease propagation. 
 
1.3 The contribution of alternate Bcr structure to Bcr-Abl 
oncogenesis 
1.3.1 Bcr-Abl structure diversity and leukaemic phenotype 
Approximately 95% of the BCR-ABL1 breakpoints in CML patients occur between exons 12 
and 16 of BCR, and within intron 1 of ABL1, in a region known as the ‘major’ breakpoint cluster 
region, M-bcr (Figure 1.3). Approximately half of the CML BCR-ABL1 transcript breakpoints 
occur immediately 3’ of exon 14, resulting in an 8.5 kb transcript known as e14a2 (formerly 
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b3a2) (60, 61). Normal BCR-ABL1 fusion transcript nomenclature joins the BCR 3’ breakpoint 
location (e.g. BCR exons 1-14: e14) with the ABL1 5’ breakpoint location (e.g. ABL1 exons 2-
14: a2). Another ~30% of BCR-ABL1 breakpoints in CML result in fusion of BCR exon 13 with 
ABL1 exon 2, generating the e13a2 (formerly b2a2) transcript. Both the e14a2 and e13a2 
transcripts are translated as the typical p210 Bcr-Abl protein. 
 
However, several other BCR breakpoints have been identified in CML patients, ranging from 
BCR exon 1 to exon 19 (61). The e1a2 fusion transcript is translated as the smaller p190 Bcr-
Abl protein isoform (62). As previously stated, this isoform is most commonly associated with 
Ph+ ALL; an aggressive, often fatal disease (62). These patients typically have less favourable 
treatment response and a fast disease progression (63, 64). There is conjecture as to whether 
the p190 isoform is a result of, or causative of, the more aggressive ALL phenotype (61). 
Conversely, the e19a2 transcript is translated as a 230 kDa protein. This p230 isoform is 
associated with a more benign leukaemic phenotype, characterised by a higher mature 
granulocyte and platelet count; it has been hypothesised that this is due to the leukaemic 
cells retaining the capacity for normal neutrophilic granulocyte differentiation (61). 
Conversely, Pane et al hypothesised that disease indolence was due to p230 having a lower 
intrinsic kinase activity (22), with other studies describing lower levels of transcript expression 
associated with the e19a2 BCR-ABL1 fusion (65). 
 
Following identification of the e1a2 chromosomal fusion in cases of Ph+ ALL, several studies 
investigated the differences in disease phenotype associated with different Bcr-Abl isoforms. 
Melo reviewed the contribution of the Bcr sequence, observing that while p210-induced CML 
is characterised by expansion of granulocytic and megakaryocytic lineages, p190 associated 
disease presents with monocytosis and variable basophilia (66). Cell line and animal model 
studies concluded that the p190 Bcr-Abl isoform confers a more aggressive malignancy than 
the one induced by p210. A bone marrow reconstitution leukaemogenesis model 
demonstrated both e14a2 and e1a2 isoforms induce similar haematological disease, 
however, transformation with e1a2 resulted in a shorter disease latency period than e14a2 
(67). Other studies demonstrated that the e1a2 isoform induced a B-lymphocyte malignancy, 
in contrast with e14a2, which conferred a mixed B-, T- and myeloid cell disease with a long 
latency period (68). When transduced into myeloid 32D and lymphoid Ba/F3 cells, p210, p190 
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and p230 each transform cells to IL-3 independent growth, and induce a CML-like disease in 
recipient mice; transduction of p190 resulted in a higher leukaemic cell proliferative rate than 
p210 or p230, and had increased potency for induction of B-lymphoid leukaemia (17). 
Conversely, the p230 isoform conferred an indolent disease phenotype. Taken together, 
these studies demonstrate that the Bcr-Abl isoform expressed by the leukaemic cell is 
causative of the associated disease. 
 
1.3.2 Rare Bcr-Abl isoforms: e6a2 and e8a2 
In addition to p210, p190 and p230, alternate isoforms of Bcr-Abl have been identified in rare 
cases of CML. The BCR-ABL1 e6a2 fusion transcript has been documented in over 20 clinical 
case reports, of CML (69-79), AML (80, 81), chronic myelomonocytic leukaemia (82), B- and 
T-ALL (83-85), and basophilic myeloid leukaemia (86-88). While the patient outcomes have 
been variable, the e6a2 association with several leukaemic phenotypes suggests that 
presence of this fusion does not exclusively confer a particular cell fate or disease outcome 
However, Colla et al suggested that the presence of e6a2 results in a more aggressive disease 
and poorer patient outcome (71, 74, 89). The functional mechanisms behind this disease 
phenotype remain to be elucidated. 
 
Similar to the Bcr-Abl e6a2 fusion, the e8a2 fusion transcript has been identified in rare cases 
of CML (90-95). While patients with the e8a2 fusion have responded to therapy, investigators 
have described an aggressive disease phenotype and poorer prognosis associated with e8a2 
(91, 92, 95). Both the e6a2 and e8a2 fusions result in truncation of the PH domain in the 
central Bcr region, while keeping intact the N-terminal serine/threonine kinase domain and 
RhoGEF DH domain. In contrast, the e1a2 fusion completely lacks the DH and PH domains 
(Figure 1.3). The importance of the Bcr region on Abl kinase activity, leukaemic phenotype, 
and potential therapy resistance, is yet to be fully explored, and is expanded on in Chapter 4. 
 
1.4 Therapeutic options for treatment of CML 
1.4.1 Methods for monitoring of disease and treatment response 
Regardless of the therapy used, the measurement of CML disease burden is essential for both 
diagnosis and evaluation of treatment response. As previously mentioned, initial diagnosis is 
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primarily made based on disease symptoms and diagnostic assays. Haematological analysis 
provides a description of the white blood cell counts, with a reduction in their levels indicating 
remission. However, with increasing understanding of the underlying molecular biology of 
CML, molecular methods for measuring treatment response are now available to most first 
world clinicians. Using cytogenetic techniques such as G banding or FISH, Ph positive cells are 
detected in the peripheral blood and bone marrow (96). Analysis of Ph positive cells allows 
determination of cytogenetic response and remission. Using more sensitive RT-qPCR based 
methods, quantitation of BCR-ABL1 transcripts is the current Australian standard of care for 
monitoring of CML (97, 98). A ratio of BCR-ABL1 transcripts in patient samples is calculated, 
quantitated and compared with a standard curve of reference genes, typically ABL1, BCR, or 
GUSB (99). Molecular assessment typically occurs at diagnosis and in the months following 
induction of therapy. The international exchange of patient samples across CML laboratories 
allowed development of an international reporting scale (IS) and designation of molecular 
response (MR) targets (98, 100). A deep molecular response is associated with a 4-log 
reduction in BCR-ABL1IS transcripts from diagnosis levels to below 0.01% (MR4) (100). The 
timely achievement of a deep molecular response is associated with high rates of progression-
free survival, and following treatment success, some of these patients are able to discontinue 
therapy without disease recurrence (101). In these patients, the sensitive detection of 
residual disease may be important for predicting leukaemic cell expansion following 
treatment discontinuation.  
 
1.4.2 Non-targeted CML therapies 
Prior to the development of current kinase inhibition therapies, the most successful 
treatments for CML were not particularly targeted to the leukaemic cell. Allogeneic stem cell 
therapy utilises high dose chemotherapy and/or radiotherapy to deplete the leukaemic cell 
population, followed by bone marrow or peripheral blood stem cell transplantation from a 
HLA matched donor (102). While being potentially curative, stem cell transplant is not always 
suitable. Chemotherapy side effects are significant, and can be associated with secondary 
malignancies. The procedure often results in patient mortality as the engrafted cells attack 
the new host, known as graft-versus-host disease. Furthermore, the requirement for a HLA 
matched donor, often a sibling or other relative, is often prohibitive (103). Nevertheless, 
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transplant can be curative, and remains a treatment option for patients with advanced 
disease or following the failure of other therapies. 
 
Interferon-α is a naturally occurring human protein secreted by many cell types, including 
lymphocytes, macrophages and endothelial cells, and is used as a therapy for CML. The 
current understanding of how interferon-α exerts its antileukaemic effect is incomplete (104). 
Interferon-α treatment in vitro is known to inhibit cell proliferation, promote cell 
differentiation and apoptosis, and induce an immunomodulatory response, possibly 
activating the patient’s immune system. Interferon-α treatment was once considered 
standard of care in CML (105). The common flu-like side effects are relatively mild, however 
neurological effects can be debilitating, and poor response rates have largely relegated it to 
being a historical treatment. Nevertheless, interferon-α is still indicated when more modern 
therapies cannot be used due to intolerance or failure (104). 
 
1.4.3 Imatinib and the introduction of tyrosine kinase inhibitor therapy 
In 1996, Druker et al described the in vitro efficacy of the first clinically available tyrosine 
kinase inhibitor (TKI), imatinib (Gleevec™, formally STI571, Novartis International AG). 
Imatinib effectively impeded the proliferation and survival of the K562 Bcr-Abl positive cell 
line at low nanomolar concentrations (106). A derivative of 2-phenylaminopyrimidine, 
imatinib was synthesised along with a series of other compounds, designed to compete for 
the ATP binding site in the kinase domain of Abl (Figure 1.6) (25, 107, 108). By downregulating 
Bcr-Abl kinase signalling, imatinib not only prevents the proliferation of leukaemic cells, but 
also induces apoptosis through downregulation of BCL family regulators of apoptosis (109). 
In addition to Bcr-Abl, imatinib also potently inhibits the kinase activity of native Abl, PDGFR, 
and c-Kit tyrosine kinases (110, 111). The IRIS clinical trial, comparing imatinib against 
interferon-α + cytarabine, demonstrated imatinib was significantly more effective than the 
contemporaneous standard of care (112). In that study, response to treatment was defined 
as having normal peripheral blood counts with <5% bone marrow blast cells, between 1-3 
months following treatment induction, which was termed haematological remission (113); 
remarkably, oral dosing over 300 mg daily resulted in haematological remission in 53/54 CML 
patients (114). After demonstrating clinical efficacy for the treatment of CML, imatinib was 
further used in trials of Ph+ ALL (115), and other malignancies driven by PDGFR and c-Kit 
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activation (110). Compared with traditional chemotherapy, imatinib has proven to be 
remarkably safe with relatively few adverse effects. Follow up studies demonstrated the long 
lasting efficacy of imatinib, with 83% event free survival after 5 years (116). Incredibly, overall 
survival after 14 years was 87%, approaching survival rates of healthy, age-matched 
populations (117). Today, durable remission on imatinib therapy is common, and some 
patients are able to cease treatment (101). Imatinib remains one of the great success stories 
of molecular biology and targeted drug design. 
 
While most patients treated with imatinib are able to achieve deep and durable remissions, 
imatinib treatment is not without its shortcomings. Analysis of the IRIS patient samples found 
that although most patients on imatinib achieved good haematological response, 32% of 
patients failed to achieve the more sensitive complete cytogenetic response (112). Imatinib 
failure rates are significantly higher in patients with advanced disease (113). Additionally, 
imatinib therapy is not always tolerated by patients, and while side effects are usually 
minimal, patients are typically required to be on therapy indefinitely, significantly affecting 
lifestyle (101). Most importantly, imatinib resistance in leukaemic cells can result in secondary 
resistance and therapy failure, even following successful therapy and remission (113). Indeed, 
even after successful imatinib induction therapy, BCR-ABL1 gene expression remains 
detectable in 95% of patients even following 12 months of treatment. Elucidating why some 
leukaemic cells are resilient to imatinib and other TKIs is of clear clinical importance for 
improving patient outcomes. 
 
1.4.4 2nd generation TKIs: nilotinib, dasatinib and bosutinib 
Following the success of imatinib, several other TKIs were developed for clinical use (Figure 
1.6). Newer TKIs were designed for several reasons, including increasing drug potency, 
specificity and tolerance. However, the principle function of second and third generation TKIs 
is to overcome leukaemic cell resistance to imatinib, which would otherwise result in therapy 
failure. Crystallographic studies of the Abl kinase domain demonstrated that imatinib binding 
stabilises a kinase inactive state of Abl, whereby the activation loop motif mimicked peptide 
substrate binding (118). However, mutations in the Abl kinase domain can result in loss of 
imatinib binding and drug efficacy (further discussed in Section 1.5). Using structural 
knowledge of Abl-imatinib binding, a number of 2nd generation TKIs were developed, 
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including nilotinib (formerly AMN107, Tasigna™, Novartis International AG), dasatinib 
(formerly BMS-354825, Sprycel™, Bristol-Myers Squibb), and bosutinib (formerly SKI-606, 
Bosulif™, Pfizer Inc.) (119, 120). 
 
Nilotinib was designed on the structural backbone of imatinib, and binds and stabilises Abl in 
the inactive conformation. However, nilotinib is significantly more potent than imatinib at 
inducing antiproliferative activity in Bcr-Abl positive cell lines (121, 122). Like imatinib, 
nilotinib demonstrates inhibition of Abl, c-Kit, and PDGFR kinases (123). Trialled in CML and 
Ph+ ALL patients, nilotinib was active in many otherwise imatinib refractory cases (124). When 
compared with imatinib in newly diagnosed CML patients, nilotinib is significantly more likely 
to induce molecular response, and responses are deeper and faster (125). The drug is 
generally well tolerated, however can induce neutropenia, thrombocytopenia, and vascular 
toxicity (124). Nevertheless, nilotinib remains an important front line clinical therapeutic 
option for CML. 
 
Unlike imatinib and nilotinib, dasatinib was designed to bind and inhibit the active Abl 
conformation, as well as members of the Src family of kinases (126). In vitro data 
demonstrated that dasatinib is over 300 times more potent than imatinib in antileukaemic 
activity (123, 127). However, the structure of dasatinib also results in reduced specificity of 
kinase binding and increased off target effects (128). Therefore, more severe adverse side 
effects are noted with dasatinib treatment, and can include fluid retention, haemorrhage, 
pleural effusion, dyspnea and diarrhoea, as well as neutropenia and thrombocytopenia (123, 
129, 130). Nevertheless, a phase 1 clinical trial in imatinib resistant CML and Ph+ ALL patients 
found dasatinib was able to overcome almost all imatinib resistance mutations (131), and the 
drug is now available both as a frontline and salvage therapy following imatinib or nilotinib 
failure (132). The thesis presented here interrogates the cellular mechanisms granting 
resistance to dasatinib in a cell line model, in order to identify ways to circumvent drug 
resistance. 
 
1.4.5 The 3rd generation TKI: ponatinib 
A single nucleotide mutation in BCR-ABL1 is able to confer resistance to imatinib, nilotinib, 
bosutinib and dasatinib. The T315I ‘gatekeeper’ mutation was identified in TKI-resistant CML 
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and Ph+ ALL patients, and several efforts have been made to synthesise inhibitors of T315I-
mutated Bcr-Abl. The importance of the T315I mutation will be further discussed in Section 
1.5.3. One clinically available compound targeting T315I-mutated Bcr-Abl is ponatinib 
(formerly AP24534, Iclusig™, Ariad Pharmaceuticals), currently used as salvage therapy for 
patients harbouring a T315I Bcr-Abl mutation (133). Ponatinib was designed to bind the 
inactive conformation of Bcr-Abl, and uses a carbon triple bond to straighten out its structure, 
accommodating the steric bulk of isoleucine 315 while excluding the hydrogen bond requisite 
for the binding of other 1st and 2nd generation TKIs (Figure 1.6) (134, 135). It has been shown 
to be effective in clinical trials, inducing haematological and molecular responses where 
previous TKI therapy had failed (136). Unfortunately, ponatinib also has increased off target 
inhibition of several other kinases, including PDGFR, VEGFR, and Src family kinases (137). This 
purportedly induces several possible adverse effects, such as pancreatitis, arterial thrombotic 
events, hepatotoxicity, and drug induced rashes (135). Concerns about cardiac toxicity 
resulted in ponatinib being temporarily withdrawn from the market, and it is now available 
with a black box warning. Furthermore, certain single nucleotide or compound mutations 
dramatically alter the protein structure, and are able to confer ponatinib resistance (138). 
Resistance to ponatinib severely limits patient treatment options, and therefore the ponatinib 
resistance and cross resistance mechanisms investigated in this study have direct clinical 
relevance. 
 
1.4.6 Other future therapies 
While most Bcr-Abl TKIs were designed to bind the ATP binding site in the kinase domain of 
Abl, others have been designed to inhibit Abl by stabilising the inactive kinase conformation. 
These small molecules bind to the allosteric binding site, where the myristate moiety usually 
sits to autoinhibit native c-Abl (139, 140). Recently, the allosteric inhibitor asciminib (ABL001, 
Novartis International AG) entered phase 1 clinical trials, where it demonstrated efficacy 
against several Bcr-Abl kinase domain mutants (141). However, some leukaemic cells are able 
to evade Bcr-Abl inhibition via a different spectrum of kinase domain mutations (139), or drug 
efflux mediated by membrane transporters ABCB1 and ABCG2 (142). Asciminib resistance 
may be circumvented by co-treatment with conventional ATP binding site TKIs, marking novel 
strategies simultaneously overcoming toxicity and resistance (143). 
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1.5 TKI resistance mechanisms and next generation TKI design 
The selective pressure of TKI therapy in CML patients has resulted in the emergence of TKI 
resistant leukaemic cells, which expand in the leukaemic cell population and result in disease 
relapse and patient mortality. TKI resistance mechanisms can be broadly defined by four 
distinct groups: overexpression of Bcr-Abl and its cellular signalling, lowering of leukaemic cell 
intracellular TKI concentrations, loss of TKI binding and inhibition of Bcr-Abl, and loss of 
leukaemic cell dependence on Bcr-Abl kinase activity for proliferation. Additionally, there are 
patient specific reasons for the loss of TKI effectiveness, extrinsic to changes in the leukaemic 
cell. 
 
1.5.1 Increases in Bcr-Abl expression and kinase activation 
CML cells are reliant on Bcr-Abl kinase activity for maintaining cell proliferation, and CML cells 
often overcome TKI treatment by compensatory upregulation of Bcr-Abl expression and 
kinase activation. In order for imatinib to effectively restrain growth of the CML cell 
population, Bcr-Abl kinase activity must be inhibited in each tumour cell. Several studies have 
generated in vitro models with CML cell lines resistant to imatinib and other TKIs, and many 
of these cell lines display similar characteristics to patient study samples. In these studies, 
authors demonstrated that TKI resistant leukaemic cells expressed significantly more Bcr-Abl 
protein and gene transcript levels than TKI sensitive cells; this has the net effect of increasing 
the oncogenic signalling pathway activation, while titrating the amount of available 
intracellular TKI (144-146). This effect is clinically relevant, and has been identified in imatinib 
resistant patients (147). Bcr-Abl overexpression is associated with disease progression, and is 
a common resistance mechanism to all therapeutics targeting Bcr-Abl kinase activity (148). 
Overexpression of the Bcr-Abl protein often results from increases in BCR-ABL1 gene 
transcript expression. The increases in transcript expression can be driven by duplication of 
the Ph chromosome, or genomic amplification of the BCR-ABL1 locus by tandem duplication 
or expansion on extrachromosomal elements such as double minutes (149-151). However, 
like other proteins, increased Bcr-Abl levels have been detected in the absence of gene 
overexpression or DNA amplification, indicating multiple dynamic levels of Bcr-Abl protein 
expression control (145). 
 
 1-31 
1.5.2 Bcr-Abl kinase mutations 
The most commonly detected mechanism of resistance to TKIs is the emergence of mutations 
in the kinase domain of Bcr-Abl, and are identified in most patients who fail to achieve 
responses to TKI treatment. Detected via sequencing of BCR-ABL1 mRNA transcripts, over 100 
nucleotide mutations have been identified (Figure 1.7). These result in the substitution of 
amino acid residues, affecting the drug-protein interaction and resulting in a loss of TKI 
efficacy (146, 152). Protein crystallography studies have identified the conformational 
changes caused by Abl kinase domain mutations, and how these result in the loss of TKI 
binding (118). Several of these mutations cluster around the P-loop of Abl kinase (Figure 1.6), 
and increase the level of kinase phosphorylation, increasing activation (153). Interestingly, 
mutations occur not only at the site of TKI binding, but also at more distant regions, forcing 
the protein into a conformational state which prevents drug access (152). Kinase domain 
mutations vary widely in both the level of resistance conferred, as well as the frequency 
detected in patients (113, 152, 154). However, detection of a kinase domain mutation during 
imatinib treatment is almost always accompanied by clinical resistance (155). 
 
1.5.3 The T315I ‘gatekeeper’ kinase domain mutation, and development of ponatinib 
Despite several treatment options available to clinicians, there remains an Achilles heel in TKI 
therapy. The first report of clinical imatinib resistance in CML patients by Gorre et al identified 
a single amino acid exchange occurring in over half of the TKI refractory patients (146). Known 
as the ‘gatekeeper’ mutation, a cytosine to thymine mutation at ABL1 position 944 leads to a 
threonine-to-isoleucine substitution at amino acid position 315, in the kinase domain of the 
Abl protein. Interaction of imatinib with the ATP binding site of Bcr-Abl is mediated through 
hydrogen bonding to the threonine hydroxyl group; substitution with the non-polar isoleucine 
residue abrogates this interaction, while the physical bulk of isoleucine protects the binding 
site by steric hindrance (156, 157). T315I mutant CML and Ph+ ALL cells are thus completely 
resistant to all 1st and 2nd generation TKIs (158). Crystallographic studies of the Abl kinase 
domain have demonstrated that mutation of the gatekeeper residue results in stabilisation 
of the active kinase conformation, restoring constitutive Bcr-Abl activity leading to Ba/F3 cell 
transformation (159). Azam et al further demonstrated that the T315I mutation results in 
stronger ATP binding, and confers further increases in Bcr-Abl kinase activation and 
transformation potential compared with unmutated Bcr-Abl (159). Griswold et al 
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demonstrated that T315I imposed a significant growth advantage to Bcr-Abl harbouring cells 
(160), postulating that this was due to alterations in adaptor protein binding and kinase 
substrate phosphorylation (153). Furthermore, a study by Härtel et al demonstrated that 
unlike native Bcr-Abl, Bcr-Abl harbouring T315I exhibits compensatory MAPK pathway 
activation in response to TKI treatment (161). Indeed, significant differences in gene 
expression have been identified in cells harbouring the T315I mutation (162). Thus, even in 
the absence of TKI therapy, T315I may confer kinase activating transformations, functional 
alterations, and an altered disease phenotype. That said, T315I rarely emerges clinically in the 
absence of TKI based selection, and unpublished observations in our laboratory indicate that 
in the absence of TKI, T315I harbouring cells do not outcompete wildtype Bcr-Abl cells, 
suggesting that the altered kinase activity associated with T315I is only advantageous under 
the selective pressure of TKI exposure. 
 
1.5.4 Lowering of intracellular TKI concentrations: ABCB1 and ABCG2 
In addition to absolute Bcr-Abl levels, the amount of intracellular TKI available to bind Bcr-Abl 
also affects the proliferation of CML cells. Being highly water soluble, imatinib does not readily 
diffuse through the lipid bilayer of the cell membrane, requiring active import to mediate its 
effects. Lowered leukaemic cell activity of the organic cation transporter 1 (OCT1), a cell 
membrane small molecule importer, has been associated with primary resistance to imatinib, 
and the activity of OCT1 is predictive of imatinib response in CML patients (163, 164). In 
addition to lowered TKI import, increased drug export from the leukaemic cell is known to 
confer therapeutic resistance. The most well studied of the drug efflux transporters are the 
members of the ATPase binding cassette (ABC) transporter superfamily. 
 
The ABC transporters are responsible for translocating a wide variety of substrates across the 
cellular lipid membrane. With both cellular export and import function, they are expressed 
by eukaryotes, prokaryotes and archaea (165, 166). Within the human genome, there are at 
least 49 distinct ABC transporter genes divided into 7 subfamilies, expressed predominantly 
in the liver, kidneys, intestines and at the blood-brain barrier (165, 167). ABC transporters 
have several critical functions in cellular homeostasis and physiology, transporting a wide 
array of substrates, including metal ions, peptides, sugars and hydrophobic compounds 
across cell lipid bilayers (167). While the function and sequences of human ABC transporters 
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are highly diverse, there are structural and mechanistic attributes common to members of 
the transporter superfamily. All members rely on ATP binding and hydrolysis for transporter 
function; two conserved nucleotide binding domains contain a catalytic core responsible for 
the hydrolysis of ATP. Two variable transmembrane domains form a translocation pathway 
through the plasma membrane, and a short α helix couples the conformational change from 
nucleotide binding to allow alternating transmembrane access (168). 
 
The prototypical ABC transporter, ABCB1 (P-glycoprotein, MDR-1), was the first 
demonstration of an ABC transporter contributing to altered cell membrane drug 
permeability (169) and chemotherapy resistance (170). Overexpression of ABCB1 is 
associated with resistance to several cytotoxic chemotherapeutics (171), and is often induced 
following exposure to single agent therapy. Its broad substrate transport specificity can result 
in cross-resistance to several chemotherapeutics, known as a multidrug resistant phenotype 
(172). Commonly associated with therapeutic resistance in colon, kidney, liver and adrenal 
carcinomas, ABCB1 also contributes to poor therapy response in several leukaemic subtypes 
(172-175). In the CML setting, cell line models have identified ABCB1 as a transporter of 
imatinib (176, 177), and ABCB1 overexpression as a significant contributor to TKI resistance 
(144, 175, 178, 179). In CML patients, high ABCB1 expression is significantly associated with 
imatinib failure (180), and poor response upon switching to nilotinib (181). ABCB1 
overexpression has been also observed in cell line models as a result of exposure to nilotinib 
(182) and dasatinib (183, 184). However, TKIs have also been demonstrated to act as 
inhibitors of ABCB1 activity. Several studies have reported the inhibition of ABCB1 substrate 
transport in ABCB1 expressing lines treated with imatinib (178, 185, 186), nilotinib (186, 187), 
and dasatinib (186). The contrasting nature of TKIs as both substrate and inhibitor is often TKI 
concentration dependent, highlighting the complex nature of drug-transporter interactions 
(173). 
 
The ABCG2 transporter (formerly known as breast cancer resistance protein, Bcrp1) was first 
identified in 1998 (188). ABCG2 has been implicated in chemotherapy resistance in several 
cancer types and has a promiscuous substrate transport profile, ferrying both hydrophobic 
and anionic compounds across the phospholipid bilayer. Several cancer therapeutics are 
transported by ABCG2, and ABCG2 overexpression has been associated with poor outcome 
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and chemotherapy failure in the myeloid malignancy, AML (189), as well as several solid 
tumours (190). The functional ABCG2 complex consists of one nucleotide binding domain and 
six transmembrane helices, dimerising to form a ~144 kDa functional transporter (191). 
McDevitt et al demonstrated the existence of a higher order tetrameric complex of ABCG2 
homodimers, forming an aqueous central region to facilitate transport (192). The binding of 
ATP to ABCG2 switches the ABCG2 complex from inward facing to outward facing, 
transporting its small molecule cargo; the subsequent loss of bound ATP reverts the 
conformational change, exposing the substrate binding site to the inner leaflet of the plasma 
membrane, to again recruit a transported molecule (193). Recently, Jackson et al described 
the structure of ABCG2 bound to the ABCG2 inhibitor, Ko143, demonstrating that the 
compound binds to the central cavity of the inward-facing molecule, blocking substrate 
access and preventing ATP hydrolysis (194). This compound was used in the current study to 
inhibit ABCG2 function, following the identification of ABCG2 overexpression in the described 
dasatinib resistance model (Chapter 5). 
 
The interaction of ABCG2 with imatinib, dasatinib, and nilotinib has been previously 
demonstrated, with the TKIs functioning both as transported substrate and transporter 
inhibitor. Studies have identified ABCG2 overexpression in TKI-resistant cell populations (173, 
195-197). Imatinib efflux is mediated by ABCG2, while at higher concentrations imatinib 
inhibits ABCG2 transport activity (198). The overexpression of ABCG2 is associated with poor 
imatinib response, and poor response to salvage therapy with 2nd generation TKIs (199). 
Studies have also demonstrated the selective advantage conferred by ABCG2 overexpression 
during TKI treatment. Gromicho et al described the increase of ABCG2 expression in K562 
cells following prolonged culture in imatinib (200). Interestingly, mRNA expression did not 
increase linearly with TKI exposure, instead peaking early in dose escalation before 
significantly falling with increasing TKI concentration, likely due to the selection for clones 
harbouring alternate TKI resistance mechanisms. In our own laboratory, we have 
demonstrated that overexpression of ABCG2 in K562 cells does not significantly decrease the 
intracellular concentrations of imatinib or nilotinib, nor does inhibition of ABCG2 decrease 
the cytotoxic sensitivity to these TKIs (201). The body of evidence for imatinib-ABCG2 
interactions demonstrates a marked complexity, with function of ABCG2 differing depending 
on cell type, imatinib concentration, and the analytical methods used. 
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Studies of dasatinib-ABCG2 interactions have been less comprehensive and conclusive. Our 
laboratory first described significantly lower intracellular dasatinib in cells overexpressing 
ABCG2 compared with parental cell line controls, which was reversible upon treatment with 
the ABCG2 inhibitor, Ko143 (184). Similarly, dasatinib uptake was significantly increased in 
ABCG2-overexpressing K562 cells, when treated with Ko143. Consistent with these data, Bcr-
Abl kinase sensitivity to dasatinib was decreased in K562-ABCG2 cells, and was significantly 
reduced with Ko143 treatment. ABCG2 has subsequently been demonstrated to confer 
resistance to both nilotinib and dasatinib (183). However, higher concentrations of dasatinib 
have an inhibitory effect on ABCG2 function, though only above clinically relevant levels (183, 
186). The emergence of ABCG2 overexpression has also been described following dasatinib 
dose escalation in a K562 cell model similar to the study described here (200). A study of CML 
patients resistant to imatinib and subsequently treated with dasatinib salvage therapy, 
identified ABCG2 expression contributing to failure to achieve molecular response on 
dasatiib, and to shorter progression-free survival (202). 
 
1.5.5 Bcr-Abl independent leukaemic cell growth 
The gain of an alternate driver mutation can override the requirement for Bcr-Abl activity, 
granting the leukaemic cell Bcr-Abl independent growth. Some studies of imatinib resistant 
cells have demonstrated the loss of dependence on Bcr-Abl, with cellular proliferation instead 
driven by other proliferative drivers, such as Lyn kinase (203). Lyn has previously been 
implicated in TKI resistance (182, 204-206), providing a potential mechanism for differential 
resistance through kinase activation. Mahon et al also demonstrated that a relative increase 
in the expression of Lyn was associated with failure of imatinib and nilotinib (207). Authors 
also suggested that the TKI resistant CML patients with overexpression of Src family kinases 
be treated with dasatinib, due to its dual function as Bcr-Abl and Src kinase inhibitor. 
Furthermore, Bcr-Abl independent growth has been associated with increases in MAPK 
pathway activation, which can be therapeutically targeted (208, 209). The compensatory 
upregulation of proliferative signalling pathways regardless of Bcr-Abl activity inhibition 
demonstrates the need to confirm the leukaemic cell’s reliance on continued Bcr-Abl activity. 
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1.5.6 Leukaemic cell extrinsic TKI resistance mechanisms 
As with most other cancer therapies, the efficacy of TKI treatment is influenced by several 
factors independent of the leukaemic cell. Pharmacokinetic factors are known to significantly 
influence treatment response. The oral bioavailability of imatinib is ~98%, and a long half-life 
of 18 h allows effective once daily dosing regimens in the majority of patients (210, 211). The 
main metabolite of imatinib, N-desmethyl imatinib (CGP74588), is also known to have anti-
leukaemic potency in vitro (212). Nevertheless, genetic polymorphisms in gastrointestinal and 
liver drug transporters are known to affect the uptake and clearance of most TKIs (211). As a 
substrate of the cytochrome P450 3A4 (CYP3A4) enzyme, inducers of CYP3A4 result in 
lowered imatinib exposure, and as always care must be taken by clinicians to maintain 
adequate drug dosing (210, 211). Additionally, the leukaemic stem cell population can 
repopulate the malignancy following TKI treatment (213, 214). Residing in the bone marrow, 
the cytokine laden microenvironment can support the ongoing maintenance of leukaemic 
cells, further complicating the absolute elimination of the malignancy (215). Hiwase et al 
described the protective effect of the cytokines granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) under TKI exposure on 
leukaemic cells, and TKI sensitisation following inhibition of the cytokine’s main effector, Jak 
(216). Paracrine signalling effects have also been reported; a study by Liu et al demonstrated 
that the increased production of IL-3 by dasatinib resistant DA1-3b murine leukaemic cells 
conferred a TKI protective effect on co-cultured leukaemic cells, which were otherwise 
sensitive in monoculture (217). 
 
1.5.7 Selective pressures in the context of TKI resistance 
While the use of TKI therapy in CML has been clinically effective, the therapy provides a 
selective pressure, which shapes the evolution of the cell population (174). If the CML cell 
population is not completely eliminated, TKI exposure selects out the most adaptive, TKI-
resistant cells (218). The genetic instability, fast proliferation rate, diverse initial genetic 
heterogeneity, and vast initial pool of cancer cells, can facilitate the rapid clonal evolution of 
leukaemic cells to a resistant phenotype (219, 220). The common targeting of Bcr-Abl to elicit 
antileukaemic effects, in addition to the structural homogeneity of the TKI molecules, often 
results in multidrug resistance. This is exemplified by the T315I mutation or overexpression 
of ABCB1, whereby the gained resistance to one TKI can result in failure of secondary TKI 
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treatments (221). In this context, the potency and timeliness of the therapy becomes critical. 
With prolonged culture, stochastic variances in the cancer cell population can spontaneously 
develop into pro-survival characteristics (218). This makes the study of TKI resistance in CML 
not a simple listing of identified individual resistance mechanisms, but an investigation of how 
the tumour subpopulations interact with each other. Several previous studies have generated 
TKI resistant cells, comparing them directly against TKI naïve cells, while ignoring the 
fluctuations in the resistance mechanisms which occur over time and drug treatment. Thus, 
this thesis aims to investigate the longitudinal aspects of TKI resistance generation. 
 
1.6 Research questions, hypotheses and approach 
To further investigate the molecular mechanisms of TKI resistance in CML, several research 
questions were posed, which served to direct investigative procedure. These were mostly 
centred around a cell line model of induced dasatinib resistance, which was previously 
generated in our laboratory. The cell line, here named K562 DasR, overexpresses Bcr-Abl p210 
(e14a2), and in the later stages of dasatinib dose escalation, harbours the T315I mutation 
(205). However, there remained several unexplored aspects of the TKI resistance mechanisms 
present, and indeed, entirely undiscovered resistance mechanisms at play. This thesis serves 
to explore deeper into the resistance mechanisms present, and how they contribute towards 
the gain of total TKI therapy resistance. To gain further understanding of how TKI resistance 
was mediated, the following research aims and hypotheses were posed: 
 
• To explore the factors altering the propensity for leukaemic cells to develop the T315I 
mutation under dasatinib selection 
o Hypothesis: Prior to the acquisition of T315I, subpopulations of leukaemic cells 
harbour and express alternate resistance mechanisms, allowing cells to evade TKI treatment 
 
• To determine how cellular adaptations conferring resistance to dasatinib affect 
response to the salvage therapy TKI, ponatinib 
o Hypothesis: Resistance mechanisms arising in response to dasatinib exposure can 
provide leukaemic cells a means to evade ponatinib treatment 
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• To determine how drug resistance mechanisms can be circumvented and overcome 
o Hypothesis: Targeting of the individual drug resistance mechanisms will allow re-
sensitisation to TKI treatment 
 
To investigate the cellular adaptations involved in dasatinib and ponatinib resistance, 
dasatinib dose escalation intermediates of the K562 DasR cell line were subjected to a 
combination of genetic, transcriptomic, protein and functional analysis. Previously 
established resistance mechanisms (e.g. BCR-ABL1 overexpression and the T315I mutation) 
were validated using RT-qPCR, western blotting and transcript sequencing, and aspects of 
these resistance mechanisms were further explored with DNA qPCR and cytogenetic analysis, 
which determined the origin and outcome of BCR-ABL1 gene overexpression. Dasatinib 
resistance was determined in dose escalation intermediates using the TKI induced cell death 
and phospho-CrkL IC50 assays; cross resistance to ponatinib was determined using the same 
method. To determine alternate resistance mechanisms, transcriptome sequencing of 
selected K562 DasR dose escalation intermediates was performed, and was interrogated to 
identify changes in gene expression and the formation of genetic alterations (nucleotide 
variants, indels and genetic fusions). The overexpression of ABCG2 was identified in certain 
K562 DasR dose escalation intermediates, and its functional role in TKI resistance was 
determined. It was demonstrated that ABCG2 expression contributes to dasatinib resistance, 
and for the first time, to ponatinib cross resistance. Furthermore, genetic fusion analysis 
detected a rare BCR-ABL1 fusion associated with TKI resistance, e6a2, which was, for the first 
time to our knowledge, cloned into a Ba/F3 cell line to determine its effects on dasatinib 
susceptibility. Finally, analysis of the fluctuations in each of the different TKI resistance 
mechanisms gave insight into the selective advantages each mechanism provided, which 
provided evidence for a model of TKI resistance accrual, governed by the cellular energy 
efficiency of the individual resistance mechanisms. 
 
The data and interpretation presented here has added significantly to the understanding of 
drug resistance in CML, not only in identification of individual TKI resistance mechanisms, but 
also how each mechanism contributes to the evolution of resistance, allowing prediction of 
which cell populations will end up predominating under TKI selection, and suggesting how 
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these cell populations may be effectively targeted. This improved understanding will guide 


















Figure 1.2: Representation of the Philadelphia chromosome translocation event. 
Translocation between chromosomes 9 and 22 brings the BCR and ABL1 genes into 
juxtaposition. For the National Cancer Institute © (2007) Terese Winslow LLC, U.S. Govt. has 




I&U#,(!NOSV!@!5&+U,+00+%&*! ,(',(/(.%+%&).!)H!,)-.! _U,((.a!+.5!)*+! _,(5a!(Z).!+.5! &.%,).!
$)*+%&)./G!+.5!-)4!%-(7!2,(+;!%)!H),0!%,+./*,&'%!&/)H),0/!)H!)*+Q,)-.O!")/%!%,+./*,&'%/!-+J(!
%-(! /+0(!X\!(Z).&*!,)-.!2,(+;')&.%G!2(U&..&.U!+%!(Z).!+LO!E)4(J(,G! /(J(,+$!5&HH(,! &.! %-(!














_]=Ia! ,(U&)./O!>).(!)H! %-(!<*,Q@2$! &/)H),0/! *).%+&.! %-(!>Q%(,0&.+$! <*,!]3P+/(! +*%&J+%&.U!
',)%(&.! _]@Pa!5)0+&.O! 3-(!(Z&/%(.*(!)H! 5&HH(,(.%!<*,! ,(U&)./! &/! $&;($7! %)! *).H(,! H#.*%&).+$!
J+,&+.*(O!
















Figure 1.5: A diagram of the signalling pathways activated by Bcr-Abl. These include the MAPK 
(orange), JAK/STAT (pink), PI3K/AKT (blue), and Src family kinase (yellow) pathway members. 
Important scaffolding proteins (purple) mediate interactions with several effector proteins. 
Phosphorylated amino acid residues (dark blue P’s) are crucial for signalling pathway 
activation, which leads to increases in cell survival and proliferation, and loss of apoptotic 
signalling. 
 
Adapted from Haematologica, Mughal TI et al. Chronic myeloid leukemia: reminiscences and 
dreams (222). 
  










































Figure 1.6: a) Crystal structure of the Abl kinase domain in complex with clinically available 
TKIs. The yellow region indicates the phosphate binding P-loop, and green the kinase 
activation loop. Highlighted amino acid residues indicate point mutation locations which can 
confer resistance to the TKI. b) The structure of the TKIs determines the binding conformation 
to Bcr-Abl, critical amino acid interactions, and drug potency. 
 
Reproduced from Genome Biology, Eiring AM, Deininger MW. Individualizing kinase-targeted 











2 Methods and Materials 
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2.1 Reagent sourcing 
Reagent Supplier Part number 
7-Aminoactinomycin D (7-AAD) Life Technologies A1310  
ABCB1 PE antibody Beckman Coulter PN IM 2370U 
ABCG2 PE antibody R & D Systems FAB995P 
Agarose (for gel electrophoresis) Sigma-Aldrich A6013-100G 
Ampicillin Sigma-Aldrich A5354-10ML  
Annexin-V PE Becton Dickinson 556421 
Aprotinin Sigma-Aldrich A1153-5MG  
BCR-ABL TaqMan Gene Expression Assay for e1-a2 Applied Biosystems Hs03024844 
BenchMark Protein Ladder Life Technologies 10748010 
Bovine serum albumin (BSA) Sigma-Aldrich A9418-500G  
Bromophenol blue Sigma-Aldrich 114405-5G 
Buffer saturated phenol Life Technologies 15513039 
Chloroform Sigma-Aldrich C2432-1L 
Colcemid Thermo Fisher Scientific 15210-040 
Complete protease inhibitor cocktail Sigma-Aldrich 4693124001 
Criterion TGX precast gel Bio-Rad assorted 
Custom oligos Sigma-Aldrich VC00021  
Dasatinib Selleckchem S1021 
DC Protein Assay Bio-Rad 500-0116 
DEPC-treated water Thermo Fisher Scientific ICN821739 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 1029522500 
DNA Hydration Solution  Qiagen 158914 
Donkey anti-mouse-IRDye-800CW antibody Li-Cor Biosciences 926-32212 
Donkey anti-rabbit-IRDye-680LT antibody Li-Cor Biosciences 926-68023 
ECF substrate Bio-strategy RPN5785  
Ethanol Thermo Fisher AJA726-20L 
Expand Long Template PCR System  Sigma-Aldrich 11681842001 
Foetal calf serum (FCS) Fisher Biotec FBS-AU-015 
Glycerol Sigma-Aldrich G5516-1L  
Glycine Sigma-Aldrich G8898-1KG  
Glycogen (for RNA/DNA extraction) Sigma-Aldrich 10901393001 
Hank's balanced salt solution (HBSS) Sigma-Aldrich H9394 
HEPES Sigma-Aldrich H0887-100ML  
Imatinib mesylate Sapphire Bioscience G407002  
Iscove's modified Dulbecco medium (IMDM) Sigma-Aldrich I3390-500ML  
Isopropanol Chem Supply PA013-2.5L-P  
Kanamycin Life Technologies 15160054 
Ko143 Sigma-Aldrich K2144-5MG 
L-glutamine Sigma-Aldrich G7513-100ML 
Leupeptin Sigma-Aldrich L0649-5MG  
Lipofectamine Life Technologies 11668019 
Luria broth base Thermo Fisher Scientific 12795-084 
Marabu Fixo Gum rubber cement 
Leica Biosystems 
Amsterdam LK-071A 
Methanol Chem supply MA004-20L-P  
Mouse anti-Abl (c-, v-, Bcr-) clone 24-21 antibody Merck Millipore MABT203 
Mouse anti-IgG2a PE antibody Agilent Technologies X0950 
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Mouse anti-IgG2b PE antibody Agilent Technologies X0951 
Newborn calf serum Sigma-Aldrich 12023C-500ML  
NEXTFlex Rapid Directional RNA Seq Library Prep Kit  Geneworks BIOO-5138-10  
Nilotinib Sapphire Bioscience N465303  
NP-40 Thermo Fisher Scientific 85124 
One Shot® MAX Efficiency® DH5α™-T1R Competent Cells Life Technologies 12297016 
Opti-MEM reduced serum media Life Technologies 51985034 
Penicillin-Streptomycin Sigma-Aldrich P4333-100ML 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich 78830 
Phosphate buffered saline (PBS), 10x Life Technologies 14200-166  
Polybrene Thermo Fisher SC-134220  
Polyvinylidene fluoride (PVDF) Adelab MIL-IPVH00010  
Ponatinib Sapphire BioScience S1490  
Precision Plus Protein Kaleidoscope Standards Bio Rad 1610395 
Proteinase K Sigma-Aldrich 3115887001 
Q5 Site-Directed Mutagenesis Kit  Genesearch E0554S 
QIAGEN Plasmid Plus Midi Kit Qiagen 12643 
QIAprep Spin Miniprep Kit Qiagen 27104 
QIAquick Gel Extraction Kit Qiagen 28706 
Rabbit anti-CrkL (C-20) antibody Santa Cruz Biotechnology sc-319 
Rabbit anti-IgG antibody (alkaline phosphatase conjugated) Santa Cruz Biotechnology sc-2007 
Rabbit anti-phospho-Bcr (Tyr177) Cell Signalling Technology 3901 
Rabbit anti-phospho-c-Abl (Tyr245) Cell Signalling Technology 2861S 
Rabbit anti-phospho-STAT5 antibody (Tyr 694) Cell Signalling Technology 9359S 
Rabbit anti-STAT5 antibody Cell Signalling Technology 94205S 
Rabbit anti-β-Tubulin (9F3) antibody Cell Signalling Technology 2128 
RNase A Qiagen 19101 
RPMI-1640 Sigma-Aldrich R0883-500ML  
Select Agar (For solid microbial growth media) Thermo Fisher Scientific 30391-023 
Sodium azide Sigma-Aldrich S2002 
Sodium chloride Thermo Fisher Scientific AJA465-2.5KG  
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 75746-1KG 
Sodium fluoride Sigma-Aldrich S7920-100G 
Sodium orthovanadate Sigma-Aldrich S6508 
Sodium pyrophosphate Sigma-Aldrich P8010-500G 
ß-mercaptoethanol Sigma-Aldrich M6250-100ML  
SuperScript II Reverse Transcriptase Kit Life Technologies 18064014 
SureSelect XT Target Enrichment System Integrated Sciences 5190-9491 
SYBR® Green Real-Time PCR Master Mix system Qiagen 330503 
TOPO XL-2 Complete Cloning Kit  Life Technologies K8050-10 
Tris Sigma-Aldrich 252859-500G  
TRIzol reagent Life Technologies 15596018 
Trypan Blue Sigma-Aldrich T0776 
UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1, 
v/v) Thermo Fisher Scientific 15593031 
Vectashield Antifade Mountin Medium with DAPI Abacus VEH1200  




2.2 Reagent recipes 
Reagents were made up by myself or members of the Leukaemia Research Laboratory, as 
needed. Final molar concentrations are shown, and/or volumes added in typical recipes 
made. Stock concentrations and pH are shown in brackets. 
 
2.2.1 Cell culture medium 
RPMI 1640 medium – 500 mL 
10% FCS – 50 mL 
25000 Units penicillin-streptomycin (5000 U/mL) – 5 mL 
2 mM L-glutamine (200 mM) – 5 mL 
 
Media made sterile and stored at 4˚C, and warmed to 37˚C in a water bath before use. 
 
2.2.2 Ba/F3 (naïve and empty vector control) cell culture medium 
Cell culture medium from 2.1.1 – 47.5 mL 
5% WEHI-3B conditioned media – 2.5 mL 
 
Media made sterile and stored at 4˚C, and warmed to 37˚C in a water bath before use. 
 
2.2.3 HEK293T cell culture medium 
Dulbecco’s modified Eagle’s medium (DMEM) – 500 mL 
10% FCS – 50 mL 
25000 Units penicillin (5000 U/mL) – 5 mL 
25000 µg/mL streptomycin (5000 µg/mL) – 5 mL  
2 mM L-glutamine (200 mM) – 5 mL 
 
Media made sterile and stored at 4˚C, and warmed to 37˚C in a water bath before use. 
 
2.2.4 WEHI-3B conditioned medium (source of murine IL-3) 
Conditioned media from WEHI-3B murine monomyelocytic leukaemia cells was used as a 
source of murine IL-3 for stimulation of Ba/F3 cells. WEHI-3B cells were subcultured at 2x105 
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cells/mL in 200 mL cell culture medium for 48 h or until confluent. Conditioned media was 
harvested and frozen in 50 mL aliquots at -20˚C until needed, and sterile filtered before use. 
 
2.2.5 Minimal media 
Iscove’s modified Dulbecco’s medium (IMDM) – 500 mL 
1% w/v bovine serum albumin (BSA) – 5 g 
2 mM L-glutamine (200 mM) – 5 mL 
 
BSA was dissolved in IMDM with L-glutamine by agitation at room temperature, then filter 
sterilised and stored at 4˚C, and warmed to 37˚C in a water bath before use. 
 
2.2.6 HBSS + HEPES (final concentration) 
Hanks balanced salt solution (HBSS) 
200 mM HEPES 
 
2.2.7 Freeze solution (final concentrations) 




Fresh solution was prepared ice cold as needed. 
 
2.2.8 Binding buffer 
HBSS + HEPES – 47.5 mL 
100 mM CaCl2 – 2.5 mL 
 
2.2.9 Annexin V / 7-AAD staining solution (per sample) 
Binding buffer – 50 µL 
Annexin-V PE – 1 µL 
7-AAD stock – 0.1 µL 
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2.2.10 FACS fixative 
PBS – 500 mL 
Formaldehyde (40% w/v) – 5 mL 
D-glucose – 10 g 
Sodium azide – 0.1 g 
 
Prepared, sterile filtered and stored at 4˚C. 
 
2.2.11 Laemmi’s lysis buffer (final concentrations) 




0.1% bromophenol blue 
1 mM sodium orthovanadate 
10 mM sodium fluoride 
 
The buffer was prepared and stored in 1 mL aliquots at -20˚C, and briefly thawed in a 95˚C 
heat block before use. 
 
2.2.12 4x loading buffer 
Tris HCl (2M, pH 6.8) – 1.25 mL 
SDS – 0.8 g 
Glycerol – 4 mL 
ß-mercaptoethanol – 2 mL 
Bromophenol blue – 500 µL 
MilliQ H2O up to 10 mL 
 
The buffer was prepared and stored in 1 mL aliquots at -20˚C, and briefly thawed in a 95˚C 
heat block before use. 
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2.2.13 NP40 lysis buffer 
Tris-HCl (1M, pH 7.4) – 10 µL 
Sodium chloride (1M) – 137 µL 
Glycerol – 100 µL 
1% NP-40 (10%) – 100 µL 
MilliQ H2O – 415 µL 
ß-glycerol phosphate (1M) – 10 µL 
Sodium vanadate (0.1 M) – 20 µL 
Sodium fluoride (0.5M) – 4 µL 
PMSF (0.2M in ethanol) – 10 µL 
Sodium pyrophosphate (0.25M) – 10 µL 
Leupeptin (1 mg/mL) – 1 µL 
Aprotinin (1.7 mg/mL) – 3 µL 
1x CompleteTM protease inhibitor cocktail (1x tablet in 1 mL MilliQ H2O) - 100 µL 
 
The buffer prepared ice cold as needed, immediately before use. 
 
2.2.14 Tris buffer A 
MilliQ H2O – 500 mL 
1.5 M Tris-HCl (pH 8.8) – 90.885 g 
 
2.2.15 Tris buffer B 
MilliQ H2O – 500 mL 
0.5 M Tris-HCl – 30.285 g (pH 6.8) 
 
2.2.16 10x SDS-PAGE running buffer 
250 mM Tris-HCl (pH 8.3) – 30.26 g 
1.92 M glycine – 144.13 g 
1% SDS – 10 g 
 
Dissolved in 750 mL RO H2O and made up to 1 L. Diluted to 1x in RO H2O before use. 
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2.2.17 Tris buffered saline (TBS), 10x stock 
200 mM Tris-HCl – 24.2 g (pH 7.5) 
1.5 M NaCl – 87.6 g 
 
Dissolved in 750 mL RO H2O and adjusted to pH 7.5 with HCl, then filled to 1 L. Diluted to 1x 
in RO H2O before use. 
 
2.2.18 1x Tris buffered saline + Tween20 (TBST) 
10x TBS stock – 100 mL 
0.1% Tween20 – 1mL 
RO H2O – 900 mL 
 
2.2.19 10x Transfer buffer stock 
Glycine – 144.414 g 
Tris – 30.26 g 
RO-H2O – 950 mL 
 
2.2.20 1x Transfer buffer 
10x Transfer buffer stock – 100 mL 
Methanol – 200 mL 
RO-H2O – 700 mL 
 
2.2.21 2.5% skim milk 
2.5% non-fat milk powder – 12.5g 
1x TBST – 500 mL 
 
2.2.22 dNTP set (25 mM stock) 
40 µL of each 100 mM dNTP stock, stored at -20˚C. 
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2.2.23 Luria broth agar plates 
Luria broth was prepared according to manufacturer’s directions, with the addition of 1.2% 
Select Agar. This was made in 500 mL Schott glass bottles and autoclaved at the SAHMRI 
washing facility. 
 
2.2.24 Carnoy’s fixative 
Methanol  – 75 mL 
Glacial acetic acid – 25 mL 
 
Prepared fresh and kept on ice. 
 
2.2.25 DNA Lysis Buffer 
10 mM Tris (pH 8.0) 
10 mM NaCl 
10 mM EDTA (pH 8.0) 
 
2.2.26 Tyrosine kinase inhibitors 
Dasatinib and ponatinib were dissolved into DMSO to prepare a 10 mM stock, which was 
stored at -20˚C and diluted in DMSO as needed. 
 
2.3 Cell culture and generation of cell lines 
2.3.1 General cell culture 
All sterile cell culture was performed in a laminar flow cabinet. For cell maintenance, filter 
capped flasks were stored in a CO2 incubator at 37˚C in 5% CO2 at 100% relative humidity. To 
account for spontaneous mutations associated with long term subculture, cells were 
maintained under 30 passages post thawing, at which point they were discarded. Cells were 
maintained at cell density appropriate for cell type to ensure exponential growth, typically 
between 1 x 105 – 1 x 106 cells/mL. To assess cell density and viability, trypan blue dye 
exclusion was performed every 2-4 days, depending on cell type. Trypan blue dye was mixed 
1:1 with cell suspension and counted on a Neubauer haemocytometer. 
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2.3.2 Thawing of cells 
Cells were thawed and cultured from liquid nitrogen storage as required. Briefly, cells were 
retrieved from liquid nitrogen storage and thawed rapidly in a 37˚C water bath. The cell 
suspension was transferred to a conical centrifuge tube, and cell culture medium (Chapter 
2.2.1) was added dropwise to 10 mL total volume, with constant mixing. Cells were pelleted 
by centrifugation and supernatant discarded, and media addition was repeated to remove 
residual DMSO from the freeze solution. Following this, cells were resuspended in cell culture 
medium as required. 
 
2.3.3 Cryopreservation of cells 
Cell ampoules were cryopreserved in the liquid nitrogen storage facility in SAHMRI, Adelaide. 
To prepare cells for preservation, 5-10 x 106 cells were harvested by centrifugation and 
resuspended in 1.5 mL freeze solution (Chapter 2.2.7). 1.5 mL ampoules were chilled first to 
-80˚C in a Mr Frosty freezing container, before transfer to liquid nitrogen storage. Listings of 
cell lines generated are located in SAHMRI leukaemia laboratory databases.  
 
2.3.4 Generation of the K562 dasatinib resistant cell lineage (K562 DasR) 
The dasatinib resistant K562 leukaemic cell line, K562 200 nM Das (herein named K562 DasR), 
was previously developed by our laboratory (205). K562 cells were obtained from American 
Type Culture Collection (ATCC) and cultured in the presence of dasatinib, increasing from 0.5 
to 200 nM over 9.5 months. Over this period, cell ampoule samples were stored at various 
stages of dasatinib resistance (dose escalation intermediates). A K562 vehicle control line, 
K562 DMSO, was concurrently generated by culture in 0.02% DMSO. To assess the resistant 
characteristics of these cell populations, samples were thawed, and interrogated in various 
experiments. These cells were cultured in the dasatinib concentration to which they had been 
made resistant during experimentation (e.g. the K562 15 nM Das cell line was cultured in 15 
nM dasatinib). 
 
2.3.5 Single cell cloning of K562 200 nM Das cell line 
In efforts to assess the genetic and phenotypic heterogeneity within the K562 200 nM Das 
resistant cell line, single cell cloning of the line was performed. Previously, the line was 
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demonstrated to express both ‘wildtype’ BCR-ABL1 transcripts, as well as those harbouring 
the T315I mutation. Single cell clones were generated by limiting dilution into 96 well plates, 
followed by clonal expansion over 30 days. Cell populations with two distinct genotypes were 
identified, one expressing ~50% T315I mutated BCR-ABL1 transcripts, and another with no 
measurable T315I mutation by kinase domain Sanger sequencing. Both of these populations 
were demonstrated to be similarly resistant to dasatinib and ponatinib; this has been 
described in my honours thesis (University of Adelaide, BHSc Honours). To further investigate 
differences in their transcriptional profile, three T315I negative clones (A8, C10 and G5) and 
two T315I positive clones (B9 and E2) were thawed and used in RNAseq transcriptional 
profiling experiments. 
 
2.3.6 The HL60 BCR-ABL1 and HL60 T315I cell lines 
HL60 cell lines transduced with BCR-ABL1 were previously generated by Dr Jane Engler. 
Briefly, lentiviral particles containing co-expressing eGFP and BCR-ABL1 in a pHIV-1SDm-
based lentiviral vector were kindly provided by Professor John Rasko and Dr Charles Bailey, 
(Centenary Institute, Sydney, Australia). Vectors contained 5’- and 3’- HIV-1 long terminal 
repeat, Rev response element, CMV promoter and a woodchuck hepatitis virus 
posttranscriptional regulatory element. These were transduced into the acute promyelocytic 
leukaemia cell line, HL60. Cells were FACS sorted for eGFP expression as required to maintain 
high BCR-ABL1 expression. 
 
2.4 Cloning of BCR-ABL1 sequences into Ba/F3 cell lines 
2.4.1 Plasmid DNA preparation techniques 
Plasmid DNA was expanded, stored in, and extracted from transformed E. coli DH5a 
chemically competent cells. Cells were streaked onto antibiotic selection Luria broth plates, 
and single colonies were picked for overnight expansion in Luria broth. Glycerol stocks were 
made as needed using 500 µL of culture mixed with 500 µL of 80% glycerol, and stored at -
80˚C. 
 
To expand, extract and purify plasmid DNA from E. coli expression cells, miniprep and 
midiprep were used, as per the amount of DNA required. Transformation of plasmid DNA into 
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E. coli was performed by heat shock at 42˚C for 40 seconds. A single colony culture was 
expanded in Luria broth. For purification of up 20 µg of DNA, plasmid was prepared using 
QIAprep Spin Miniprep Kit, according to manufacturer’s protocol. For midiprep above these 
volumes, plasmid midiprep was used with QIAGEN Plasmid Midi Kit, according to 
manufacturer’s protocol.  
 
To isolate DNA bands of specific sizes following gel electrophoresis, DNA products were 
electrophoresed in a 2% agarose gel at 100V until differentiated by size, and purified using 
the QIAquick Gel Extraction Kit, according to manufacturer’s protocols. 
 
2.4.2 Acquisition and modification of BCR-ABL1 sequences 
The BCR-ABL1 cDNA sequences, e14a2 and e6a2, were procured from the online plasmid 
repository, Addgene (224), following unsuccessful attempts at cloning directly from the K562 
DasR line in which they originated. An outline of the cloning procedure and methodology can 
be found in Supplementary Data (Figure S1). The Bcr/Abl P210-pLEF plasmid, deposited by 
Professor Nora Heisterkamp (Figure S2, #38158), was selected for further experimentation, 
and has previously been used by Kweon et al, for determining the activity of the BCR Rho 
GTPase domain (225). This was received by stab culture under Materials Transfer Agreement 
for Addgene order #331443. GMO work was performed under SAHMRI IBC ID: BC07/2016. 
Cells were expanded under ampicillin selection, plasmid was extracted by miniprep. Extracted 
plasmid DNA was digested using EcoRI and BamHI to test for the correct digest products 
(Figure S3) and the BCR-ABL1 portion was sequenced for validation.  
 
All BCR-ABL1 full length sequencing of plasmid DNA was performed by AGRF, according to 
their PD+ protocol, using the following sequencing primers:  
BCR-ABL1 seq F1: 5’-GAG GGT TCT CCG GGT AAG GC-3’ 
BCR-ABL1 seq F2: 5’-CTA CCA GAG CAT CTA CGT CGG G-3’ 
BCR-ABL1 seq F3: 5’-CAT TGA TGA CTC GCC CTC CTC A-3’ 
BCR-ABL1 seq F4: 5’-GAG AAC CTG AGA GCC AGA AGC A-3’ 
BCR-ABL1 seq F5: 5’-GCT GGA CGC TTT GAA GAT CAA GA-3’ 
BCR-ABL1 seq F6: 5’-GCT GGA CCC AGT GAA AAT GAC C-3’ 
BCR-ABL1 seq F7: 5’-AGC CCA CTG TCT ATG GTG TGT C-3’ 
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BCR-ABL1 seq F8: 5’-GGT AGC TGA TTT TGG CCT GAG C-3’ 
BCR-ABL1 seq F9: 5’-CTG AGA TGC CTC ACT CCA AGG G-3’ 
BCR-ABL1 seq F10: 5’-GCT TCC TGC GCT CTT GCT C-3’ 
BCR-ABL1 seq F11: 5’-AGG GAG GGA CAA GGG GAA ATT G-3’ 
BCR-ABL1 seq F12: 5’-CTA GGA ACT CCG AGC AGA TGG C-3’ 
BCR-ABL1 seq R1: 5’-ATC GCT GCC GGT CAT AGC TC-3’ 
BCR-ABL1 seq R2: 5’-TTC AAC TCG GCG TCC TCG TAG-3’ 
BCR-ABL1 seq R3: 5’-CAT CGT TGG GCC AGA TCT GC-3’ 
BCR-ABL1 seq R4: 5’-CTT CTG GAA GAG GTC GCC CAC-3’ 
BCR-ABL1 seq R5: 5’-AGT CAT ACT GCT GCG TTT TGC C-3’ 
BCR-ABL1 seq R6: 5’-TGG CTG AGT GGA CGA TGA CAT T-3’ 
BCR-ABL1 seq R7: 5’-GCT TGC CAT CAG AAG CAG TGT T-3’ 
BCR-ABL1 seq R8: 5’-TGA CGA GAT CTG AGT GGC CAT G-3’ 
BCR-ABL1 seq R9: 5’-TGT TTC CCC AGC TCC TTT TCC A-3’ 
BCR-ABL1 seq R10: 5’-CAC TGC CCT TTC CAG CTT CTT C-3’ 
BCR-ABL1 seq R11: 5’-CCG AAG AGA CAC TCG GGT TGA T-3’ 
BCR-ABL1 seq R12: 5’-TGT CAC TGA TTT CCT TCA CCG A-3’ 
 
The sequencing chromatogram files were analysed using Benchling (California, USA), aligning 
to BCR and ABL1 sequences curated from the Ensembl through the Benchling web application. 
 
In order to minimise the size of the plasmid construct for cloning work, the BCR-ABL1 e14a2 
sequence was cloned from the 7400 bp pLEF vector backbone into the 3960 bp pCR-XL-2-
TOPO vector using the TOPO XL-2 Complete Cloning Kit. The E. coli line harbouring Bcr/Abl 
P210-pLEF was expanded from the stab culture under ampicillin selection and used as a 
template for PCR amplifying the BCR-ABL1 sequence (Figure S5). This was performed using 
the SuperFi PCR kit supplied with the TOPO XL-2 Complete Cloning Kit, used with the following 
primers (bolded region indicates BCR-ABL1 alignment): 
 
Forward: 5’-GCA TGA ATT CAC CAT GGT GGA CCC GGT GGG CTT C-3’ 
Reverse: 5’-GCA TCA TAT GCT ACC TCT GCA CTA TGT CAC TGA TTT CCT TCA C-3’ 
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PCR was performed under the following cycling conditions: 
Cycle Temp (˚C) Time Cycles 
1 98 30 sec x1 
  98 10 sec   
2 66 30 sec X28 
  72 4 min   
3 72 5 min x1 
4 4 infinity x1 
 
A ~6 kb PCR product was gel purified and cloned into the pCR-XL-2-TOPO vector as per the 
manufacturers protocol. The plasmid was transformed into competent E. coli DH5α for 
expansion under kanamycin selection, and BCR-ABL1 portion was sequenced, and colonies 
with successful cloning were expanded and stored as glycerol stocks (Figure S6). To generate 
the e6a2 fusion from the e14a2 construct, site directed mutagenesis was performed using 
the Q5 Site-Directed Mutagenesis Kit (NEB). A PCR mutagenesis reaction was performed as 
per manufacturer’s instructions, using the following primers: 
 
Forward: 5’-TTT CCA GAG AGT TCT TGG TCG TTG GAT C-3’ 
Reverse: 5’-AAG CCC TTC AGC GGC CAG TAG CAT-3’ 
 
This was performed under the following PCR conditions: 
Cycle Temp (˚C) Time Cycles 
1 98 30 sec x1 
  98 10 sec   
2 69 30 sec X25 
  72 4 min   
4 72 4 min x1 
5 4 infinity x1 
 
Concurrently, the e1a2 fusion was also generated by site directed mutagenesis under the 
same PCR conditions, using the following primers: 
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Forward: 5’-CTG CGT CTC CAT GGA AGG C-3’ 
Reverse: 5’-AAG CCC TTC AGC GGC CAG-3’ 
 
The template and mutagenised plasmids were digested with EcoRI to ensure correct band 
sizes (Figure S7). The e6a2 and e1a2 mutagenised plasmids were ligated and transformed into 
E. coli DH5α cells for plasmid expansion and EcoRI test digest (Figures S8/S9). The pCR-XL-2-
TOPO BCR-ABL1 e6a2 and e1a2 mutagenised plasmids were sequenced over the BCR-ABL1 
fusion breakpoint, and colonies with successful mutagenesis were expanded and stored as 
glycerol stocks. The mutagenised BCR-ABL1 sequences were then cloned into the pRuf-iG2 
retroviral expression vector. The pCR-XL-2-TOPO vector was digested with EcoRI and 
separated by gel electrophoresis, and the BCR-ABL1 sequences were excised and gel 
extracted (Figure S10/S11). The BCR-ABL1 sequence was cloned into the pRuf-iG2 vector, 
kindly provided by Professor Andrew Zannettino (University of Adelaide), via the EcoRI site 
(Figure S12). The e14a2, e6a2 and e1a2 vectors were transformed into E. coli DH5α cells under 
ampicillin selection, and restriction digested using EcoRI and electrophoresed to determine 
the size of the ligated sequence (Figure S13). Sequencing was performed over the insertion 
site to determine the correct orientation of the insert. BCR-ABL1 sequences inserted in the 
correct orientation were then sequenced in full. No additional single nucleotide or insertion-
deletion mutations were identified (data not shown). 
 
2.4.3 Retroviral transduction of BCR-ABL1 sequences 
The Ba/F3 murine pro-B cell line is often used for assessment of the potency and downstream 
signalling of kinase oncogenes. Ba/F3 cells are typically dependent on supplementation with 
IL-3 for ongoing proliferation and survival, however transformation with an oncogenic kinase 
allows growth factor independent proliferation (226). This, coupled with the co-expression of 
green fluorescent protein (GFP), allowed the purification of BCR-ABL1 transduced cells. 
 
For expression of BCR-ABL1 sequences in the Ba/F3 cell lines, retroviral particles were 
produced by expansion in HEK293T cells. 1 x 106 HEK293T cells were seeded in 5 mL of 
HEK293T cell culture medium for 24 h. A DNA lipofection solution was prepared with 500 µL 
Opti-MEM reduced serum media, 4 µg of the pRuf-iG2 expression construct, and 4 µg of pEQ-
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Eco viral packaging plasmid (227). Separately, a lipofectamine solution was prepared with 500 
µL Opti-MEM media and 20 µL Lipofectamine and incubated for 10 minutes. These two 
solutions were combined and incubated for 2 h at room temperature, before dropwise 
addition to the HEK293T cell flasks and incubation for 24 h. Media was refreshed and cells 
incubated a further 24 h, after which viral supernatant was collected by centrifugation and 
filtered through a 0.45 µm syringe filter. Polybrene was added to viral supernatant to give a 
final concentration of 4 µg/mL. Ba/F3 cells were pelleted by centrifugation and resuspended 
in 3.5 mL of viral supernatant from BCR-ABL1 e14a2, e6a2, e1a2, or the pRuf-iG2 empty vector 
control. Cells were transduced by spinfection at 1800 rpm for 1 h in a 6 well culture plate. 
Following a 24 h incubation at 37˚C in viral supernatant, cells were expanded in fresh media 
and FACS sorted for GFP fluorescence, attaining a pure population of BCR-ABL1 expressing 
cells. To ascertain the malignant transformation of the Ba/F3 cells by Bcr-Abl kinase activity, 
WEHI-3B conditioned media was withdrawn from Ba/F3 cell culture medium, and 
phosphorylation of CrkL was determined by western blotting. 
 
2.5 Quantitation of TKI resistance 
2.5.1 TKI-induced cytotoxicity assay 
To determine and quantify the level of resistance to kinase inhibitors, K562 and Ba/F3 cell 
lineages were subjected to the TKI-induced cytotoxicity assay. Cells were cultured in a 
concentration gradient of a TKI, with an appropriate vehicle control, in 1 mL volume of 
minimal media (Chapter 2.2.5) in a sterile 24-well cell culture plate. Following 72 h incubation 
at 37˚C / 5% CO2, cells from 200 µL of culture medium were harvested by centrifugation at 
1400 rpm for 5 min, washed with 200 µL binding buffer, and stained with 50 µL Annexin V / 
7-AAD staining solution for 20 min at room temperature. 7-AAD can penetrate the plasma 
membranes of dead cells, intercalating into double stranded DNA. Annexin-V PE is a 
phycoerythrin conjugated phospholipid protein that binds to the inverted inner surface of the 
cell membrane, on the outer surface of dying cells. Staining for both allows the determination 
of the live, dead, and dying fractions of a cell population. Single stained (Annexin V only or 7-
AAD only) and unstained controls were simultaneously performed, using a mix of live and 
dead cells. Following addition of 200 µL binding buffer, cells were analysed on either a BD 
FACSCantoTM II or BD LSRFortessa X-20 at the SAHMRI Flow Cytometry Core Facility, with the 
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assistance of Dr Randall Grose. FCS file processing was performed using either FCS Express 
version 4.07.0019 (De Novo Software, California, USA) or FlowJo version 9 (FlowJo LLC, 
Oregon, USA), adjusting compensation based on single stained and unstained controls. 
 
2.5.2 Phospho-CrkL IC50 analysis of Bcr-Abl kinase activity 
To quantify the level of cellular Bcr-Abl activity in the presence of TKI, the phospho-CrkL IC50 
was performed as previously described (228). This uses the phosphorylation of the Bcr-Abl 
target, CrkL, as a measure of Bcr-Abl kinase activity. An IC50, the half maximal inhibitory 
concentration, can be calculated following culture in a TKI concentration gradient. Briefly, 
2x105 cells were washed with RPMI 1640 medium and resuspended 10 mL of RPMI 1640 + 
10% NCS + 0.5% DMSO in a 50 mL centrifuge tube. Nine concentrations of TKI were identically 
set up, which spanned the expected IC50 concentration. These experiments were also 
performed in the presence of the ABCG2 inhibitor, Ko143, in order to determine the role of 
ABCG2 in TKI transport. Cells were incubated at 37˚C / 5% CO2 for 2 h, before being pelleted 
by centrifugation, washed in 5 mL ice cold PBS, transferred to a 1.7 mL microfuge tube, and 
lysed in 20 µL of Laemmli’s lysis buffer in a 100˚C heat block for 12 min. Lysates were clarified 
by brief centrifugation and stored at -20˚C. 
 
CrkL and pCrkL were visualised by western blot. Frozen protein lysates were heated in a 100˚C 
heat block for 12 mins, then separated on a denaturing 10% polyacrylamide gel for ~2 hours 
at 20 V per gel at 4˚C, until pCrkL separated from CrkL. Protein was transferred to PVDF 
membrane in transfer buffer overnight at 50 mA. Membrane was blocked with 2.5% skim milk 
powder in TBST for 1 h and probed with 1:1000 anti-CrkL antibody for 2 h. Membrane was 
washed 3x in TBST for 5 min, then probed with 1:2000 anti-rabbit IgG alkaline phosphatase 
antibody for 1 h. Membrane was finally washed 3x in TBST and 3x in TBS for 5 min, then 
treated with ECF substrate for 90 sec and analysed on a ChemiDoc Gel Imaging System (Bio-
Rad Laboratories Inc., California, USA). Scan files were analysed using provided Image Lab 
software version 5 build 8, to perform band densitometry. Relative CrkL/pCrkL band 




2.6 Genetic analysis of resistance mechanisms 
2.6.1 RNA extraction and cDNA synthesis 
RNA used for cDNA synthesis and subsequent RT-qPCR analyses was extracted and purified 
from cell lines using TRIzol reagent extraction. Using 2x106 cells per 1 mL of TRIzol, cells were 
mixed and lysed by pipetting, at which point they were optionally stored at -80˚C for later 
extraction. Phase separation was performed with the addition of 200 µL of chloroform and 
mixed by shaking for ~10 sec and incubation for 3 minutes at room temperature, before 
centrifugation at 12 000 xg for 15 min at 4˚C. The top aqueous layer was transferred to a new 
1.7 mL microfuge tube, and RNA was precipitated with the addition of 500 µL isopropanol and 
1 µL glycogen. Samples were mixed gently and incubated for 10 min at room temperature, 
before pelleting RNA by centrifugation at 12 000 xg for 10 min at 4˚C. Supernatant was 
removed by pipetting and the RNA pellet was washed with the addition of 1 mL of ice cold 
75% ethanol and centrifugation at 7500 xg for 5 min at 4˚C. Supernatant was removed, 
samples were re-centrifuged and remaining supernatant also removed, and RNA pellet was 
briefly dried before resuspension in 20-50 µL of DEPC-treated water at 55˚C for 10 minutes. 
 
RNA concentration was quantitated using a NanoDrop microvolume spectrophotometer 
(Thermo Fisher Scientific, Massachusetts, USA) , and cDNA was synthesised from 500 ng RNA 
using the SuperScript II First Strand Synthesis System for RT-PCR, according to manufacturer’s 
protocols. 
 
2.6.2 DNA extraction from cell lines 
DNA was extracted from cell line material using the phenol chloroform extraction method. 
Up to 5x106 cells were pelleted by centrifugation and washed with 1 mL PBS at 4˚C. Cell pellet 
was resuspended in 480 µL DNA Lysis Buffer by pipetting. SDS was added to a final 
concentration of 0.5%, as well as 10 µL of Proteinase K, and mixed by inversion 30 times. 
Samples were incubated overnight at 37˚C to complete cell lysis. 5 µL of RNase A was added 
and tubes were mixed by inversion 50 times, and incubated at 37˚C for 10 min. 10 µL of 5 M 
sodium chloride, 1 µL of glycogen, and 500 µL of buffer saturated phenol was added, and 
samples were mixed by shaking 50 times, before centrifugation at 16 000 xg for 5 min at room 
temperature, and the top aqueous later was transferred to a new 1.7 mL microfuge tube by 
 2-66 
pipetting. 500 µL of phenol:chloroform:isoamyl alcohol mixture was added, and sample mixed 
by shaking 50 times, before centrifugation at 16 000 xg for 3 min. The top aqueous later was 
transferred to a new 1.7 mL microfuge tube, and Phenol:Chloroform:Isoamyl alcohol 
extraction was repeated as required for purity. DNA was precipitated with the addition of 1 
mL of ethanol at -80˚C and mixing by inversion. Samples were centrifuged at 20 000 xg for 10 
min at 4˚C, supernatant was removed, and DNA pellet was washed with 600 µL ice cold 70% 
ethanol. Ethanol was removed by centrifugation at 20 000 xg for 5 min at 4˚C, and DNA pellet 
was dried briefly at room temperature. DNA pellet was resuspended in 200 µL of DNA 
Hydration Solution at 55˚C for 2 h and quantitated using NanoDrop microvolume 
spectrophotometry, before use or storage at 4˚C. 
 
2.6.3 BCR-ABL1 RT-qPCR 
For quantitation of the BCR-ABL1 transcript levels, RT-qPCR was performed using the SYBR® 
Green Real-Time PCR Master Mix system. For quantitation of the typical e14a2 (p210) 
transcript, found in drug naïve K562 cells, the following primers were used:  
 
Forward: 5’-GGG CTC TAT GGG TTT CTG AAT G-3’ 
Reverse: 5’-CGC TGA AGG GCT TTT GAA CT-3’ 
 
To our knowledge, quantitation of the BCR-ABL1 e6a2 transcript had not been previously 
performed, requiring the design of RT-qPCR primers and experiments for this purpose. Using 
the Primer Express© Software for Real-Time PCR (Applied Biosystems), the following primers 
were designed for amplification of the BCR-ABL1 e6a2 breakpoint: 
 
Forward: 5’-AAC GAC CAA GAA CTC TCT GGA AA-3’ 
Reverse: 5’-TGA GGC TCA AAG TCA GAT GCT ACT-3’ 
 
For quantitation of BCR-ABL1 e1a2 (p190) transcripts from transduced Ba/F3 cell lines, the 
commercially available BCR-ABL TaqMan Gene Expression Assay for e1-a2 was used according 
to manufacturer’s protocol. 
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To normalise between samples, RT-qPCR was also performed for the control gene GUSB, using 
the following primers: 
 
Forward: 5’-CTG AAC AGT CAC CGA CGA GA-3’ 
Reverse: 5’-GAA CGC TGC ACT TTT TGG TT-3’ 
 
Reactions were performed under standard 3 step SYBR Green qPCR protocol conditions, 
including melt curve analysis: 
Cycle Temp (˚C) Time Cycles 
1 95 3 min x1 
  95 10 sec   
2 55 10 sec X40 
  72 30 sec   
4 95 10 sec x1 
5 65-95 5 sec per 0.5˚C x1 
 
 
In the K562 DasR cell line experiments, data were reported as a ddCt value, comparing gene 
expression levels with the K562 DMSO control line. In the Ba/F3 cell lines, data were reported 
as a dCt value against the GUSB control gene. 
 
2.6.4 BCR-ABL1 kinase domain Sanger sequencing 
Sequencing of the BCR-ABL1 kinase domain allowed the efficient detection of the kinase 
domain mutations commonly associated with TKI resistance. Briefly, a region of the BCR-ABL1 
e14a2 was amplified using the Expand Long Template PCR System, according to 
manufacturer’s protocols, using the provided Expand Long Template Buffer 3 and the 
following primers: 
 
Forward: 5’-ACT ATG AGC GTG CAG AGT GGA-3’ 
Reverse: 5’-GAG GGA GCA ATG GAG ACA CG-3’ 
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The BCR-ABL1 e6a2 transcript kinase domain was amplified using the following primers: 
 
Forward: 5’-CAT GAA GCC TTT GAA AGC CG-3’ 
Reverse: 5’-GAG GGA GCA ATG GAG ACA CG-3’ 
 
These were amplified using the following PCR cycling conditions: 
Cycle Temp (˚C) Time Cycles 
1 94 2 min x1 
2 
94 10 sec   
60 30 sec X10 
68 2 min   
3 
94 10 sec   
60 30 sec x15 
68 2 min, increasing by 20 sec each round   
4 68 7 min x1 
5 4 infinity x1 
 
Sequencing was performed by AGRF, using the following sequencing primers:  
 
Forward: 5’-CGC AAC AAG CCC ACT GTC T-3’ 
Reverse: 5’-CAA GGT ACT CAC AGC CCC ACG GA-3’ 
 
Sequencing chromatogram files were aligned to ABL1 sequences using Benchling or Mutation 
Surveyor® version 3.30 (SoftGenetics LLC, Pennsylvania, USA). 
 
2.6.5 PCR validation and kinase domain sequencing of BCR-ABL1 e6a2 transcript detection 
Following the putative identification of the e6a2 fusion in FusionCatcher analysis of K562 DasR 
mRNA sequencing data, validation experiments were designed and performed. A PCR forward 
primer was designed within BCR exon 5 (ABLe5F): 
 
Forward: 5’-CAT GAA GCC TTT GAA AGC CG-3’ 
 2-69 
 
Additionally, a forward primer straddling the BCR-ABL1 e6a2 breakpoint was designed: 
 
Forward 5’-CTC TCT GGA AAA AGC CCT TCA-3’ 
 
Both forward primers were used with the existing reverse primer for BCR-ABL1 kinase domain 
amplification: 
 
Reverse: 5’-GAG GGA GCA ATG GAG ACA CG-3’ 
 
Reactions were amplified using the Expand Long Template PCR System, as previously 
described for BCR-ABL1 e14a2 transcript PCR. The PCR amplicons generated were resolved 
by 1% agarose gel electrophoresis. Additionally, amplicons were sequenced over the ABL1 
kinase domain, as per sequencing for BCR-ABL1 kinase domain Sanger sequencing for e14a2 
transcript mutations. Templates used were cDNA samples from the K562 DMSO, 10, and 200 
nM DasR lines used in mRNAseq experiments. 
 
2.6.6 MassARRAY sensitive BCR-ABL1 kinase domain sequencing 
The sensitivity of Sanger sequencing used for BCR-ABL1 kinase domain mutation analysis was 
only 5-10%, therefore a more sensitive MALDI-TOF mass spectrometry based method of 
sequencing was also used (229), to determine whether cell populations with low T315I 
expression were present in K562 DasR dose escalation intermediates and single cell clones. 
The MassARRAY iPLEX System BCR-ABL1 sequencing was performed with thanks to Mr Adrian 
Purins from the Leukaemia Unit at SA Pathology (Adelaide, Australia). 
 
2.6.7 Target enrichment sequencing and validation for BCR-ABL1 breakpoint detection 
To identify the different BCR-ABL1 fusions present in the K562 DasR cell lines dose escalation 
intermediates, target enrichment sequencing was performed using the SureSelect Target 
Enrichment System for Illumina Paired-End Multiplexed Library Sequencing, as per 
manufacturer’s protocol. Briefly, DNA was extracted from selected K562 DasR dose escalation 
intermediate samples and single cell clones. A panel of capture probes spanning ABL1 and 
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BCR genomic regions was designed by Dr Ilaria Pagani (SAHMRI Cancer Theme, Adelaide, 
Australia). Samples were hybridised with a fragmented and adaptor tagged genomic DNA 
library prepared from K562 samples, purified by magnetic bead wash, and sequenced on the 
Illumina NextSeq 500 platform (Illumina Inc., California, USA), generating 2x150 bp paired end 
reads. Sequencing data was uploaded to the Illumina BaseSpace Sequencing Hub.R Genomic 
breakpoints were determined using the FACTERA genomic fusion detection tool, and 
visualised using the NCBI Genome Data Viewer. 
 
The BCR-ABL1 e6a2 DNA breakpoint was validated by PCR, gel electrophoresis, and Sanger 
sequencing in selected K562 DasR dose escalation intermediates, using the following primers 
flanking the breakpoint, designed using Primer3 version 1.1.4: 
 
Forward: 5’-GTC CAG AGT TGC TGG GAA AG-3’ 
Reverse: 5’-GAA GAC CTT GAG TGC CAA GC-3’ 
 
2.6.8 BCR-ABL1 DNA qPCR 
Following identification of the BCR-ABL1 e14a2 and e6a2 fusion breakpoints in the K562 DasR 
cell line, the genomic quantity of each fusion was determined using DNA qPCR. TaqMan FAM-
TAMRA primers and probe were used to amplify the e14a2 genomic breakpoint: 
 
Forward: 5’-TGA CCA CGG GAC ACC TTT G-3’ 
Reverse: 5’-AGG GTA TTT CTG TTT GGG TAT GGA-3’ 
Probe: 5’-CTG GCC GCT GTG GAG TGG GTT TTA TC-3’ 
 
MGB-TAMRA qPCR probes were designed over the e6a2 breakpoint: 
 
Forward: 5’-AAG ATC TCA CAA CAG CTA TGA AGC A-3’ 
Reverse: 5’-GAG CAG GTC TCC CTC CAG AAT-3’ 
Probe: 5’-AGA CAG GAT TCC CC-3’ 
 
These were used in conjunction with TaqMan FAM-TAMRA control primers and probe 
amplifying genomic GUSB sequences: 
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Forward: 5’-ATT TTG CCG ATT TCA TGA CTG A-3’ 
Reverse: 5’-GAC GGG TAC GTT ATC CCA TGA G-3’ 
Probe: 5’-ATC CCA TGA GCC AAA CTG CCA CTT ACA C-3’ 
 
These primer/probe combinations were used with K562 DasR dose escalation intermediate 
DNA samples, as well as in serial dilutions of GUSB and BCR-ABL1 e14a2 plasmid DNA, allowing 
relative quantitation of genomic BCR-ABL1 copy numbers. This was reported as a percentage 
of GUSB quantity. 
 
2.6.9 Cytogenetic BCR-ABL1 analysis by fluorescence in situ hybridisation (FISH) 
To investigate the genomic quantity and characteristics of BCR-ABL1 fusions in K562 lines, 
cytogenetic analysis was performed. FISH analyses were performed with the assistance of  Mr 
Jeffrey Suttle from the SA Cancer Cytogenetics Unit at IMVS, SA Pathology (Adelaide, 
Australia). Log phase K562 cells were cell cycle arrested by treatment with 10 µL/mL colcemid 
for 30 min at 37˚C, before centrifugation and aspiration of supernatant to 300 µL. Hypotonic 
potassium chloride (0.075 M) was added to a total volume of 9 mL, and cells were allowed to 
swell for 30 min at 37˚C. Carnoy’s fixative was added to 10 mL total volume, and cells were 
pelleted by centrifugation for 10 min at 1000 rpm. Cells were repeatedly fixed and washed a 
further 2-3 times. Finally, fixative was aspirated to a minimal volume and ~0.5 mL of fixative 
was added to form a thin dispersion. Cells were dropped onto a glass slide from ~20 cm above 
and air dried, before immediate probing using 2 µL of the Vysis LSI BCR-/ABL Dual Color FISH 
probe. Samplers were sealed with a coverslip and sealed with Fixo Gum rubber cement, 
before performing probe denaturation / hybridisation by incubating in a Hybaid Omnislide 
thermal cycler (Thermo Fisher Scientific, Massachusetts, USA) at 72˚C for 4 minutes, then 37˚C 
overnight. Slides were stored in the dark from this point onwards. Slides were washed firstly 
with 0.4x saline sodium citrate + 0.1% NP-40 for 2 minutes at 72˚C, then 2x saline sodium 
citrate at room temperature for 1 minute. Slides were dried, and mounted with a small 
volume of Vectashield Antifade Mounting Medium with DAPI, and sealed with a cover slip. 
Cells were examined on a 100x oil lens using a red/green dual band pass filter. 
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2.6.10 ABCG2 RT-qPCR 
To determine the gene expression of ABC transporters, RT-qPCR was used. For quantitation 
of the ABCG2 transcript, the following primers were used:  
 
Forward: 5’-CAC CTT ATT GGC CTC AGG AA-3’ 
Reverse: 5’-CCT GCT TGG AAG GCT CTA TG-3’ 
 
For quantitation of the ABCB1 transcript, the following primers were used: 
 
Forward: 5’-AGA CAT GAC CAG GTA TGC CTA T-3’ 
Reverse: 5’-AGC CTA TCT CCT GTC GCA TTA-3’ 
 
Both of these primer pairs were used with a standard 3 step SYBR Green qPCR protocol, as 
per the BCR-ABL1 RT-qPCR thermal cycling protocol. 
 
To normalise between samples, RT-qPCR was also performed for the control gene GUSB, as 
per BCR-ABL1 RT-qPCR protocol. Data were reported as a ddCt value, comparing gene 
expression levels with the K562 DMSO control line. 
 
2.7 Protein and functional analysis of resistance mechanisms 
2.7.1 Bcr-Abl and signalling partner western blot analysis 
To visualise the level of Bcr-Abl protein in leukaemic cells, normal and phospho western 
blotting was performed. K562 cells were incubated in the presence of dasatinib or ponatinib 
for 2 h at 37˚C / 5% CO2. Cells were washed in PBS and lysed by incubation with NP40 lysis 
buffer on ice for 20 min, followed by clarification of the lysate by centrifugation at 14000 rpm 
for 15 min at 4˚C. A sample of the supernatant was taken for protein quantification, and the 
remainder was added to 0.333 the volume of 4x LB, boiled in a 100˚C heat block for 12 
minutes, and stored at -20˚C. Protein quantification for western blotting was performed using 
the  DC Protein Assay, according to manufacturer’s protocol. Lysates were equally loaded by 
total protein, typically at 40 µg. Lysates were separated by size exclusion SDS-PAGE gel 
electrophoresis on a Criterion TGX Precast gel, using the Precision Plus Protein Kaleidoscope 
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Standards or the BenchMark Protein Ladder. Protein was transferred to PVDF membrane 
using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories Inc., California, USA), using 
the high molecular weight setting. Membrane was cut appropriately and blocked using Li-Cor 
Odyssey Blocking Buffer for 1 h, then probed with anti-phospho-Bcr (1:1000), anti-phospho-
Abl (1:1000), anti-Abl (1:1000), anti-phospho-STAT5 (1:1000), anti-phospho-STAT5 (1:1000), 
or β-Tubulin (1:2000) antibodies in Odyssey Blocking Buffer at 4˚C for 16-24 h. Membranes 
were washed 4x with TBST, then probed with donkey-anti-rabbit IRDye680LT (1:10000) and 
donkey-anti-mouse IRDye 800CW (1:10000) in Odyssey Blocking Buffer + 0.1% Tween20 + 
0.01% SDS for 1 h at room temperature in darkness. Membranes were then washed 3x in TBST 
and 3x in TBS, before analysis on the Li-Cor Odyssey CLx Imaging System (Li-Cor Biosciences, 
Nebraska, USA). Image analysis was performed using supplied ImageStudio software version 
5.2.5. 
 
2.7.2 Flow cytometry for cell surface ABC transporter expression 
To determine the cell membrane protein expression of ABC transporters, flow cytometric 
analyses were performed. Staining was performed on 5x105 cells, which were pelleted by 
centrifugation and resuspended in 250 µL of flow cytometry blocking buffer on ice for 30 
minutes. Cells were stained with either 20 µL of ABCG2 PE (with IgG2b PE isotype control) or 
ABCB1 PE (with IgG2a PE isotype control) antibodies, on ice for 40 min. Cells were washed 
twice with 1 mL HBSS + HEPES, and resuspended in PBS. Cells were analysed on either a BD 
FACSCantoTM II or BD LSRFortessa X-20 at the SAHMRI Flow Cytometry Core Facility, with the 
assistance of Dr Randall Grose. FCS files were analysed in FlowJo, gating ABC transporter 
positivity against known negative control samples. 
 
2.7.3 BODIPY-prazosin efflux assay 
To demonstrate the functional substrate transport activity of the ABCG2 transporter, 
leukaemic cells were analysed for uptake and/or efflux of the BODIPY-prazosin ABCG2 
substrate. Cells were cultured in cell culture media at 37˚C for 1 h, in the presence and 
absence of the fluorescent marker BODIPY-prazosin, and in the presence and absence of the 
ABCG2 inhibitor Ko143, which effectively blocks ABCG2 function and BODIPY-prazosin efflux 
(230). Cells were subsequently washed of BODIPY-prazosin twice in PBS, and resuspended in 
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400 µL PBS supplemented with 5% BSA. BODIPY-prazosin fluorescence was detected by flow 
cytometry in the FITC channel; stain negativity was used as an indication of functional ABCG2. 
 
2.7.4 Dasatinib intracellular uptake and retention assay 
The IUR assay was performed with thanks to Mrs Sophie Watts, as previously described (163). 
Briefly, 2 x 105 cells were incubated with 0 or 2 µM C14-dasatinib (kindly provided by Bristol 
Myers Squibb), in the presence or absence of 0.5 µM Ko143. This was performed for 2 h at 
37⁰C, in 2 mL of RPMI-1640 medium containing 10% FCS. Following incubation, cells were 
pelleted by centrifugation for 5 min at 6800 rpm then 30 sec at 13000 rpm. Radioactivity of 
C14-dasatinib was determined independently in the supernatant and cell pellet using a Tri-
Carb 2810R Liquid Scintillation Counter (Perkin Elmer, Inc.). The IUR was reported as ng of 
dasatinib incorporated per 200,000 cells, and results were expressed as mean +/- SEM. 
 
2.8 Transcriptome sequencing and analysis 
2.8.1 mRNA next generation sequencing 
To explore the changes in the K562 DasR cell line associated with the acquisition of TKI 
resistance, sequencing of RNA transcripts from K562 DasR dose escalation intermediates was 
performed. Additionally, to explore the transcriptional diversity within the population of the 
cell line, previously generated single cell clones of the K562 200 nM Das line were sampled 
for mRNAseq experiments. RNA was extracted from 12 samples, which included K562 naïve 
and DMSO control lines, the 10, 15, 25, 50 and 200 nM K562 DasR lines, and the A8, C10, G5, 
E2 and F5 K562 200 nM Das single cell clones. Sequencing libraries were prepared using the 
NEXTFlex Rapid Directional RNA Seq Library Prep Kit. This kit utilises magnetic beads 
conjugated to oligo(dT) to isolate polyadenylated messenger RNA, depleting ribosomal and 
non-coding RNA. Initial quality control of RNA was performed using the Agilent 2100 
Bioanalyzer (Agilent Technologies, California, USA), using the Bioanalyzer RNA 6000 Nano 
assay (Figure S14). 
 
Libraries were sequenced on the Illumina MiSeq instrument (Illumina Inc., California, USA), 
using a 150 cycle to produce 2x75 bp paired end reads. Sequencing data was uploaded to the 
Illumina BaseSpace Sequencing Hub, which was used for FastQC quality control (Figure S15). 
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Read data was downloaded from BaseSpace for differential expression and fusion gene 
interrogation. 
 
2.8.2 Differential expression analysis 
To explore the differences in mRNA transcript expression in the K562 DasR samples, 
differential expression analysis was performed using the EdgeR pipeline (231), which was 
performed in RStudio version 1.1.447 using R version 3.5.0. The R script used can be found in 
the github repository found at: https://github.com/benleow/holy-grail 
 
Sequencing reads were aligned to the hg19 reference genome using the STAR aligner (232). 
Lowly expressed reads (<10 counts per million) were filtered out, and samples were 
normalised based on library size. Gene symbol names were annotated from the NCBI 
database. 
 
Hierarchical clustering dendrograms were generated based on the Euclidean distance 
between pooled sequencing samples, using Ward’s minimum variance method (Figure S16). 
Based on these results, samples were clustered into discrete groupings to perform differential 
expression analysis. The K562 10, 15 and 25 nM Das cell lines were grouped together, for 
comparison with naïve and DMSO treated K562 control samples (Figure S17). Similarly, the 
K562 50 and 200 nM Das samples were grouped for analysis (Figure S18). Differential 
expression analysis was then performed using the Linear Models for Microarray and RNA-seq 
Data (limma) package for R. A heatmap of the 100 most differentially expressed genes, as 
ranked by p-value, was generated from each sample grouping compared with the K562 
controls (Figures S19 and S20). Differentially expressed genes were also visualised with a 
volcano plot, highlighting genes with false discovery rate (FDR) <0.005, and log fold change 
(logFC) > 2 (Figure S21). 
 
2.8.3 FusionCatcher analysis of fusion gene transcripts 
To determine the novel genetic and transcriptional fusions associated with dasatinib 
resistance in the K562 DasR line, the FusionCatcher fusion gene detection tool was used, 
according to recommended guidelines (233). RNA sequencing reads were filtered, removing 
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reads aligning to ribosomal or transfer RNA, mitochondrial DNA, microorganism genomes, 
and the frequently spliced HLA genes. Adaptors and poly-nucleotide tails were trimmed. 
Reads were aligned to Ensemble genome annotations, and unmapped reads are kept for 
further analyses. Filtering steps enrich for reads which map to multiple genomic locations, 
such as fusion genes. To determine the fusion partners in the fusion gene, a list of candidate 
fusion partners is generated by aligning portions of the read to different genes. This 
preliminary list of candidate fusion genes is further filtered for paralogs, pseudogenes, micro 
RNA and transfer RNA, and other known false positive events such as conjoined HLA genes or 
overlapping genes. For increased sensitivity, the process is repeated four times using the 
Bowtie, BLAT, STAR and Bowtie2 aligners. A list of fusions and the amount of breakpoint 
supporting reads is provided as output. This output was manually interrogated for relevant 
fusions, and a figure of BCR-ABL1 fusions and the supporting read numbers was generated. 
 
2.9 Statistical analyses and generation of figures 
Statistical analyses for comparative analysis of cell viability, IC50, and qPCR replicate 
experiments was performed in GraphPad Prism version 7.0, using unequal variance t-test to 
account for expected differences in variance and number of sample replication. Figures were 
prepared using Microsoft Powerpoint version 16.17, before transfer to Microsoft Word 
version 16.17. Tables were prepared using Microsoft Excel version 16.17. 
  
 3-77 
3 Amplification and overexpression of the BCR-
ABL1 oncogene drives primary TKI resistance, 




Induced resistance to targeted chemotherapeutics in cell line models is a well-established 
method for the study of drug resistance mechanisms, including for kinase inhibition therapy 
in CML (182, 200). Using a K562 cell line model (K562 DasR), the gradual accumulation of TKI 
resistance was explored. Assays were performed to validate and quantify the level of 
dasatinib resistance. The K562 DasR cell line was previously generated in our laboratory (205). 
K562 cells were passaged over ~11 months, in concentrations of dasatinib increasing from 0.5 
to 200 nM (Figure 3.1). At each increment of dasatinib concentration, cells were expanded 
and stored for subsequent analysis. The K562 DasR line was already known to exhibit BCR-
ABL1 overexpression and the T315I mutation as dasatinib resistance mechanisms, and the 
later intermediates in dasatinib dose escalation are highly resistant to dasatinib. These 
findings were thoroughly investigated at the beginning of this study, firstly by determining 
the level of TKI resistance of cells following prolonged dasatinib culture, then by exploring in 
detail the known TKI resistance mechanisms in the cells. BCR-ABL1 expression was 
determined by RT-qPCR, and kinase domain mutations were determined by Sanger 
sequencing. 
 
The level of dasatinib resistance was quantitated using the TKI-induced cell death assay, 
which utilises AnnexinV / 7-AAD staining of cell death markers, to ascertain the dose 
escalation intermediates in which resistance to therapeutic concentrations of dasatinib was 
acquired. It was hypothesised that positivity for the T315I mutation would be the biggest 
predictor of dasatinib resistance in the K562 DasR dose escalation intermediates. Dose 
escalation intermediate cell line samples were chosen before and after acquisition of T315I 
for viability analysis (10, 15, 25, 50, 200 nM Das, DMSO vehicle control). In order to link 
dasatinib resistance to Bcr-Abl activity in the presence of TKI, and demonstrate the cell line’s 
dependence on Bcr-Abl for maintaining cell viability, selected dose escalation intermediates 
(2, 3.5, 5, 10, 15, 25, 50, 200 nM Das, DMSO control) were characterised by TKI pCrkL IC50 
(IC50Das). This was performed by utilising western blot analyses for phosphorylated CrkL, a 
marker of Bcr-Abl kinase activity (228). 
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Although BCR-ABL1 (p210) transcript overexpression had previously been demonstrated in 
the K562 DasR line (Figure 3.1), the cellular aberrations causing this overexpression were 
unclear. Duplication of the Philadelphia chromosome is a recognised mechanism of treatment 
resistance and disease progression in CML (234). Chromosome duplication is reflected by 
increases in the gene expression and protein production of the BCR-ABL1 gene, and excess 
oncoprotein can drive further proliferative signalling, leading to disease progression (10, 149). 
Understanding the mechanisms of BCR-ABL1 gene and protein overexpression is beneficial 
from a disease prognosis standpoint, and may direct the design of therapeutic strategies. 
Therefore, studies were performed to quantify the genomic levels of BCR-ABL1. DNA 
amplification was determined by qPCR using a FAM-TAMRA primer/probe set designed for 
quantifying the typical K562 BCR-ABL1 e14a2 genomic fusion breakpoint, and chromosomal 
abnormalities and BCR-ABL1 gene amplification were observed by fluorescence in situ 
hybridisation (FISH) using a BCR-ABL1 probe. 
 
The presumed level of Bcr-Abl protein increases coinciding with DNA amplification and gene 
expression had not previously been measured, nor had the phosphorylation and activation of 
downstream signalling partner proteins such as STAT5. The predicted increases in Bcr-Abl 
protein levels, coinciding with rising BCR-ABL1 transcript levels, were demonstrated by 
western blotting. Additionally, western blotting for phosphorylated Bcr-Abl (pAbl-Y245 and 
pBcr-Y177) was performed in selected intermediates to determine the association between 
gene expression and protein phosphorylation/activation. These were performed in gradient 
dasatinib and ponatinib. Expression and phosphorylation of the downstream signalling 
proteins STAT5 and CrkL was also simultaneously performed. 
 
Mutation of the Bcr-Abl gatekeeper residue, T315I, was previously demonstrated as a 
resistance mechanism occurring in the K562 DasR line (Figure 3.1), conferring complete 
resistance to the TKIs dasatinib, nilotinib, and imatinib (134). The third generation TKI, 
ponatinib, is often used as salvage for therapy-resistant patients expressing the T315I 
mutation. Though it was designed to inhibit T315I-mutated Bcr-Abl, significantly higher 
concentrations of ponatinib are required to inhibit Bcr-AblT315I, when compared to Bcr-Ablwt. 
There is also evidence that the gatekeeper residue mutation is kinase activating, resulting in 
increased transformative activity (160, 161). The T315I mutation was detected in the final 200 
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nM dasatinib line, with approximately 50% of BCR-ABL1 (e14a2) transcripts expressing the 
C944T (T315I) base pair change. The mutation was retrospectively found at a low level in the 
25 nM dasatinib intermediate (205). These data were replicated for validation. To detect 
presence of the T315I mutation at a low level, as might be expected with a minor population 
of T315I+ founder clones, additional Sequenom MassARRAY sequencing of the BCR-ABL1 
kinase domain was performed in selected K562 DasR intermediates. The Sequenom 
MassARRAY iPLEX platform utilises MALDI-TOF mass spectrometry to sensitively detect 
genetic mutations from PCR amplicons (235). 
 
The acquisition of severely limits treatment options in CML, for which the only clinically 
available TKI is ponatinib. Loss of ponatinib efficacy in the cells of these patients often results 
in refractory disease. Hence, it was of clear importance to determine the sensitivity of the 
dasatinib resistant K562 cell lines to ponatinib induced cell death. To quantify the level of 
cross-resistance to ponatinib, ponatinib-induced cell death and ponatinib pCrkL IC50 assays 
(IC50Pon) were performed in K562 DasR dose escalation intermediates. Again, K562 DasR 
intermediates before and after acquisition of T315I were analysed (10, 15, 25, 50, 200 nM 
Das, DMSO vehicle control). 
 
While the K562 DasR cell line used in these analyses provides an adequate backbone for 
exploring emergent drug resistance mechanisms, the continually evolving nature of the cell 
line does not allow for determining the effect on kinase activity of isolated point mutations, 
such as T315I. A genetically purer model was therefore required to explore the effect of single 
point mutations of BCR-ABL1. To explore the effect of the T315I mutation on Bcr-Abl kinase 
function in the presence of dasatinib and ponatinib, the HL60 p210 and T315I cell lines were 
analysed by IC50Das and IC50Pon. These lines were previously generated by transducing HL60 
cells with a pHIV-1SDm-based lentiviral vector containing both the EGFP gene and a BCR-
ABL1wt or BCR-ABL1T315I gene, respectively. These  were compared and contrasted with pCrkL 
IC50s calculated in the K562 DasR lines, to estimate the contribution of the T315I mutation to 





3.2.1 Dose escalation intermediates demonstrate gradual increases in resistance to 
dasatinib-mediated cell death 
The dasatinib-induced cell death assay data demonstrated the gradual accrual of dasatinib 
resistance in the K562 DasR line, evidenced by increasing IC50Das with ongoing passage in 
dasatinib. In the DMSO vehicle control line, cell viability was ablated by 100 nM dasatinib 
(Figure 3.3). However, this effect was attenuated in the K562 10 nM Das intermediate, and 
cells were significantly more viable that DMSO control (15% vs 48%, n=3, p=0.0057). Between 
the 10 and 15 nM Das intermediates, dasatinib resistance was significantly increased (48% 
viability vs 75%, n=3, p=0.0147). Complete dasatinib resistance was attained in the K562 25 
nM Das and later intermediates, which exhibit stable cell viability in all dasatinib 
concentrations up to 5000 nM. 
 
3.2.2 Bcr-Abl activity in K562 DasR resistance intermediates is maintained in the presence 
of dasatinib 
To investigate the contribution of Bcr-Abl kinase activity to acquired dasatinib resistance, 
levels of phospho-CrkL (a surrogate marker of Bcr-Abl activity) were measured in K562 DasR 
dose escalation intermediates and control cells. Summary data of pCrkL IC50Das demonstrate 
the gradual accrual of dasatinib resistance in the K562 DasR line (Figure 3.4). The dasatinib 
IC50 increases from 7.4 nM in the DMSO control to 37.5 nM in the K562 2 nM Das 
intermediate (n=4, p=0.0084). Between the 5 nM and 15 nM dasatinib intermediates, the IC50 
increases significantly to over 700 nM (29.5 vs 743 nM, n=3, p=0.004). Confirming the findings 
of dasatinib cell death assay experiments, Bcr-Abl kinase activity in the 25 nM and higher 
intermediates cannot be inhibited, even in the presence of 5000 nM dasatinib, an 
unachievable clinical plasma concentration. Taken together with dasatinib cell death data, 




3.2.3 K562 DasR cells acquire the T315I mutation following long term culture in dasatinib, 
conferring complete dasatinib resistance 
The presence of the Bcr-Abl T315I mutation in late-stage intermediates of the K562 DasR cell 
line correlated with complete dasatinib resistance. Sanger sequencing of the BCR-ABL1 kinase 
domain in the K562 DasR dose escalation intermediates investigated the timeline of the 
emergence of T315I (Figure 3.5). The mutation was undetectable in K562 naïve and DMSO 
control lines, as well as all K562 DasR dose escalation intermediates up to the 50 nM Das, in 
which C944T was detectable in ~30% of amplified transcripts. Sequencing results from the 
BCR-ABL1 transduced HL60 cell lines transcribing genetically pure BCR-ABL1 mutants are 
included for reference. 
 
Subsequent sequencing results from the more sensitive Sequenom MassARRAY platform 
demonstrated the emergence of the T315I mutation in the 25 nM Das intermediate, detected 
at very low frequency (0.5-2% of transcripts, Figure 3.5b). No other kinase domain mutations 
were detected. These data were consistent with previously published findings in the cell line 
(205). This suggests that a very low percentage of T315I expression is sufficient for the 
induction of dasatinib resistance. 
 
To demonstrate the direct effect of the T315I mutation on dasatinib TKI efficacy, the pCrkL 
IC50 assay was performed on BCR-ABL1 transduced HL60 lines harbouring wildtype (p210wt) 
or mutated (p210T315I) Bcr-Abl. HL60 cells expressing wildtype Bcr-Abl had a dasatinib IC50 of 
8.9 nM, however, in the HL60 line expressing T315I mutated Bcr-Abl, kinase activity could not 
be inhibited, even in 5000 nM dasatinib (Figure 3.6).  
 
3.2.4 BCR-ABL1 e14a2 gene overexpression contributes to early dasatinib resistance 
Data on expression levels of BCR-ABL1 in K562 DasR dose escalation intermediates 
demonstrate transient fluctuations in BCR-ABL1 gene expression (Figure 3.7). Over the course 
of dasatinib dose escalation, BCR-ABL1 expression in K562 DasR cells trended upward, with 
the 2 nM Das intermediate expressing over 12-fold higher expression than DMSO control 
(n=3, p=0.0224). Of the dasatinib resistant intermediates tested, BCR-ABL1 expression was 
highest in the 3.5 nM Das intermediate (13.9-fold increase over DMSO), however, due to large 
inter-assay variance, this did not reach statistical significance (n=3, p=0.0855). Interestingly, 
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over prolonged exposure to high concentration dasatinib, BCR-ABL1 expression decreased, 
with the final 200 nM Das line expressing significantly lower transcript levels than the 2 nM 
Das intermediate (3.8 vs 12.1, n=3, p=0.0221). DMSO exposure did not significantly affect 
BCR-ABL1 expression levels when compared with naïve K562 cells (1 vs 1.21, n=3, p=0.6809, 
data not shown). 
 
3.2.5 Bcr-Abl protein levels are higher in K562 DasR lines; increased kinase signalling likely 
leads to resistance 
Western blot analysis indicated an overexpression of Bcr-Abl protein in the K562 DasR dose 
escalation intermediates compared with control lines. Bcr-Abl protein levels increased in all 
intermediates compared with the DMSO-treated vehicle control (Figure 3.8). This was likely 
due to the increased BCR-ABL1 mRNA expression levels observed (Figure 3.7). Also confirming 
RT-qPCR data, Bcr-Abl protein expression levels peaked early in the course of dose escalation, 
reducing after prolonged and increased dasatinib exposure. Intriguingly, a second protein 
band was identified, which migrated faster than the typical 210 kDa (e14a2) Bcr-Abl band 
observed in the control cells. This smaller Abl band was present in varying levels in all K562 
DasR cells. The nature of this protein was further explored and is discussed in Chapter 4. 
 
Bcr-Abl phosphorylation and activation typically results in the downstream phosphorylation 
of signalling proteins to elicit proliferative activity. To determine the effect of TKI exposure 
on Bcr-Abl signalling pathway activation, three K562 DasR dose escalation intermediates were 
selected for investigation of Bcr-Abl phosphorylation status (pBcr Y177 and pAbl Y245), 
STAT5a/b activation, and phosphorylation of the CrkL adaptor protein (Figure 3.9). K562 5 nM 
DasR, K562 200 nM DasR and K562 DMSO control cells were exposed to gradient TKI (5, 20, 
200 nM dasatinib, 200 nM ponatinib, DMSO control). Results were concordant with pCrkL 
IC50Das data, demonstrating the K562 DasR lines’ continued activation of Bcr-Abl kinase 
signalling in the presence of TKI; this observation was particularly evident in the K562 200 nM 
DasR cells. In the 5 nM DasR intermediate, phosphorylation of Bcr Y177 was maintained in up 
to 20 nM dasatinib, although Abl (Y245) and CrkL (Y207) phosphorylation was inhibited with 
5 nM dasatinib. Additionally, total Bcr-Abl expression was higher in K562 DasR lines than in 
the DMSO control line. Once again, the multiple apparent Bcr-Abl isoforms were observed in 
both K562 DasR lines, but not in the DMSO vehicle control. Total STAT5 protein levels 
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remained unchanged across all samples, however, phosphorylation of STAT5 was increased 
in DasR lines, likely indicative of increased Bcr-Abl signalling. Confirming dasatinib IC50 
results, the 200 nM Das line remained kinase active in all dasatinib concentrations, however, 
kinase activity was ablated following two hours exposure to 200 nM ponatinib. 
 
3.2.6 Genomic BCR-ABL1 e14a2 copy increase coincides with increased BCR-ABL1 e14a2 
mRNA levels and acquisition of TKI resistance 
DNA qPCR for BCR-ABL1 copy number analysis showed a strong trend with both mRNA and 
protein expression levels, indicating that genomic amplification of the BCR-ABL1 gene is likely 
causative of gene and protein overexpression (Figure 3.10). When normalised to PCR 
amplification of GUSB, the genomic level of BCR-ABL1 quickly increased from 7.5% in the K562 
DMSO line to 71% in the 2 nM DasR intermediate (n=3, p<0.0001). Note this is a relative 
expression level, and there is differential PCR amplification efficiency between GUSB and BCR-
ABL1. BCR-ABL1 copy number per cell is maximal in the 3.5 nM DasR intermediate, however, 
decreased significantly in the 5 nM DasR intermediate (102% vs 48.2%, n=3, p=0.001). BCR-
ABL1 DNA levels then fluctuated over the remainder of TKI dose escalation, transiently rising 
again in the 10 nM DasR intermediate, then falling with ongoing TKI exposure, such that BCR-
ABL1 levels were significantly lower in the final 200 nM DasR line (10 nM vs 200 nM, 69.7% vs 
28.4%, n=3, p=0.014). 
 
To investigate whether increased BCR-ABL1 expression was associated with duplication of the 
Philadelphia chromosome or the addition of extrachromosomal elements, FISH analyses of 
BCR-ABL1 gene fusions were performed in selected K562 DasR lines (Figure 3.11). Both 
interphase and metaphase spreads of K562 200 nM Das line indicated BCR-ABL1 amplification 
occurred following prolonged dasatinib exposure. Notably, metaphase spreads revealed that 
gene amplification occurred within the original Philadelphia chromosome locus and was not 
present throughout the genome or on extrachromosomal elements. 
 
3.2.7 Dasatinib resistant cells exhibit lowered ponatinib-induced cell death 
Given ponatinib is often used as salvage therapy in dasatinib-resistant disease, cross-
resistance to ponatinib was examined in K562 DasR. Data from ponatinib cell death assays in 
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dose escalation intermediates demonstrated decreases in ponatinib sensitivity coinciding 
with loss of dasatinib sensitivity (Figure 3.12). In the presence of 10 nM ponatinib, K562 10 
nM DasR cells were significantly more viable than DMSO control cells (86% vs 23.6%, n=3, 
p=0.0007). However, unlike dasatinib sensitivity, decreases in ponatinib sensitivity did not 
occur linearly, and ponatinib resistance was not maximal in the 200 nM DasR line. Indeed, 
ponatinib resistance peaked in the 15 nM DasR intermediate, which upon culture in 50 nM 
ponatinib (a typical peak plasma concentration) was 63% viable, compared with 13% viable 
in the 200 nM DasR line in the same ponatinib concentration (n=3, p=0.0002). Importantly, 
all K562 DasR intermediates exhibited lower sensitivity to ponatinib than the DMSO vehicle 
control line, suggesting that the acquired dasatinib resistance mechanisms, such as 
overexpression of Bcr-Abl, also confer a loss of sensitivity to ponatinib. 
 
3.2.8 K562 DasR dose escalation intermediates exhibit lower ponatinib IC50, and is not 
entirely dependent of %T315I 
Ponatinib IC50 data in K562 DasR dose escalation intermediates supported cell death assay 
findings. All K562 DasR dose escalation intermediates exhibited ponatinib tolerance 
compared with vehicle control (Figure 3.13). As observed in cell death assay experiments, 
ponatinib sensitivity was lower in all K562 DasR lines when compared with DMSO control 
cells, and lowest in the 10 and 15 nM DasR intermediates (101 and 99 nM Das, respectively; 
p<0.01). Correlating with ponatinib cell death assay data, the 25, 50 and 200 nM DasR lines 
trended towards higher ponatinib sensitivity than the 10 and 15 nM Das intermediates, 
however, this did not reach significance. 
 
3.2.9 HL60 cells harbouring Bcr-Abl with the T315I mutation are less sensitive to 
ponatinib-based kinase inhibition 
While ponatinib was designed to inhibit T315I mutated Bcr-Abl, it has been previously 
demonstrated that it does so with lesser activity (138). To quantify the effect of the T315I 
mutation on ponatinib efficacy, HL60 cells harbouring Bcr-AblT315I were subjected to ponatinib 
IC50 (IC50Pon). Summary IC50Pon data from HL60 lines reiterated previous findings: while 
ponatinib was able to effectively inhibit T315I-mutated Bcr-Abl, it did so with lower efficacy 
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(Figure 3.14). Ponatinib IC50 calculated for wildtype Bcr-Abl was 9.4 nM ponatinib, compared 
with 59.3 nM for Bcr-Abl harbouring T315I (n=3, p=0.0095). 
 
3.3 Discussion 
The K562 DasR cell line was generated in our laboratory and preliminary experiments 
identified BCR-ABL1 overexpression and the T315I mutation as mechanisms of resistance 
(205). In the current study, a comprehensive interrogation of dose escalation intermediates 
validated these findings, allowing confident use of the model. 
 
The emergence of the T315I mutation in the 25 nM Das intermediate coincided with the gain 
of complete dasatinib resistance, as demonstrated by both dasatinib-induced cell death and 
pCrkL IC50Das results. Furthermore, the lack of dasatinib response in the 25 nM Das 
intermediate indicated that each cell in the population harboured and expressed T315I 
mutated Bcr-Abl. Consistency between cell death assay and pCrkL IC50 assay results indicated 
that the cell line remained dependent on Bcr-Abl kinase activity for proliferation and survival. 
 
3.3.1 Unknown mechanisms contribute to TKI resistance in the K562 10 and 15 nM DasR 
intermediates 
In the DasR intermediate prior to acquisition of T315I (K562 15 nM DasR), the increased 
IC50Das indicated a comparative decrease in sensitivity to dasatinib. Previously published BCR-
ABL1 RT-qPCR data (205) suggested this was a result of increased BCR-ABL1 gene and protein 
expression. However, IC50Das in the 10 and 15 nM DasR intermediates was significantly higher 
than the 2, 3.5 and 5 nM DasR intermediates, despite DNA BCR-ABL1 qPCR and RT-qPCR data 
demonstrating no further increases in BCR-ABL1 expression or genomic amplification. 
Additionally, IC50Pon and cell death assays demonstrated that ponatinib sensitivity was lowest 
in the 10 and 15 nM DasR intermediates. IC50Pon values calculated from retrovirally 
transformed HL60 p210wt vs HL60 p210T315I cells indicated that gatekeeper residue mutation 
conferred a significantly higher IC50Pon compared with T315I mutation-harbouring cells. 
Based on these observations, it was expected that the K562 50 nM and 200 nM DasR lines 
would be less sensitive to ponatinib than earlier intermediates not harbouring T315I. The 
unexpectedly high IC50Pon in the 10 and 15nM DasR intermediates suggested that resistance 
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mechanisms, in addition to either T315I or Bcr-Abl overexpression, were present in the 
intermediate lines, but not in the final resistant lines. While the IC50Pon in the 50 and 200 nM 
Das intermediates were not significantly lower than the 10 and 15 nM Das intermediates, 
they were comparatively sensitive to ponatinib. The lack of significance may be attributable 
to the wide variance in individual IC50 values, due to a combination of fluctuating biological 
and experimental batch effects. To explore the resistance mechanisms at play in the dasatinib 
escalation intermediates, K562 DasR samples were selected for transcriptome sequencing 
analysis, the results of which are detailed in Chapters 4 and 5. 
 
3.3.2 Bcr-Abl expression and TKI resistance 
DNA qPCR, RT-qPCR, and western blotting experiments demonstrated early increases in Bcr-
Abl gene and protein levels; prolonged and increased dasatinib exposure resulted in 
decreased Bcr-Abl expression levels. Correlation between increases in BCR-ABL1 DNA 
content, and mRNA and protein expression levels, indicated that the primary mode of 
overexpression was driven by gene amplification. The mechanisms of gene duplication have 
been well studied (236, 237). The use of FISH analysis of K562 DasR cells revealed the tandem 
duplication of the BCR-ABL1 gene within the original Philadelphia chromosome locus, which 
coincided with increased mRNA gene expression. However, to our knowledge, the rapid loss 
of BCR-ABL1 DNA copy number has not been previously observed, and it is hypothesised that 
this was the result of the expansion and outgrowth of a leukaemic clone which had lower 
BCR-ABL1 content, but which harboured an alternate, unknown dasatinib resistance 
mechanism. As the protein driver of oncogenesis and cellular proliferation in CML, Bcr-Abl 
levels often increase alongside disease progression, and there is a strong selective pressure 
for cells harbouring multiple copies of the fusion gene. However, our data suggest that while 
increased Bcr-Abl expression did contribute to TKI resistance, this effect was self-limiting; Bcr-
Abl levels did not continue rising with prolonged TKI exposure. Our data also suggest there is 
an upper limit to the amount of Bcr-Abl a leukaemic clone can express and/or tolerate. Under 
dasatinib selective pressure, emergence of alternate resistance mechanisms such as T315I 
allowed these leukaemic clones to efficiently outcompete the BCR-ABL1 overexpressing cells. 
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3.3.3 Bcr-Abl isoforms and TKI resistance 
Western blot analyses of Bcr-Abl kinase and downstream signalling partners in K562 DasR 
dose escalation intermediates provided insight into Bcr-Abl activity in the presence and 
absence of TKI. As expected, Bcr-Abl kinase phosphorylation was associated with the 
phosphorylation of downstream partner, STAT5, as well as the adaptor protein CrkL. 
Additionally, a smaller band binding both Bcr and Abl antibodies was demonstrated in K562 
DasR dose escalation intermediates. It was possible that this band represented a smaller Bcr-
Abl fusion, similar to the p190 (e1a2) fusion observed in cases of Ph+ ALL, an aggressive 
lymphoid malignancy. There was a critical need to identify this Bcr-Abl isoform. While the 
contribution of this isoform to TKI resistance was not determined, the smaller fusion likely 
contributed to overall Bcr-Abl overexpression and kinase activity, even if the truncated fusion 
was not inherently less sensitive to TKI-based inhibition. Interestingly, phosphorylation of the 
smaller Bcr-Abl isoform would also allow Bcr-Abl harbouring the T315I mutation to 
phosphorylate wildtype Bcr-Abl, thereby maintaining protein kinase activation. In addition, 
the smaller Bcr-Abl fusion may confer the protein an alternate cell signalling profile. The 
delineation of this Bcr-Abl isoform and its contribution to TKI resistance was explored further 
in Chapter 4. 
 
3.3.4 Chapter summary 
The experiments presented here demonstrate that the K562 DasR model of TKI resistance 
accurately represents clinical observations TKI resistance mechanisms. BCR-ABL gene 
overexpression was validated in dose escalation intermediates, and correlated with gene 
duplication within the Philadelphia chromosome. The resultant Bcr-Abl protein 
overexpression allowed continuing activation of downstream signalling in moderate TKI 
concentrations, and protein visualisation identified a smaller Bcr-Abl fusion which was further 
explored. Determination of T315I mutation status was associated with loss of dasatinib 
sensitivity, as well as lowered ponatinib sensitivity, however the concurrent measurement of 
TKI sensitivity suggested alternate resistance mechanisms in the K562 10 and 15 nM DasR 
intermediates. Clonal selection of the cell line was observed and indicated that while Bcr-Abl 
overexpression is sufficient in lower TKI concentrations, other resistance mechanisms were 
more advantageous or necessary in higher concentrations. Experimental repetition will 
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determine whether these are stochastic events, or whether the selective pressures 






$&.(O!<+,/! ,(',(/(.%!06>@!(Z',(//&).!)H! %-(!)*+3,)-.# H#/&).! %7'&*+$$7!(Z',(//(5!27!8XWL!
*($$/G!(NT+LO!6(/#$%/!5(0)./%,+%(!%-(!U,+5#+$! &.*,(+/(!)H!)*+3,)-.!(Z',(//&).G!'(+;&.U! &.!
%-(! SOX! ."! e+/! &.%(,0(5&+%(G! 2(H),(! H+$$&.U! /&U.&H&*+.%$7! &.! %-(! X! ."! e+/! &.%(,0(5&+%(O!
C.'+&,(5! %Q%(/%! 4+/! '(,H),0(5! 2(%4((.! 5)/(! (/*+$+%&).! &.%(,0(5&+%(/h! /&U.&H&*+.*(! &/!
5(.)%(5!27!_„a!H),!'tMOMXO!@55&%&).+$$7G!%-(!'(,*(.%+U(!)H!3SNX9!0#%+%(5!)*+3,)-.!(NT+L!
%,+./*,&'%/!&/!/-)4.!).!%-(!$&.(!U,+'-O!I&,/%!5(%(*%(5!&.!%-(!LX!."!e+/!&.%(,0(5&+%(G!f3SNX9!






Figure 3.2: Flow chart of the generation of the K562 DasR cell line and dasatinib dose 
escalation intermediates, and experiments performed for quantitation of TKI resistance, and 




































• Quantify TKI resistance of K562 DasR intermediate
• pCrkL IC50 (das/pon)
• Cell death assay (das/pon)
• Examine Bcr-Abl expression levels
• Protein western blotting
• Gene expression qPCR
• Genomic DNA qPCR
• Kinase domain mutation screening (T315I)
• Sanger sequencing
• MassARRAY screening
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Figure 3.3: K562 cells cultured in dasatinib exhibit decreased sensitivity to dasatinib induced 
cell apoptosis. a) Cell viability of K562 DasR dose escalation intermediates cultured in gradient 
dasatinib for 72 h. Values indicate mean -/+ SEM of at least 3 independent replicate 
experiments. Unequal variances t-test was performed between dose escalation 
intermediates at each dasatinib concentration; significance is denoted by (*) for p<0.05, (**) 
for p<0.01. b) Representative data of AnnexinV (x-axis) / 7-AAD (y-axis) co-staining for cell 
viability in 0, 100 and 5000 nM dasatinib. Percent viable cells (AnnexinV / 7-AAD negative) 






















Figure 3.4: a) Dasatinib IC50 data for K562 dose escalation intermediates, based on loss of 
phosphorylated (Phospho-) CrkL. Data confirms that prolonged culture in increasing doses of 
dasatinib coincides with a decrease in dasatinib sensitivity. Whiskers indicate mean -/+ SEM 
of at least 3 independent replicate experiments. Unequal variances t-test was performed 
between dose escalation intermediates; significance is denoted by (**) for p<0.01, (***) for 
p<0.001. b) Representative dasatinib pCrkL IC50 western blotting. Samples are selected K562 
DasR dose escalation intermediates; red arrows indicate the approximate point of 50% Bcr-
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Figure 3.8: Western blotting analysis of total c-Abl from NP40 lysates in K562 DasR dose 
escalation intermediates. Results indicate an increase in Bcr-Abl expression concurrent with 
increasing dasatinib concentration levels, as well as the emergence of at least one additional 
Bcr-Abl isoform, appearing ~10-20 kDa smaller than the typical 210 kDa (BCR-ABL1 e14a2) 
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Figure 3.11: Representative interphase (upper half) and metaphase (lower half) FISH analyses 
of K562 200 nM Das and DMSO control lines revealed genomic BCR-ABL1 amplification. 
Increased BCR-ABL1 signal in metaphase spreads of K562 200 nM Das line (lower right) 
indicate that gene amplification has occurred. The condensed signal suggests that 
amplification occurred within the original BCR-ABL1 locus on the Philadelphia chromosome, 
and not on extrachromosomal elements. Green = BCR, red = ABL1. 
  




Figure 3.12: K562 cells cultured in ponatinib exhibit decreased sensitivity to ponatinib induced 
cell apoptosis. Cell viability of K562 DasR dose escalation intermediates cultured in gradient 
ponatinib for 72 h as determined by Annexin V / 7-AAD staining. Values indicate mean -/+ 
SEM of at least 3 independent experiments. Unequal variances t-test was performed between 
dose escalation intermediates at each ponatinib concentration; significance is denoted by 
(***) for p<0.001. 
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4 The e6a2 BCR-ABL1 isoform arises in response to 
dasatinib exposure; cells expressing e6a2 are 




Results from the previous chapter indicated that in addition to Bcr-Abl overexpression and 
T315I, the K562 DasR cell line harboured resistance mechanisms which had not yet been 
elucidated. Transcriptome sequencing has been described as the gold standard for the 
determination of the cellular adaptations involved in drug resistance (238). This method can 
reveal the genetic mechanisms of drug resistance, as well as suggest novel drug targets to re-
sensitise leukaemic cells to treatment (239). To determine the cellular adaptations occurring 
over dasatinib dose escalation, the K562 10, 15, 25, 50, and 200 nM Das intermediates were 
sampled for exploratory mRNAseq experiments, along with the DMSO treated and TKI naïve 
K562 controls. 
 
The mRNAseq data generated was interrogated using several analytical methods, including 
measurement of global gene expression changes, identification of single nucleotide variants, 
and identification of chimeric fusion gene transcripts, such as BCR-ABL1 and its isoforms. To 
determine the fusion genes present in transcriptome analysis samples, the FusionCatcher 
fusion gene finder software tool was used. The FusionCatcher algorithm aligns reads using 
Bowtie, BLAT, STAR and Bowtie2 programs, compiling unmapped reads as evidence for 
candidate gene fusions, mapping the two gene halves of the read to separate genetic 
elements (233). A summarised list of genetic fusions and the number of supporting reads is 
provided as output. Using this method, the BCR-ABL1 e6a2 fusion was identified. Presence of 
the fusion was detected in all of the K562 DasR intermediate lines sampled for transcriptome 
sequencing, however, was not present in the drug naïve controls. 
 
Following identification of the e6a2 fusion, the following research questions regarding e6a2 
required addressing:  
1. What is the transcriptional expression of BCR-ABL1 e6a2 in the K562 DasR cell line? 
2. Is the e6a2 transcript the result of a gene splicing isoform or a de novo genomic breakpoint? 
3. Does the e6a2 isoform harbour kinase domain mutations? 
4. What is the contribution of e6a2 to TKI resistance? Does expression of e6a2 confer a 
selective advantage from increased kinase activity in the presence of dasatinib? 
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Prior to the identification of e6a2 in K562 DasR resistant lines, only the typical isoform of 
e14a2 (b3a2, p210), had been quantitated by standard diagnostic tests. The BCR-ABL1 RT-
qPCR performed previously was specific for the e14a2 transcript, and PCR for BCR-ABL1 kinase 
domain sequencing amplified only e14a2. Bcr-Abl western blot analysis of K562 DasR dose 
escalation intermediates had suggested an alternate and distinct Bcr-Abl fusion, and 
identification of the e6a2 fusion transcript allowed genetic analyses to be performed. To 
validate the presence of the e6a2 transcript, PCR forward primers were designed within BCR 
exon 5, as well as spanning the e6a2 breakpoint junction, designed for use with the existing 
reverse primer used in BCR-ABL1 e14a2 kinase domain amplification. Primers were used with 
K562 DasR dose escalation cDNA samples to amplify e6a2 transcripts present. The PCR 
products were sequenced for detection of ABL1 kinase domain mutations. To quantify mRNA 
expression of the alternate e6a2 transcript, RT-qPCR primers were designed to amplify e6a2. 
These were used in a SYBR Green qPCR system to quantify the relative BCR-ABL1 expression 
in K562 DasR dose escalation intermediates. Ct values were normalised to the endogenous 
control gene, GUSB. 
 
The expression of the e6a2 transcript may have resulted from a number of different cellular 
events, i.e. an alternative splicing product, a de novo chromosomal fusion, or intra-
chromosomal deletion of an existing BCR-ABL1 fusion. Determination of the DNA breakpoint 
location would provide evidence for the origin of the e6a2 transcript, and furthermore, allow 
the qPCR determination of relative copy number levels. To achieve this, target enrichment 
DNA sequencing was performed in selected K562 DasR samples, using the Agilent SureSelect 
Target Enrichment system (240). Genomic DNA was extracted from K562 DasR samples and 
fragmented to ~300 bp, and fragments harbouring BCR-ABL1 sequences were pulled down 
using a panel of probes spanning genomic ABL1 and BCR sequences, designed by Dr Ilaria 
Pagani (SAHMRI Cancer Theme). 150 bp paired end read sequencing was performed by Mark 
Vanderhoek (SAHMRI Genomics Core Facility). Data generated was analysed using the 
FACTERA program (241) with the assistance of Dr Chung Kok and Dr Benjamin Mayne 
(SAHMRI Cancer Theme). In this method, discordant reads are used to locate genomic regions 
involved in potential fusions, followed by an in silico validation whereby the number of 
supporting reads gives confidence to the determined breakpoints. The determination of the 
e6a2 BCR-ABL1 DNA fusion breakpoint allowed the subsequent qPCR quantification of the 
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genomic BCR-ABL1 levels. To achieve this, a TaqMan MGB primer/probe combination 
spanning the e6a2 junction was designed, with the assistance of Dr Ilaria Pagani. PCR Ct values 
were normalised to amplification of the endogenous control gene GUSB. A standard curve 
was generated using a plasmid harbouring the GUSB sequence, such that absolute genomic 
volumes could be quantified. BCR-ABL1 e6a2 levels are reported as a percentage of GUSB 
genetic quantities. 
 
The determination of BCR-ABL1 expression and amplification levels suggested that expression 
of the e6a2 BCR-ABL1 isoform was selected over dasatinib dose escalation. This may be due 
to the e6a2 isoform having inherently elevated TKI resistance, or providing an associated 
proliferative advantage due to differential signalling pathway activation. To further explore 
these possibilities, we tested the BCR-ABL1 isoforms: e14a2, e6a2, and e1a2, using the Ba/F3 
transformation assay popularised by Daley and Baltimore (14). Attempts to clone the e14a2 
and e6a2 sequences from K526 DasR cDNA samples were unsuccessful, thus the BCR-ABL1 
e14a2 sequence was purchased from the plasmid repository, Addgene (225). The e6a2 
sequence was generated via site directed mutagenesis and inserted into the multiple cloning 
site of the lentiviral pRuf-iG-2 lentiviral expression vector (242). Lentiviral vectors were 
transfected into HEK-293T cells and viral particle supernatant was used to infect Ba/F3 murine 
pro-B cells. The Ba/F3 cell line is typically dependent on a source of murine IL-3 for growth 
factor-dependent survival and proliferation (226). Transduction with an oncogenic driver 
gene, such as BCR-ABL1, confers the cell line growth factor-independent survival. Validation 
of BCR-ABL1 expression was performed by BCR-ABL1 RT-qPCR using a SYBR green PCR 
platform. This was again normalised to expression of the endogenous control gene, GUSB. 
Bcr-Abl kinase activity in the cell lines were validated using western blotting for 
phosphorylation of Bcr-Abl kinase substrate, CrkL. To test for TKI resistance associated with 
expression of BCR-ABL1 e6a2, the pCrkL IC50 and TKI-induced cell death assays were 




4.2.1 Identification of an alternate BCR-ABL1 transcript in K562 DasR cell line 
transcriptome samples 
To determine potential resistance mechanisms in the K562 DasR cell line, transcriptome 
analysis of K562 DasR dose escalation intermediates was performed. Using the FusionCatcher 
fusion detection program, several fusion gene transcript breakpoints were detected over 
several genes. After filtering the detected transcripts for BCR-ABL1 breakpoints, several 
transcript isoforms were identified in the various K562 DasR and control lines (Table 4.1). 
Among those identified was the BCR-ABL1 e14a2 transcript, which as expected, was found in 
all K562 samples. Additionally, a BCR-ABL1 breakpoint corresponding with the rare e6a2 
transcript was also identified, however only in the dasatinib resistant samples tested (K562 
10, 15, 25, 50, 200 nM Das). The number of e6a2 breakpoint spanning reads was comparable 
to that of e14a2, indicating that this was not a spurious, lowly expressed transcript. To confirm 
the presence of the e6a2 transcript, primers were designed flanking the breakpoint for use 
with PCR, qPCR, and sequencing validation. 
 
4.2.2 The BCR-ABL1 e6a2 fusion is expressed in the K562 DasR cell line 
Validation of the e6a2 BCR-ABL1 fusion transcript was performed by PCR and gel 
electrophoresis (Figure 4.1). Unlike the LongF0810 forward primer used in PCR amplification 
of the BCR-ABL1 e14a2 fusion in Chapter 3, the primer pair used here were designed 
specifically to amplify e6a2. Primers were based on sequencing information derived from 
mRNAseq experiments (ABLe5F, LongR0510). Amplification products indicated a 1994 bp 
band corresponding to the presence of the e6a2 fusion in K562 DasR lines, and a 2855 bp 
band corresponding to the typical BCR-ABL1 e14a2 fusion. Interestingly, an unidentified band 
of approximately 2500 bp was also identified in DasR lines; the significance of this band is 
discussed. The K562 DMSO control line harboured only the e14a2 fusion. Amplification 
products from alternate primers (e6a2breakpoint, LongR0510) resulted in a single 1652 bp 
band in both 10 and 200 nM DasR lines, corresponding to presence of e6a2. Again, the K562 
DMSO line demonstrated no evidence of the e6a2 isoform. 
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Following successful demonstration of the presence of the e6a2 fusion in two K562 DasR dose 
escalation intermediates, the presence of this isoform was ascertained in all remaining K562 
DasR intermediates. PCR amplicon analysis indicated that the e6a2 fusion first appeared in 
the K562 2 nM DasR intermediate, and remained in all later K562 DasR intermediates, 
including the final 200 nM Das line (Figure 4.2). Again, the naïve and DMSO control K562 lines 
demonstrated no expression of BCR-ABL1 e6a2. 
 
4.2.3 The BCR-ABL1 e6a2 fusion expressed by K562 DasR lines does not harbour kinase 
domain mutations 
Kinase domain sequencing previously performed was specific to e14a2 transcripts (Chapter 
3). Following validation of the presence of e6a2 in K562 DasR lines it was necessary to 
ascertain whether the BCR-ABL e6a2 transcripts also harboured kinase domain mutations. 
However, sequence analyses demonstrated the complete absence of kinase domain 
mutations, including the already identified T315I mutation (Figure 4.3), in e6a2 transcripts 
from any of the K562 DasR lines. 
 
4.2.4 Expression of the BCR-ABL1 e6a2 fusion gene transcript is selected for following 
prolonged culture in dasatinib 
Similarly, transcriptional mRNA expression was previously measured in e14a2 BCR-ABL 
transcripts only (Chapter 3.2.4). Therefore, it was also necessary to quantify the expression 
of BCR-ABL1 e6a2 transcripts in K562 DasR dose escalation intermediates. As the e6a2 fusion 
was not expressed by the K562 naïve or DMSO vehicle control lines, a ddCt value (fold change) 
could not be calculated. As such, data are reported as a -dCt value, normalised to GUSB 
expression; the background e6a2 amplification in K562 controls was set at 0 (Figure 4.4). RT-
qPCR results demonstrated the first significant expression of the e6a2 fusion in the 2 nM Das 
intermediate, with higher relative expression than DMSO control (0 vs 8.7, n=3, p<0.001). 
Expression continued to rise with ongoing dasatinib dose escalation, peaking in the K562 10 
nM DasR line (8.7 vs 16.4, n=3, p=0.027). However, further dasatinib dose escalation did not 
result in consistent increases in e6a2 gene expression, and no further significant differences 
were observed beyond the 10 nM DasR intermediate. 
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4.2.5 Expression of the BCR-ABL1 e6a2 transcript is due to a genomic e6a2 fusion 
To determine the origin of the e6a2 transcript, target enrichment DNA sequencing of ABL1 
and BCR sequences was performed in genomic samples from K562 DasR samples (15 and 200 
nM Das, naïve K562 control). FACTERA analysis for gDNA breakpoint analysis revealed that 
expression of the e6a2 fusion transcript was due to unique chromosomal fusion, distinct from 
the e14a2 fusion in the dasatinib naïve K562 control line (Table 4.2). K562 15 and 200 nM 
DasR lines both harboured two distinct BCR-ABL1 fusions, corresponding to e14a2 and e6a2 
genomic breakpoints, whereas the drug naïve K562 line harboured only e14a2. Whereas the 
e14a2 5’ BCR breakpoint is in BCR intron 14, the e6a2 BCR breakpoint is in intron 6. Both 
e14a2 and e6a2 3’ ABL1 breakpoint locations are within ABL1 intron 1, however, at different 
locations (Figure 4.5). Due to regions of homology between the BCR and ABL1 breakpoint 
regions, FACTERA analysis called different breakpoints between the lines, differing in location 
by 1-5 nucleotides; an inherent caveat of the program. Two alternate BCR fusions were also 
identified, fused 5’ to VWF and XKR3, however these were not further explored due to the 
low supporting read numbers. 
 
To validate the e6a2 DNA breakpoint location, PCR primers were designed flanking the 
breakpoint, amplifying a predicted 741 bp product. Gel electrophoresis of selected K562 DasR 
lines identified the fusion in dasatinib resistant lines, but not in K562 control (Figure 4.6). The 
e6a2 PCR amplicon was verified by Sanger sequencing, aligning to genomic BCR and ABL1 
sequences (Figure 4.7), which identified the breakpoint to single nucleotide specificity. This 
sequence was used for the design of primers in follow up experiments. 
 
4.2.6 Increased expression of the BCR-ABL1 e6a2 fusion in K562 DasR cells is driven by 
genomic amplification of the fusion gene 
Following identification of the e6a2 genomic BCR-ABL1 breakpoint, the relative genomic copy 
number of BCR-ABL1 e6a2 was quantified in K562 DasR dose escalation intermediates. 
Following confirmation that the nucleotide sequence did not occur elsewhere in the genome, 
DNA samples from K562 DasR dose escalation intermediates were interrogated for genomic 
BCR-ABL1 e6a2 expression (Figure 4.8). Normalised to the amplification of GUSB, the genomic 
quantity of BCR-ABL1 e6a2 increased significantly, from undetectable levels in the K562 
DMSO control line to 57% in the 5 nM DasR intermediate (p=0.006, n=3). Genomic BCR-ABL1 
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e6a2 levels again significantly increased to 92% in the 10 nM DasR line (p=0.006, n=3), before 
significantly falling to 5% in the 15 nM DasR intermediate (p<0.001, n=3). However, with 
increasing dasatinib escalation, genomic levels of BCR-ABL1 e6a2 again rose to 37% in the 
final 200 nM DasR resistant line (p=0.001, n=3). 
 
Taken in conjunction with BCR-ABL1 e6a2 RT-qPCR analysis, as well as Bcr-Abl western 
blotting (Chapter 3), results suggest that expression of e6a2 is clonally selected for, though 
only during some stages of dasatinib dose escalation. 
 
4.2.7 Expression of the BCR-ABL1 e6a2 fusion is transforming in Ba/F3 cells 
To assess the inherent TKI resistance of the Bcr-Abl e6a2 fusion product, Ba/F3 cells 
transformed with vectors containing e14a2 or e6a2 BCR-ABL1 were studied using TKI 
sensitivity assays. Empty pRuf-iG2 vector and BCR-ABL1 e1a2 transformed lines were 
concurrently generated as experimental controls. An outline of the generation of the Ba/F3 
BCR-ABL1 e14a2, procedure can be found in Chapter 2.4. The correct size of the BCR-ABL1 
insert in each vector was confirmed by restriction enzyme digest, and the full length BCR-
ABL1 sequence was validated by Sanger sequencing. 
 
Fluorescence of eGFP, indicative of gene of interest expression, was measured in cells by light 
and eGFP microscopy (Figure 4.9). Results indicated the eGFP positivity of all pRuf-iG2 
transduced Ba/F3 lines, indicative of successful gene transduction. Transformation of Ba/F3 
cells was confirmed by the withdrawal of WEHI-3B conditioned media containing IL-3. Cells 
transformed with BCR-ABL1 constructs maintained viability in the absence of IL-3. Conversely, 
IL-3 withdrawal from the empty vector control cells resulted in a complete loss of viability. 
Cells were enriched by flow assisted cell sorting (FACS) for eGFP positivity. 
 
Transformation was further confirmed by western blot analyses assessing phosphorylation of 
the Bcr-Abl kinase substrate, CrkL (Figure 4.10). In the Ba/F3 empty vector control line, no 
phosphorylation of CrkL was evident; conversely, CrkL in BCR-ABL1 transduced Ba/F3 cell lines 
was almost fully phosphorylated. Unfortunately, Bcr-Abl protein levels were unable to be 
directly measured, with c-Abl western blotting not demonstrating detectable Bcr-Abl in Ba/F3 
lines. However, levels of BCR-ABL1 transcript expression were quantified by RT-qPCR for the 
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e14a2, e6a2 and e1a2 transcripts (Table 4.3). Results demonstrated the purity of expression 
for each cell line, with appropriate amplification of transcripts. 
 
4.2.8 Ba/F3 cells expressing BCR-ABL1 e6a2 are more resistant to dasatinib-induced cell 
death than those expressing BCR-ABL1 e14a2 
To determine whether the e6a2 fusion conferred an inherent dasatinib resistance advantage 
over e14a2, Ba/F3 cells expressing BCR-ABL1 e14a2, e6a2, or e1a2, or an empty vector 
control, were cultured in dasatinib for 72 h, before co-staining with AnnexinV / 7-AAD and 
flow cytometric analysis. Results demonstrated that while all three cell lines were sensitive to 
some level of dasatinib induced cell death, Ba/F3 cells harbouring BCR-ABL1 e6a2 were less 
sensitive to dasatinib induced cell death than Ba/F3 harbouring e14a2 (Figure 4.11). In the 
absence of dasatinib, there were no significant differences between cell viability between all 
three BCR-ABL1 expressing lines. However, following culture in 3 nM dasatinib, the Ba/F3 
BCR-ABL1 e6a2 line was significantly more viable than Ba/F3 BCR-ABL1 e14a2 (71.2 vs 32.8% 
n=3, p=0.023). In dasatinib concentrations above this, no significant differences in cell viability 
were observed, as the cell lines approached 100% cell death. The level of dasatinib 
susceptibility in BCR-ABL1 e6a2 expressing cells was similar to those expressing BCR-ABL1 
e1a2 (p190), with no significant differences in viability between e6a2 and e1a2 at any 
dasatinib concentration tested. 
 
4.2.9 The Bcr-Abl e6a2 fusion is not more resistant to dasatinib-induced kinase inhibition 
than Bcr-Abl e14a2 
Having demonstrated that cells expressing e6a2 are more resistant to dasatinib induced cell 
death, the phospho-CrkL IC50 assay was performed to determine whether the variations in 
resistance were due to differences in TKI induced kinase inhibition. Results indicated that the 
e6a2 kinase was not more resistant to dasatinib than e14a2 (Figure 4.12). The IC50Das for Bcr-
Abl e6a2 was in fact lower than that for Bcr-Abl e14a2, though this did not reach significance 
(7.43 vs 12.5 nM, n=4, p=0.122). A wide variance was noted in the Ba/F3 e14a2 IC50 
replicates, which may result in the lack of significant difference. Conversely, the IC50 for the 
Bcr-Abl e1a2 fusion was significantly higher than e6a2 (17.3 vs 7.43 nM, n=4, p=0.013). These 
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results demonstrate that the decreased dasatinib induced cell death of e6a2 expressing cells 
is not mediated by phosphorylation signalling through CrkL. This shall be further discussed. 
 
4.3 Chapter discussion 
The identification of cells expressing the BCR-ABL1 e6a2 transcript in K562 DasR cells is a novel 
finding, which suggested a replicative advantage of these cells in the context of TKI exposure. 
Some hypotheses suggest certain Bcr-Abl isoforms may confer more aggressive disease, 
however, in this model the mechanism was unknown by which e6a2 harbouring cells 
maintained a selective advantage. The positive selection for high BCR-ABL1 e6a2 transcript 
and protein expression may be due to differences in kinase activation and signalling, altered 
TKI binding interactions to the protein, or differential phosphatase binding and interaction, 
which each could lead to maintained kinase signalling and cell proliferation in the presence 
of dasatinib. However, the presence of additional copies of BCR-ABL1, regardless of the 
isoform, likely contributes to Bcr-Abl protein overexpression and resultant clonal dominance 
in these cells; tracking the genomic quantities and expression of BCR-ABL1 can only hint at 
the molecular mechanisms of resistance. Additionally, due to its rarity, the e6a2 transcript 
may be overlooked in diagnostic tests, resulting in incorrect disease prognosis and poorer 
associated patient outcomes. An exploration of the association between resistance and the 
expression of the e6a2 fusion was performed here using several overlapping approaches; the 
clinical implications and limitations are here discussed. 
 
4.3.1 Clinical identification of the e6a2 BCR-ABL1 fusion  
The clinical identification of the Bcr-Abl e6a2 isoform has been previously discussed (Chapter 
1), and has been associated with several leukaemic phenotypes, including CML, AML, chronic 
myelomonocytic leukaemia, B- and T-ALL, and basophilic myeloid leukaemia (69-79, 82-88). 
The presence of e6a2 in several leukaemic subtypes, and the fact that patient outcomes 
following treatment differed, indicated that this isoform does not necessarily confer a 
particular disease fate. It has been suggested, however not demonstrated, that the presence 
of e6a2 results in a more aggressive disease and poorer patient outcome (71, 74, 89). Several 
patients with e6a2 responded to TKI therapy, demonstrating that the use of TKI is still 
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indicated for BCR-ABL1 e6a2 positive disease. However, relapse and progression during TKI 
therapy was still evident in some patients (75). 
 
A key difference between the commonly observed e13a2/e14a2 transcripts and e6a2 and 
other rare isoforms is how the fusions are detected from a patient biopsy. A diagram of the 
BCR-ABL1 transcript isoforms can be found in Figure 1.3.2. PCR for the more common e13a2 
and e14a2 transcripts does not amplify the e6a2 transcript. RT-qPCR for BCR-ABL1 transcripts 
is now routine for the diagnosis of CML, however, as was the case in our study, rare transcripts 
are not typically investigated following the identification of a BCR-ABL1 driver gene. Several 
of the patient case studies only detected e6a2 via weak PCR amplification using e1a2 (p190) 
specific primers, subsequently using Sanger sequencing to validate the fusion breakpoint. In 
these cases, cytogenetic analyses provides only relatively vague description of the BCR-ABL1 
fusion location. More importantly, following identification of a BCR-ABL1 transcript in a 
patient, exploratory searches for alternate fusions is not usually performed in follow up 
examinations of molecular response. If a rare transcript were to arise in response to TKI 
treatment, as it did in our model, this would likely go unnoticed in a patient’s molecular 
analysis using typical BCR-ABL1 qPCR methods. Therefore, disease recurrence would only be 
detectable by increased white cell count or other diagnostic measures. This, in addition to 
potentially slower disease diagnosis due to difficulty in identifying the isoform, may hinder 
effective treatment strategy design. These confounding factors may all contribute to the 
poorer outcome observed in patients expressing rare BCR-ABL1 drivers. The data presented 
here suggests that in TKI resistant patients, diagnosticians should determine whether the 
presence of rare a Bcr-Abl isoform is affecting treatment. 
 
4.3.2 Expansion of the e6a2 positive clone in the K562 DasR cell line 
The expansion of leukaemic cells expressing Bcr-Abl e6a2 under the selective pressure of 
dasatinib exposure suggested a selective advantage held by these cells. Thus, efforts were 
directed at characterising the kinase function and TKI resistance profile of Bcr-Abl e6a2 in 
relation to e14a2 and e1a2. RT-qPCR analyses demonstrated the emergence of detectable 
levels of e6a2 transcripts occurring early in dasatinib dose escalation. While the K562 2 nM 
DasR dose escalation intermediate was the first to exhibit significantly higher relative 
expression than the DMSO control, a trend of increasing e6a2 transcript expression was 
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observed in dose escalation intermediates from 0.5 nM to 10 nM Das. This suggests the 
existence of a minor clone expressing e6a2 in the drug naïve K562 line, which was selected 
for under dasatinib exposure. DNA qPCR for genomic e6a2 quantities recapitulated the trend 
of increasing e6a2 levels until the K562 10 nM DasR intermediate, as well as a significant 
reduction in e6a2 amplification between the 10 and 15 nM DasR intermediates, suggesting 
that in this model, genomic BCR-ABL1 levels drive increases in protein expression. 
Amplification of BCR-ABL1 is a known mechanism of increased gene expression, and 
amplification of BCR-ABL1 by tandem duplication or Philadelphia chromosome duplication 
has been associated with disease aggression, TKI resistance, and poor outcome (148, 149, 
243). However, decreases in gene amplification and expression have not been extensively 
documented, and a mechanism for the loss of BCR-ABL1 copies and the selection of these 
cells, as was observed here, is not readily apparent. Therefore, it is postulated that the loss 
of genomic BCR-ABL1 in the cell population was due to the selection and outgrowth of a 
dasatinib resistant clone which harboured relatively lower BCR-ABL1 levels, and which gained 
TKI resistance by other mechanisms. Subsequent increases in BCR-ABL1 quantity in the K562 
25 nM DasR and later intermediates may have been due to re-selection for BCR-ABL1 
overexpressing cells, though as these cells already harboured T315I, there are no immediately 
apparent reasons for this selective pressure. 
 
4.3.3 The pleckstrin homology (PH) domain and intracellular signalling of Bcr-Abl 
Compared with the typical e14a2 fusion, e6a2 exhibits truncation of the PH domain (BCR 
exons 5-10), however, retains the Dbl homology (DH) domain (exons 3-5), the 
serine/threonine kinase domain, and N-terminal coiled coil oligomerisation regions (exon 1) 
(Figure 1.4). The PH domain is present in a diverse range of >285 proteins involved in cellular 
signalling, cytoskeletal organisation and membrane trafficking (244-246). The domain has 
well characterised roles in phospholipid binding, holding the positive electrostatic 
polarisation necessary for interactions with negatively charged phospholipids (247). The 
strong affinity of the PH domain with phospholipids can allow localisation of the protein to 
the plasma membrane and actin cytoskeleton (248). It has been demonstrated that p190 Bcr-
Abl, which lacks the DH and PH domains of Bcr, interacts with a different protein subset than 
p210 (249, 250). Thus, lack of the PH domain in Bcr-Abl e6a2 may result in protein localisation 
to the cytosol, where it would interact with a different subset of protein cofactors. 
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The DH-PH domain juxtaposition is also responsible for Rho GTPase and GEF activity: the 
catalytic exchange of GTP for GDP on Rho substrates, effected by an increased rate of GDP 
dissociation (251). GEF-mediated activation of Cdc42, Rac1 and RhoA is involved in 
cytoskeletal remodelling, modulation of proliferation and apoptosis, and myeloid 
differentiation (252). Native Bcr has been demonstrated to stimulate the GEF activity of 
Cdc42, RhoA, Rac1 and Rac2 (35); these protein interactions are conserved in Bcr-Abl (253, 
254). The loss of the DH domain in the translated p190 is hypothesised to interrupt RhoGEF 
activity and G-protein interactions (223), and localisation of the protein complex (250, 255). 
Alterations in the p190 kinase activation profile are likely to affect cellular signalling, possibly 
worsening disease prognosis and treatment response. Studies of p190 Bcr-Abl have 
determined that due to the lack of the DH domain, p190 is unable to activate RhoA, however 
does still activate Rac1 and Cdc42; it has been theorised that p190 activation of Rac1 and 
Cdc42 occurs via GEF interactions with the Dbl family GEF, Vav (256, 257). Authors 
hypothesised that progenitor cell differentiation by p210 activation of RhoA conferred a less 
aggressive leukaemic phenotype. Demehri et al compared the transforming effects of p210 
and p190 with a naturally occurring “p200” Bcr-Abl fusion, lacking the PH domain (258, 259). 
While all constructs used resulted in oncogenic transformation of 32D and Ba/F3 cells, there 
was a marked increase in the kinase activity of the p190 and p200 isoforms, with higher STAT6 
phosphorylation and shorter disease latency in engrafted mice. Taken together, the studies 
of signalling and functional differences between cells expressing Bcr-Abl lacking DH-PH GEF 
functionality suggest this deficiency will significantly alter the conferred disease phenotype. 
 
As the study presented here used a murine pro-B Ba/F3 cell line as the transformative 
backbone, we were not able to thoroughly explore the myeloid differentiation which may 
have been induced by the different Bcr-Abl isoforms. However, no obvious cellular 
morphology differences were observed between the transformed Ba/F3 lines or indeed in the 
K562 DasR line where the e6a2 isoform was originally identified. Nevertheless, a deeper 
analysis of the Ba/F3 lines may determine the differences in GEF functionality, and determine 
cell signalling perturbations due to Bcr-Abl truncation. 
 
 4-120 
4.3.4 Molecular formation of the genomic BCR-ABL1 e6a2 fusion 
Patient case studies involving e6a2 reported the presence of only the e6a2 fusion in isolation 
(69, 70, 79, 260). This is in contrast to the concurrent expression of e14a2 with e6a2 observed 
in this model, and the interactions facilitated by co-expression of the two isoforms has not 
previously been studied. The K562 cell line harbours multiple genomic copies of BCR-ABL1, 
and target enrichment sequencing experiments performed here suggest a mechanism for the 
formation of the additional e6a2 fusion observed in dasatinib resistant variants of this line. 
The location of the e6a2 breakpoint in intronic regions suggests a deletion between BCR 
introns 7-13 juxtaposing BCR exon 6 with ABL1 exon 2. FISH analysis previously demonstrated 
that K562 DasR intermediates harbouring the e6a2 fusion maintained intact native BCR and 
ABL1 genes, indicating that e6a2 did not form via their fusion (Chapter 3). Intrachromosomal 
deletion may have occurred during chromosomal replication during the S phase of cell cycle, 
however, as amplification of the BCR-ABL1 locus was previously demonstrated in Chapter 3, 
it is more likely that the deletion occurred during a gene duplication event. Interestingly, 
intronic regions within BCR have been demonstrated to act as transcriptional repressors 
(261), and the deletion of BCR introns may have also resulted in the relative increased 
expression of the e6a2 fusion. This would significantly contribute to overall Bcr-Abl levels, and 
the TKI resistant phenotype observed in these cells. 
 
4.3.5 Dasatinib sensitivity of the e6a2 Bcr-Abl fusion 
Experiments elucidating differences in dasatinib sensitivity between BCR-ABL1 transduced 
Ba/F3 lines were complex to interpret. Consistent with predictions, the e6a2 transduced line 
was less sensitive to dasatinib induced cell death, compared with Ba/F3 BCR-ABL1 e14a2. 
Dasatinib sensitivity of e6a2 was similar to that of e1a2 Bcr-Abl. These results are in line with 
hypotheses about the GEF function of the PH-DH domains in Bcr-Abl, and how a proliferative 
loss of function may occur. IC50 assays for CrkL phosphorylation demonstrated that the e6a2 
kinase was not more resistant to kinase inhibition by dasatinib; while not significant, the IC50 
was lower than that of other kinase isoforms. The hypothesis that the e6a2 fusion conferred 
increased kinase activity in the presence of dasatinib was thus disproven. This indicated that 
the observed decrease in dasatinib cell sensitivity in e6a2 and e1a2 was not due to increased 
kinase activation in the presence of dasatinib. Altered GEF activity and/or protein cofactor 
recruitment of e6a2 and e1a2 may have resulted in this loss of dasatinib sensitivity, in the 
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absence of increased kinase activation. However, it should be noted that the e1a2 isoform 
also maintained an increased dasatinib pCrkL IC50, which may have been due to kinase 
activity of the isoform. 
 
One limitation of the model is the random insertion location of the transgene, which may 
result in these non-congruous results. While it is known that lentiviral transduction integrates 
transgenes into highly expressed transcriptional units (262), there is random and stochastic 
variance in the integration site. Therefore, transgene insertion may be disruptive to 
endogenous gene function and homeostasis, potentially leading to altered proliferative 
potential or apoptosis resistance. Additionally, the variance in transcription and translation 
of the different BCR-ABL1 isoforms could lead to differential levels of TKI sensitivity. However, 
high levels of BCR-ABL1 gene and protein expression would likely increase both dasatinib IC50 
and dasatinib induced cell death. The decreased dasatinib induced cell death, but increased 
pCrkL IC50 in the Ba/F3 BCR-ABL1 e6a2 line, suggests that the decreased dasatinib induced 
cell death is not due to increased kinase activity. The effect could be further explored with 
functional studies investigating phosphoprotein differences between the cell lines, for 
example using co-immunoprecipitation of Bcr-Abl isoforms to identify protein cofactors. 
Differential GEF activity could result in the increased proliferation and/or decreased apoptosis 
in e6a2 harbouring cells. Methods of assessing GEF and GTPase activity in vitro have been 
previously documented (263), which could delineate differences between Bcr-Abl isoforms. 
However, these methodologies were not within the scope of this project. 
 
4.3.6 Clinical implications and further study 
An aspect of the emergence of e6a2 mediated TKI resistance that remains to be investigated 
was the co-expression of both e6a2 and e14a2 BCR-ABL1 in each cell of the resistant 
population. Protein characterisation of the K562 DasR cell line detailed in Chapter 3 
demonstrated the expression of both Bcr-Abl isoforms in the cell line. Phosphorylation of both 
isoforms appeared to be linked, and it was likely that transphosphorylation occurred between 
e14a2 and e6a2. In the K562 DasR line, the T315I mutation was identified only in e14a2 
transcripts, however, e6a2 protein also remained phosphorylated in the presence of 
inhibitory levels of dasatinib, demonstrating the ability of different isoforms of Bcr-Abl to 
interact with and phosphorylate each other, in addition to regular transphosphorylation 
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between identical Bcr-Abl molecules (Figure 3.9). In the Ba/F3 transformation model 
presented here, only e14a2, or e6a2, or e1a2 Bcr-Abl was present in each line, and the 
interactions between isoforms was not investigated. There may be signalling pathway and 
kinase activity perturbation of Bcr-Abl transphosphorylation between isoforms, due to 
differential binding of protein co-factors, which could be explored using a cell line model 
expressing both e14a2 and e6a2/e1a2. However, outside of e13a2 and e14a2 co-occurring as 
splice variants, the identification of multiple Bcr-Abl isoforms within a leukaemic clone is rare, 
with most patient case studies identifying only a single expressed Bcr-Abl isoform, thus 
limiting the translational relevance of this line of investigation. 
 
The identification of the rare e6a2 BCR-ABL1 fusion in a TKI resistant context is a novel finding, 
and has significant clinical implications. Modern methodology for diagnosis of Ph+ leukaemia 
typically involves the identification of a common BCR-ABL1 transcript isoform in leukaemic 
cells by targeted PCR, and disease monitoring over the course of treatment by BCR-ABL1 RT-
qPCR. However, subsequent exploration for alternate BCR-ABL1 fusions is not typically 
performed, and in this case, the emergence of e6a2 in response to TKI exposure would go 
undetected. Haematological relapse associated with rare BCR-ABL1 transcripts, expanding 
under TKI exposure, may be a significant contributor to poor treatment response and patient 
mortality, and the outcomes of this study support the ongoing determination of leukaemic 
driver genes, particularly in the case of refractory disease of unknown origin. 
 
The study performed here is the first to identify the emergence of BCR-ABL1 e6a2 coinciding 
with dasatinib treatment. Quantification of the transcript determined that e6a2 expression 
was selected for, rising with increasing dasatinib exposure, but falling with the acquisition of 
alternate resistance mechanisms. The induced expression of e6a2 resulted in the malignant 
transformation of Ba/F3 cells, resulting in a disease which was less sensitive to TKI-based 
inhibition than that of BCR-ABL1 e14a2. This reduced sensitivity was not due to kinase 
signalling through phosphorylation of CrkL. This study provides evidence for the expression 
of e6a2 as a resistance mechanism, and warrants the exploration of e6a2 mediated resistance 
in a patient setting. 
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Table 4.1: FusionCatcher analysis of transcriptome expression data demonstrated the 
presence of the BCR-ABL1 e14a2 transcript (red) in all K562 samples, as well as the e6a2 
transcript (blue) in dasatinib resistant cells. Additionally, several other BCR-ABL1 fusion 
breakpoints (black) were identified sporadically, possibly due to transcriptional error or 
partial/unfinished splicing of transcripts. 
  
BCR breakpoint ABL1 breakpoint K562 naïve K562 DMSO 10 nM Das 15 nM Das 25 nM Das 50 nM Das 200 nM Das
22:23632600:+ 9:133729451:+ 14 14 23 26 21 21 18
22:23613779:+ 9:133729451:+ 22 12 13 18 18
22:23632600:+ 9:133729454:+ 4 2 4
22:23613779:+ 9:133729454:+ 2 2
22:23632600:+ 9:133655756:+ 3 8 21 19 15 15 8
22:23632600:+ 9:133638585:+ 2 2 2
22:23632600:+ 9:133657191:+ 4 6 8 6 4 2
22:23632737:+ 9:133607147:+ 2 7 6 4 4 3
22:23632738:+ 9:133607148:+ 2 8 6 4 4 3
22:23613779:+ 9:133655756:+ 11 2 2 3 4
22:23613779:+ 9:133638585:+ 8 2 3 4
22:23632600:+ 9:133706197:+ 4 3 2
22:23632599:+ 9:133729451:+ 3 2
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Figure 4.2: PCR amplicons from K562 DasR dose escalation intermediate cDNA samples, using 
BCR-ABL1 primers spanning the e6a2 breakpoint junction (e6a2breakpoint, LongR0510). 
Results demonstrate the emergence of an e6a2 specific amplicon in K562 2 nM DasR 
intermediate which is retained in subsequent dose escalation intermediates; there is a visible 
band at the expected 1652 bp size. The e6a2 fusion was not detected in drug naïve or DMSO 













































































































*).5#*%(5! +.5! *)0'+,(5! 4&%-! %-(! ](.<+.;! ,)-.! ,(H(,(.*(! /(g#(.*(O! 3-(! .#*$()%&5(!
/(g#(.*(/!(Z+*%$7!0+%*-!%-(!,(H(,(.*(!/(g#(.*(G!4&%-!.).(!)H!%-(!*)00).!;&.+/(!5)0+&.!























.),0+$&/(5! %)! %-(! *).%,)$! U(.(!178)O! 8XWL! e"DA! *).%,)$! *($$/! (Z',(//(5! .)! (W+LG! %-#/!
(Z',(//&).!4+/! /(%! +%! c(,)G!4&%-! +$$! )%-(,! &.%(,0(5&+%(/! ,('),%(5! +/! +! ,($+%&J(! }51%O! <+,/!













Table 4.2: FACTERA analysis of target enrichment sequencing for BCR and ABL1 breakpoint 
fusion locations identified the BCR-ABL1 DNA breakpoints in selected K562 DasR lines. The 
e14a2 breakpoint (chr22:23632737 / chr9:133607147 and chr22:23632742 / 
chr9:133607152) was identified in all K562 DasR and control lines. Additionally, an e6a2 
breakpoint (chr22:23614939 / chr9:133627619 and chr22:23614938 / chr9:133627618, 
highlighted in purple) was identified, exclusively in dasatinib resistant lines.  
  
Cell line Region1 Region2 Break1 Break2 Supporting_reads1 Supporting_reads2
K562 naïve BCR ABL1 chr22:23632737 chr9:133607147 194 153
K562 15 nM Das BCR ABL1 chr22:23614939 chr9:133627619 260 282
BCR ABL1 chr22:23632737 chr9:133607147 200 162
K562 200 nM Das BCR ABL1 chr22:23614938 chr9:133627618 327 361
BCR ABL1 chr22:23632742 chr9:133607152 213 178
BCR VWF chr22:23612611 chr12:6119636 26 5
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Figure 4.9: Figure 4.9: Photos of lentivirally transduced Ba/F3 lines confirmed successful 
transduction. The mock transduction produced no eGFP positive cells. All cells transduced 
with pRuf-iG2 constructs produced a strong eGFP signal, allowing subsequent enrichment by 
FACS. Images were taken using a Zeiss Axiocam Erc 5s at 40x magnification; scale bar indicates 







Figure 4.10: Western blotting assessing phosphorylation of the Bcr-Abl kinase substrate, CrkL, 
demonstrated the successful malignant transformation of BCR-ABL1 harbouring Ba/F3 lines. 
The empty vector transduced line exhibited no phosphorylation of CrkL (Phospho-CrkL), 
whilst all BCR-ABL1 transduced lines exhibited almost complete phosphorylation of CrkL. 
K562 DasR lines overexpressing Bcr-Abl were used as positive control. Lysates were loaded 



































































































Table 4.3: RT-qPCR Ct values from BCR-ABL1 quantitation of Ba/F3 cell lines demonstrated 
that transduced lines were expressing the correct BCR-ABL1 transcript isoforms. The empty 
vector transduced line did not amplify any BCR-ABL1 products. Conversely, BCR-ABL1 
transduced lines amplified their appropriate isoforms at < 20 cycle numbers. As primers 
flanked breakpoints, e6a2 primers weakly amplify e14a2 transcripts, and e1a2 primers 
amplify e14a2 and e6a2 transcripts, however only following many amplification cycles. K562 
samples harbouring e14a2 and e6a2 were included as positive controls, as was an e1a2 
positive patient sample. Experimental samples were run in triplicate; undetermined = no 
amplification. 
  
Sample BCR-ABL1 e14a2 (SYBR) BCR-ABL1  e6a2 (SYBR) BCR-ABL1  e1a2 (TaqMan) BCR  (TaqMan)
Ba/F3 EV #1 undetermined undetermined undetermined 33.91
Ba/F3 EV #2 undetermined undetermined undetermined 35.22
Ba/F3 EV #3 undetermined undetermined undetermined 35.09
Ba/F3 e14a2 #1 18.34 31.05 34.22 34.08
Ba/F3 e14a2 #2 16.14 29.79 35.21 34.60
Ba/F3 e14a2 #3 16.34 29.50 34.54 33.88
Ba/F3 e6a2 #1 undetermined 18.64 33.31 33.92
Ba/F3 e6a2 #2 undetermined 17.21 33.71 36.35
Ba/F3 e6a2 #3 undetermined 16.99 33.94 33.98
Ba/F3 e1a2 #1 undetermined undetermined 16.96 33.84
Ba/F3 e1a2 #2 undetermined undetermined 15.96 34.27
Ba/F3 e1a2 #3 undetermined undetermined 16.03 33.91
K562 DMSO e14a2+ 25.14 undetermined 37.42 24.44
K562 3.5 nM Das e14a2/e6a2+ 20.00 25.46 22.32 24.18
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5 The expression of the drug transporter ABCG2 





The identification of the BCR-ABL1 e6a2 transcript expression in the K562 DasR cell line helped 
establish the contribution of e6a2 to TKI resistance. However, was not sufficient to explain 
the loss of TKI sensitivity observed in some K562 DasR dose escalation intermediates. 
Observed resistance to dasatinib was higher in the 10 and 15 nM DasR intermediates than 
could be explained by Bcr-Abl expression or kinase domain mutations alone (Chapter 3.2.1, 
Figure 3.3); in these intermediates, the BCR-ABL1 expression did not significantly increase, 
while TKI resistance did increase. Indeed, the highest ponatinib tolerance observed was in the 
15 nM Das cell line. Clearly, undefined resistance mechanisms were present in these cells. As 
part of the interrogation of TKI resistance mechanisms present in this model, RNA sequencing 
data was explored for global gene expression, and fluctuations in expression over the course 
of increasing dasatinib exposure. mRNAseq differential gene expression analyses comparing 
control and dasatinib-resistant cell lines were filtered for significance and large fold 
differences in transcription, and a shortlist of differentially expressed genes was generated. 
This method identified the increased expression of the ABCG2 transporter gene. 
 
Expression of the ABCG2 gene had not been examined in the other K562 DasR dose escalation 
intermediates, and it was unknown whether the gene was being translated into a functional 
transporter. Importantly, the effect of increased ABCG2 expression on the dasatinib and 
ponatinib sensitivity of the cell line had not been established. To further explore the role of 
ABCG2 in the K562 DasR line, experiments were designed to validate the findings of the 
transcriptome analysis and the following research questions were posed: 
1. What was the level of ABCG2 expressed during dasatinib escalation in the K562 DasR 
intermediates? 
2. Was ABCG2 functional in these lines, and could efflux function be chemically inhibited? 
3. Could inhibition of ABCG2 mediated efflux sensitise K562 DasR cells to TKI therapy? 
 
Sequencing of RNA transcripts from dose escalation intermediate samples of the K562 DasR 
line, revealed the overexpression of the ABCG2 gene, correlating with the acquisition of 
dasatinib resistance. This result was validated by RT-qPCR for ABCG2, against the control gene 
GUSB, and reported as a ddCt value normalised to the K562 DMSO vehicle control. The effect 
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of ABCG2 transcript overexpression on the levels and function of ABCG2 protein was 
determined. Cell surface ABCG2 expression was measured in K562 DasR lines by flow 
cytometry. As the ABC transporter ABCB1 is commonly associated with chemotherapy 
resistance, ABCB1 surface expression was concurrently measured. Using the BODIPY-prazosin 
efflux assay (264-266), the transporter function of the ABCG2 protein was interrogated, and 
the effectiveness of the ABCG2 inhibitor Ko143 was tested. 
 
Dasatinib transport by ABCG2 was measured using the dasatinib intracellular uptake and 
retention assay (IUR) assay, which was performed in the K562 15 nM DasR intermediate and 
K562 control cells by Mrs Sophie Watts in the SAHMRI leukaemia laboratory. Cells were 
cultured in radiolabelled C14-dasatinib in the presence of Ko143, and drug uptake-retention 
was measured by scintillation. 
 
To determine whether inhibition of transporter function sensitised leukaemic cells to TKI 
induced apoptosis, the dasatinib pCrkL IC50 (IC50Das) and TKI induced cell death assays were 
repeated in the presence of the ABCG2 transport inhibitor Ko143. Additionally, as ponatinib 
is often prescribed for patients who are resistant to 1st and 2nd generation TKIs, the role of 
ABCG2 in mediating ponatinib efflux was determined. Ponatinib pCrkL IC50 (IC50Pon) and cell 
death assays were performed in the presence of Ko143. 
 
5.2 Results 
5.2.1 Transcriptome sequencing identifies ABCG2 transcript overexpression in K562 DasR 
dose escalation intermediates 
We performed RNA sequencing differential expression analysis of K562 DasR samples. The 
10, 15 and 25 nM DasR intermediates were pooled as a comparative group based on 
hierarchical clustering analysis, as were the K562 naïve and DMSO vehicle control lines 
(Figures S16). Each sample was run in singlicate, thus differential expression analysis could 
not be performed between the two control groups, however, biological differences between 
the two samples would add to overall variance, and therefore increase confidence in the 
shortlisted differentially expressed genes. Plots identifying the top most differentially 
regulated genes can be found in Figures S19 and S20. Volcano plot visualisation of 
 5-141 
differentially expressed genes identified the ABCG2 gene as both significantly (FDR=1.01x10-
11) and highly expressed (logFC=9.978) compared with drug naïve controls (Figure 5.1). 
 
5.2.2 The ABCG2 gene and protein is overexpressed in K562 DasR dose escalation 
intermediates 
The RNAseq gene expression results were validated by RT-qPCR; additional K562 DasR 
intermediates were also assessed to complete the full spectrum of TKI resistant 
intermediates. A significant increase in ABCG2 expression in all K562 DasR lines was observed 
when compared with control cells (Figure 5.2). Compared with K562 DMSO control, increased 
ABCG2 expression was first observed in the 2 nM DasR intermediate (fold change (DDCt)=1 
vs 332.5, p=0.0017), after which expression plateaued until the 5 nM DasR intermediate. 
ABCG2 expression subsequently increased further and reached a peak in the 15 nM DasR 
intermediate (fold change=332.5 vs 14670.1, p=0.0023), before a significant decrease in the 
200 nM DasR line (fold change=14670.1 vs 5.3, p=0.0039). However, ABCG2 expression in the 
200 nM DasR line remained significantly higher than in DMSO control (fold change=5.3 vs 1, 
p=0.0316). 
 
The ABCB1 transporter is commonly associated with therapeutic drug resistance. Therefore, 
gene expression of ABCB1 was determined concurrently with ABCG2. Results demonstrated 
no significant changes in ABCB1 expression associated with dasatinib resistance in the K562 
DasR lines (Figure 5.2). 
 
To determine if increased ABCG2 gene expression translated to a rise in ABCG2 surface 
protein expression, flow cytometric analysis of ABCG2 expression was performed. The 
percentage of ABCG2-positive cells demonstrated a transient elevation in ABCG2 protein 
expression, consistent with mRNA levels (Figure 5.3). When compared with the K562 DMSO 
control line, significant overexpression of ABCG2 was first detected in the 10 nM DasR 
intermediate (63.0 vs 15.7% positive, p=0.0005, n=4). ABCG2 expression rose significantly to 
87.7% in the 15 nM DasR intermediate (p=0.0025, n=7), before significantly falling to 28.1% 
in the K562 200 nM Das line (p=0.0054, n=3). Further interrogation of ABCG2 expression in 
K562 DasR dose escalation intermediates indicated the early emergence of a small population 
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of cells with high ABCG2 expression (Figure 5.3b). With continued dasatinib exposure, the 
minor population of ABCG2 overexpressing cells in the 2 nM DasR intermediate became the 
dominant clonal population, with the majority of cells in the 15 nM DasR intermediate 
demonstrating a high level of ABCG2 expression. However, in the 25 nM DasR intermediate, 
a population of cells with low ABCG2 expression re-emerged, and in K562 200 nM DasR cells, 
ABCG2 expression fell close to baseline levels. 
 
5.2.3 ABCG2 is functional in K562 DasR intermediates 
In order to demonstrate ABCG2 functionality in K562 DasR intermediates, and to confirm 
adequate concentrations of Ko143 required to inhibit transport activity, the BODIPY-prazosin 
efflux assay was performed. Results demonstrated ABCG2 substrate efflux in the K562 10 nM 
and 15 nM DasR intermediates, indicated by stain negativity following 30 minutes incubation 
in BODIPY-prazosin (Figure 5.4, blue peak). The K562 DMSO vehicle control line, as well as 
K562 5 nM and 25 nM DasR intermediates stained positive for BODIPY-prazosin, indicating an 
absence of ABCG2 mediated substrate efflux. In these lines, the addition of 500 nM Ko143 
had no effect on BODIPY-prazosin fluorescence. At this concentration, Ko143 exhibits specific 
inhibition of ABCG2 (267). However, in the 10 and 15 nM DasR cell populations, addition of 
500 nM Ko143 resulted in retention of BODIPY-prazosin, demonstrating that: 1) the ABCG2 
expressed by these resistant cell lines was functionally active and 2) the concentration of 
Ko143 used was sufficient for ABCG2 inhibition. Thus, this concentration of Ko143 was used 
in subsequent IC50 and cell death assays. 
 
In addition to the BODIPY-prazosin efflux assay, the dasatinib IUR assay was performed in the 
K562 15 nM DasR intermediate (greatest expression of ABCG2), along with the drug naïve 
K562 control (Figure 5.5). Comparison indicated that the 15 nM DasR intermediate retained 
significantly less C14-dasatinib than the naïve control (24.6 vs 12.1 ng / 2x105 cells, n=5, 
p<0.001). The addition of 500 nM Ko143 to the K562 naïve control line did not alter dasatinib 
retention (22.1 vs 24.6 ng / 2x105 cells, n=5, p=0.234), however, in the 15 nM DasR line Ko143 
addition resulted in significantly elevated intracellular dasatinib concentrations (19.4 vs 12.1 
ng / 2x105 cells, n=5, p=0.004); Ko143 treated 15 nM DasR cells did not have significantly 
lower dasatinib IUR than drug naïve K562 cells in the absence of Ko143 (p=0.06). Taken 
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together, these data suggest variable increases in ABCG2 functionality during intermediate 
stages of dasatinib resistance generation.  
 
5.2.4 Inhibition of ABCG2 sensitises ABCG2 overexpressing K562 DasR cells to dasatinib-
mediated Bcr-Abl inhibition and induces cell death 
To demonstrate the causative role of ABCG2 transporter function in reducing dasatinib 
sensitivity, dasatinib-induced cytotoxicity assays were repeated in the presence and absence 
of the ABCG2 inhibitor Ko143. Results (Figure 5.6) demonstrated a key role of ABCG2 in the 
acquisition of dasatinib resistance. When cultured in a concentration gradient of dasatinib, 
the addition of Ko143 did not significantly lower the viability of K562 DMSO control cells at 
any dasatinib concentration. However, in the 10 nM DasR intermediate, cells were 
significantly less viable when Ko143 was used in addition to 50 nM dasatinib (28.4 vs 51.9% 
viable, n=3, p=0.003). Indeed, in the majority of dasatinib concentrations tested, addition of 
Ko143 was found to increase the cell death in K562 10 nM DasR cells. This trend was also 
observed in the 15 nM DasR intermediate, however, due to large variance between assays, 
differences in cellular viability due to Ko143 were not statistically significant. Interestingly, in 
the 10 and 15 nM DasR intermediates, a proportion of cells remained viable even in 5000 nM 
dasatinib. In the K562 25 nM DasR cells and all higher dose escalation intermediates, cell 
viability remained high in any dasatinib concentration, regardless of whether cells were 
cultured in the presence or absence of Ko143, suggesting ABCG2 was not required for 
dasatinib resistance in later intermediates. 
 
Sensitivity of Bcr-Abl to inhibition by dasatinib was measured in the presence of Ko143 using 
the pCrkL IC50 assay (Figure 5.7). IC50Das data confirmed previously generated IC50 data 
(Figure 3.4); the IC50Das increased with prolonged dasatinib exposure, eventually peaking at 
over 5000 nM in the 25 nM and later DasR intermediates, coinciding with the cell lines’ 
acquisition of T315I (Figure 3.5). Addition of Ko143 in the K562 DMSO line did not significantly 
alter the IC50Das (6.97 vs 7.44 nM, p=0.778, n=3). However, in the 10 and 15 nM DasR 
intermediates, addition of Ko143 significantly lowered the IC50Das, sensitising the cells to 
dasatinib induced Bcr-Abl inhibition. In the 15 nM DasR intermediate, addition of Ko143 
reduced the IC50Das from 743 to 22.3 nM (p<0.0001, n=3); a similar effect was observed in the 
10 nM DasR intermediate (150 vs 16 nM, p=0.021, n=3). Intriguingly, in the presence of Ko143, 
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the IC50Das in the K562 15 nM DasR line was not significantly higher than the K562 DMSO 
control (22.3 vs 6.97, p=0.101, n=3), indicating that the predominant mode of dasatinib 
resistance in the 15 nM DasR intermediate was ABCG2 overexpression. Ko143 also induced a 
small dasatinib sensitising effect in early dose escalation intermediates, though this only 
reached significance in the 3.5 nM DasR intermediate (41 vs 21.3 nM, p=0.006, n=3). As 
expected, late dose escalation intermediates, expressing the T315I mutation, exhibited no 
dasatinib sensitivity in the presence or absence of Ko143. 
 
5.2.5 ABCG2 contributes to ponatinib cross resistance 
Following confirmation of the involvement of ABCG2 overexpression in dasatinib resistance, 
the contribution of ABCG2 overexpression to ponatinib resistance was also assessed. TKI 
induced cytotoxicity and pCrkL IC50 assays were performed in the presence of Ko143 (Figure 
5.8). In the absence of Ko143, sensitivity to ponatinib in K562 DasR cells was consistent with 
previously generated data (Figure 3.13). In the K562 DMSO control line, addition of Ko143 did 
not result in significant changes to cell viability in the presence of gradient ponatinib. While a 
modest reduction in cell viability was observed when K562 10 nM DasR intermediate cells 
were cultured with Ko143 (Figure 5.8b), the addition of Ko143 significantly lowered 15 nM 
DasR cell viability in several of the ponatinib concentrations tested (Figure 5.8c); in 10 nM 
ponatinib, the addition of Ko143 reduced viability from 88% to 52% (p<0.001); in 50 nM 
ponatinib, Ko143 reduced viability from 52% to 28% (p=0.003). Previously, the K562 25, 50 
and 200 nM DasR lines were demonstrated as completely resistant to dasatinib induced cell 
death (Figure 3.3a); in contrast, these lines were susceptible to ponatinib induced cell death 
(Figure 5.8d-f). Ko143 did not significantly alter the cell viability in these lines, presumably 
attributable to the loss of ABCG2 expression. 
 
Bcr-Abl ponatinib IC50 experiments performed in the presence of Ko143 (Figure 5.9) was 
consistent with ponatinib cell death assays. The Bcr-Abl kinase activity in cells overexpressing 
ABCG2 was significantly less sensitive to ponatinib induced inhibition. Addition of Ko143 
restored ponatinib sensitivity and significantly lowered the ponatinib IC50 in the 10 nM (101 
vs 47 nM, n=3, p=0.006) and 15 nM (99.7 vs 58.7 nM, n=3, p=0.015) DasR intermediates. This 
effect was not observed in the K562 DMSO control line, or the 50 or 200 nM DasR lines. 
Interestingly, Ko143 had a marginal ponatinib sensitising effect in the 25 nM DasR line (bulk 
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population of cells contained ABCG2 +ve and -ve cells, Figure 5.3a), though this did not reach 
statistical significance (55.7 vs 76.7 nM, n= 3, p=0.109). 
 
5.3 Chapter discussion 
Acquired resistance to TKI therapy often results in treatment failure for CML patients, and 
there is a well-recognised role of ABC transporters in conferring resistance. A greater 
understanding of different substrate transport profiles will direct the appropriate 
administration of therapeutic agents. This study demonstrates that the drug transporter 
ABCG2 contributes to dasatinib and ponatinib efflux in vitro, and that inhibition of ABCG2 
efflux activity can re-sensitise leukaemic cells to TKI. Additionally, the emergence, selection 
and de-selection of leukaemic cells overexpressing ABCG2 as a resistance mechanism was 
assessed over long-term dasatinib exposure. Determining the circumstances under which this 
cell population undergoes clonal evolution provides insight into the forces affecting 
leukaemic cell clonal dynamics. This is an important consideration for defining novel 
therapeutic strategies for leukaemia patients who are resistant or intolerant to TKI treatment. 
 
5.3.1 Dasatinib and ponatinib efflux by ABC transporters 
The efflux of dasatinib by ABCG2 was first demonstrated by our laboratory (184). This has 
been subsequently validated in a number of in vitro studies, which have cumulatively 
demonstrated that ABCG2 expression increases the dasatinib pCrkL IC50, lowers dasatinib 
cellular uptake and retention, and is involved in in vivo brain barrier transport of dasatinib 
(173). The results presented here, using the K562 DasR cell line and its ABCG2 overexpressing 
intermediates, have corroborated these findings. This study thoroughly demonstrated that 
ABCG2 overexpressing cells have higher dasatinib pCrkL IC50, lower dasatinib-mediated cell 
death, and lower dasatinib uptake and intracellular retention. Furthermore, all the observed 
effects of ABCG2 mediated resistance can be reversed by administration of the small molecule 
inhibitor of ABCG2, Ko143. 
 
The 3rd generation TKI, ponatinib, is indicated as a second/third line treatment for CML and 
Ph+ ALL patients that are resistant or intolerant to previous TKI treatment. As discussed 
previously, upregulation of small molecule transporters such as ABCB1 has been 
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demonstrated to confer a multidrug resistant phenotype, due to the broad substrate 
specificity. This is the first demonstration of resistance to ponatinib occurring via upregulation 
of ABCG2 due to previous exposure to dasatinib treatment. Previously, studies in our 
laboratory studying ponatinib-ABCG2 interactions have demonstrated that ABCG2 does not 
mediate ponatinib transport (268, 269). Further studies have demonstrated that ponatinib is 
a potent inhibitor of ABCG2 transport (270). This is at odds with the current findings, which 
have demonstrated that high ABCG2 expression results in ponatinib resistance, and that 
inhibition of ABCG2 transport can sensitise these cells to ponatinib treatment. Similar to my 
project, previous studies have used Ko143, as well as the less specific ABC transporter 
inhibitor pantoprazole, to inhibit ABCG2 activity. However, possible points of difference 
between the studies include the absolute levels of ABCG2 expression in the cell lines. The 
K562 15 nM DasR dose escalation intermediate exhibited the highest ABCG2 expression, as 
demonstrated by flow cytometric analysis. It is possible that ABCG2 mediated transport of 
ponatinib is not as efficient as for dasatinib, and that a high level of expression is necessary 
for detectable increases in ponatinib IC50 in ABCG2-overexpressing cells; ABCG2 expression 
levels may not have been as high in previous studies. Substrate transport assays could 
definitively demonstrate ponatinib transport by ABCG2. To our knowledge, no study of 
ponatinib intracellular uptake and retention have been performed. This could demonstrate 
the transport of ponatinib by ABC transporters, and could be performed in future studies. 
 
5.3.2 Clinical use of ABCG2 inhibitors 
This study has demonstrated the effective in vitro use of Ko143 to sensitise ABCG2 
overexpressing cells to both dasatinib and ponatinib treatment. While ABC transporter 
inhibition has potential as an effective therapeutic strategy, to date, ABCG2 transporter 
inhibitors have not been used with clinical efficacy (271). Initial attempts to clinically translate 
this strategy used the ABCG2 inhibitor fumitremorgin C (a Ko143 analogue). In an in vitro 
study by Nakanishi et al., ABCG2 overexpressing K562 cells were 2-3 fold more resistant to 
imatinib than parental controls, however, ABCG2 inhibition with fumitremorgin C restored 
imatinib induced cell death. However, these findings did not translate effectively, and the 
clinical use of fumitremorgin was associated with severe neurotoxicity (271). In the 
experiments presented here, the fumitremorgin C predecessor, Ko143 was used. While Ko143 
was developed over a decade ago (230, 272), there has been limited clinical success with the 
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drug. Physiological ABCG2 expression occurs in the mammary gland, testis, intestine, colon, 
liver, kidney, venules, brain endothelium, and placental tissue, playing an important role in 
xenobiotic efflux, folate and uric acid homeostasis, and protection from toxic porphyrin build 
up (273-276). Significant toxicity can result from ABC inhibitor treatment, and the titration for 
clinically relevant dosages will likely prove difficult. Nevertheless, ABC transporter inhibition 
remains a clinically relevant avenue. Our laboratory has previously demonstrated the ABC 
transporter inhibitors pantoprazole and esomeprazole to sensitise leukaemic cells to TKI 
treatment (277), and transporter inhibition has successfully been used concomitantly with 
traditional chemotherapies (278). 
 
As previously stated, many TKIs, including imatinib, nilotinib and ponatinib, demonstrate 
inhibition of ABC transporters. This transport inhibiting effect could be exploited to sensitise 
leukaemic cells to drug induced toxicity. The co-treatment of imatinib or nilotinib with 
dasatinib has been demonstrated to increase the dasatinib sensitivity via inhibition of ABCG2 
activity (279). Ponatinib has also been demonstrated to inhibit the activity of ABCG2, 
enhancing the intracellular uptake of ABCG2 efflux substrates (270). The addition of ponatinib 
to ABCG2 transported chemotherapeutics resulted in synergistic cytotoxicity. However, this 
effect may only occur at TKI concentrations several times higher than what is clinically 
achievable (173, 197). A strategy using low doses of several TKIs could be utilised to 
circumvent this (271, 279). Using combinatorial treatment strategies, different TKIs may 
maximise the inhibition of Bcr-Abl mutants and inhibit ABC transporter mediated efflux, while 
also allowing lower dosing of individual drugs, therefore limiting off target drug toxicity (128). 
Alternatively, switching to different classes of chemotherapeutic agents which are not 
substrates of ABC transporters, ABC transporter-mediated resistance could be circumvented 
(280). 
 
5.3.3 ABCG2 and the stem cell phenotype 
Evidence indicates a critical role for ABCG2 in the protection of haematopoietic stem cell 
populations, and a stem cell ‘side population’ can be purified based on the activity of ABCG2 
(281). High levels of gene expression are observed in areas of low oxygen, such as the stem 
cell niche (282). The expression of ABCG2 is highly conserved in primitive stem cells from bone 
marrow, skeletal muscle, cultured embryonic stem cells, and the enforced expression of 
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ABCG2 in normal murine bone marrow cells increases the stem cell population proportion, 
inhibiting haematopoietic development (283). ABCG2 expression is crucial for stem cell 
survival, and ABCG2-null progenitor cells demonstrate impaired survival under hypoxic 
conditions (282). ABCG2 also plays a role in cancer stem cell maintenance, with inhibition of 
ABCG2 activity reducing the expression of stem cell markers and self-renewal capacity of 
glioma stem cells (284). In the model presented here, ABCG2 expression may be maintaining 
a stem cell-like population in the K562 10 and 15 nM DasR intermediates. The lower cell 
cycling rate of stem cells limits their sensitivity to drug treatments such as TKIs. However, the 
ABCG2 overexpressing K562 DasR cells did not exhibit a slower growth cycle in routine cell 
culture, requiring subculture at the same rate of other K562 lines. Other unknown functions 
of ABCG2 expression in determining the stem cell subtype may be causative of decreased 
dasatinib and ponatinib sensitivity, however, the primary route of cellular TKI defence is most 
likely through TKI export from the cell. It may be worthwhile to determine the expression and 
function of ABCG2 in the stem cell (CD34+) population of diagnostic CML sample, to 
determine their inherent TKI resistance, and to establish whether inhibition of ABCG2 
function will sensitise these cells to TKI. 
 
5.3.4 Selective pressure of dasatinib on ABCG2 expression 
Following identification of ABCG2 overexpression from mRNAseq of K562 DasR samples, qPCR 
and flow cytometric expression analyses were used to track gene and protein expression over 
the course of dasatinib dose escalation. A population of ABCG2 overexpressing cells was  
identified early in dose escalation, detectable in the 2, 3.5 and 5 nM Das intermediates, 
however, high ABCG2 expression was not strongly selected for until escalation to 10-15 nM 
dasatinib. Findings elaborated on in Chapters 3 and 4 indicated that BCR-ABL1 overexpression 
was highest in these early intermediates, and reached a maximum in the 3.5-5 nM Das lines. 
I hypothesise that in lower concentrations of dasatinib, BCR-ABL1 overexpression alone is 
sufficient for cells to maintain viability and proliferative activity, and high ABCG2 expression 
does not confer a selective advantage under these circumstances. However, at higher 
dasatinib concentrations, ABCG2 overexpression confers significantly greater dasatinib 
resistance, thus allowing ABCG2 overexpressing cells to proliferate. Alternatively, there may 
be a molecular switch in the control of ABCG2 gene expression, whereby higher intracellular 
TKI concentrations induce drug transporter expression. However, this remains difficult to test, 
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as a 10-15 nM dose of dasatinib to a TKI naïve BCR-ABL1+ve cell line population will typically 
result in cell death. 
 
Upon continued dasatinib dose escalation above 25 nM, ABCG2 expression significantly 
decreased. Preliminary results demonstrated that cells expressing the highly resistant T315I 
mutation first arose in the 25 nM intermediate; it is possible that a minor population of T315I 
positive clones were selected for, outcompeting the cells that overexpress ABCG2 as a 
resistance mechanism. Curiously, analysis of cell viability assay data identified a 
subpopulation of the 15 nM DasR intermediate, highly resistant to dasatinib in both the 
presence and absence of Ko143 (Figure 5.6c). This suggests that a significant proportion of 
the cell population was expressing T315I at a low level, only being selected for in higher 
dasatinib concentrations. Additionally, this finding highlights the failure of aggregate/pooled 
cell population experiments for determining cell population heterogeneity. The observed loss 
of ABCG2 expression with prolonged dasatinib escalation is likely due to an increase in the 
T315I positive, ABCG2 expression low, fraction of the cell population. 
 
Alternatively, cellular ABCG2 expression may provide the and environment conducive to 
development of a kinase domain mutation, in which there is low intracellular concentration 
of TKI and insufficient Bcr-Abl inhibition to prevent cellular proliferation. Our laboratory has 
previously demonstrated that ABC transporter overexpression precedes kinase domain 
mutation (182), however, in the current study it is unknown whether the T315I founder clones 
were also ABCG2 overexpressing. The association between T315I and ABCG2 expression could 
have been determined by sorting K562 DasR cells for ABCG2 expression, and sequencing the 
T315I region in the ABCG2 high and low populations, to establish and correlations between 
expression of these resistance mechanisms. 
 
5.3.5 Future work 
The fluctuations in ABCG2 expression dynamics and its effects on dasatinib and ponatinib 
resistance underlie a convoluted biological complexity. There remain several research 
questions regarding the stochastic induction of ABCG2 expression and TKI resistance, and as 
discussed, a number of experimental assays which could elucidate this. The translation of ABC 
transporter inhibitors into clinical use is ongoing, and molecular characterisation of ABC 
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transporter substrate transport will likely indicate potential therapeutic drug combinations. 
The results presented here demonstrate how ABCG2 can contribute to TKI resistance and 
cross resistance. However, we have demonstrated that perturbation of ABCG2 expression 
primarily occurs within a particular drug concentration window, and as such, the targeting of 
ABC transporter expression early in the course of TKI treatment may halt the progression of 






Figure 5.1: Volcano plot diagram indicating genes differentially expressed in the K562 10, 15 
and 25 nM DasR intermediates, compared with drug naïve controls. Green dots / labeled 
genes indicate genes with expression logFC>2, and FDR<0.005 as a significance cutoff. Note 
the ABCG2 gene towards the far right of the diagram, indicating a high level of expression in 
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in the 3.5 nM Das intermediate, which only exhibited marginal ABCG2 expression. No effect 
of Ko143 was observed in the 25, 50 and 200 nM DasR lines, in which an IC50Das could not be 
obtained (IC50Das > 5000 nM). Bars represent the mean of at least three independent 
experiments, with diamonds denoting IC50 calculated from individual replicates; error bars 
represent SEM. Unequal variances t-test was performed between -/+ Ko143 samples; 
significance is denoted by (ns) for p>0.05, (*) for p<0.05, (**) for p<0.01, (***) for p<0.001. 
b) Representative dasatinib IC50 western blotting. Samples are selected K562 DasR dose 
escalation intermediates; red arrows indicate the approximate point of 50% inhibition. In the 
50 and 200 nM Das lines, no concentration of dasatinib was able to inhibit Bcr-Abl activity, 
whether in the presence of absence of Ko143, demonstrating that ABCG2 was not required 
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contribution of ABCG2 to lowered ponatinib sensitivity. Addition of Ko143 lowered ponatinib 
IC50 in the 25 nM Das intermediate, although this did not reach significance. No significant 
differences were observed in the presence of  Ko143 in the 50 and 200 nM DasR lines. Data 
represent the mean of at least three independent replicate experiments; error bars represent 
SEM. Unequal variances t-test was performed between -/+ Ko143 samples; significance is 
denoted by (n.s.) for p>0.05, (*) for p<0.05, (**) for p<0.01. b) Representative ponatinib IC50 
western blotting. Samples are selected K562 DasR dose escalation intermediates; red arrows 






6.1 TKI exposure and the emergence of TKI resistance mechanisms 
The selective pressure of TKI exposure in CML results in the emergence of leukaemic cells 
with TKI resistant characteristics as the clonally dominant population. This effect was first 
identified in CML patients who became resistant to imatinib, with researchers identifying 
amplification and/or mutation of the BCR-ABL1 gene and protein as resistance mechanisms 
(146). This was subsequently replicated by in vitro models of treatment resistant CML (144). 
While some of these cell line models have identified multiple resistance mechanisms 
fluctuating in an evolving cell population (182, 200), the majority of studies identify a single 
TKI resistance mechanism as causative of treatment resistance. Often, this cause of resistance 
is identified as a Bcr-Abl kinase domain mutation, BCR-ABL1 overexpression, or increased 
efflux transporter expression, with each resistance mechanism observed in the absence of 
another. This also reflects what is generally observed in clinical studies; the T315I mutation is 
frequently described in patients as solely causative of dasatinib resistance (285). However, 
this may also be an experimental artefact, due to the approach with which patient and cell 
line studies are undertaken. Studies of TKI resistant patients typically investigate resistance 
mechanisms following the detection of TKI failure, where the leukaemic cell population has 
already expanded when symptoms re-emerge or leukaemic cell presence is detected by 
routine blood examination. While this ‘snapshot’ approach is necessitated for practical 
reasons , there is a lack of understanding of how and why complete elimination of the 
leukaemic cell population does not occur; it is possible, if not likely, that undetected 
resistance mechanisms are present in these circumstances, allowing repopulation of the 
leukaemic cells. Similarly, the majority of in vitro cell line model analyses of TKI resistance 
have been performed only following long-term drug treatment, with samples taken only at a 
single point in time (145, 178, 243, 286, 287). Rarely have studies investigated the dynamics 
of leukaemic cells during the critical period at the induction of drug resistance, and thus 
documentation of the fluctuations of resistance mechanisms in leukaemic cell populations is 
lacking. Indeed, patient studies have demonstrated that high levels of BCR-ABL1 expression 
predict and predispose cells to the gain of alternate imatinib resistance mechanisms (147, 
182). Furthermore, previous performed analyses of TKI resistance mechanisms is often not 
exploratory, but targeted, to already known and expected resistance mechanisms (144, 200, 
288). Again, these studies likely neglect many of the cellular changes occurring over prolonged 
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TKI treatment. The project presented here has detailed the fluctuations in the K562 DasR 
leukaemic cell population occurring over months of incrementally increasing dasatinib 
exposure. Three distinct TKI resistance mechanisms were identified and validated; 
overexpression of Bcr-Abl, upregulation of the ABCG2 membrane transporter, and mutation 
of the Bcr-Abl gatekeeper residue, T315I. While each resistance mechanism has been 
independently observed in isolation by other studies, to date, no other study has observed 
their sequential emergence, thus this project serves an insight to the selective pressure of TKI 
exposure and how it influences the evolution of the malignancy. The observed fluctuations in 
the cell population can be explained by a model of selection by which leukaemic cells with 
the most energy efficient TKI resistance mechanisms are selected, a theory for which evidence 
has been provided by this project. 
 
6.2 Factors influencing the selection of dasatinib resistant 
leukaemic cell populations 
The transition from Bcr-Abl overexpression, to increased ABCG2 expression, and finally 
development of the T315I mutation, the principal TKI resistance mechanism in the K562 DasR 
cell line, is reflective of the selective forces contributed by dasatinib. Models of TKI resistance 
have previously been generated and examined; the different methodologies used to generate 
TKI resistance have resulted in a different spectrum of observed and identified resistance 
mechanisms, which can be compared with our model. 
 
The overexpression of the BCR-ABL1 gene and protein product is a well characterised 
mechanism of resistance to TKI treatment (146, 147, 149, 205, 207). In the K562 DasR cell line 
model, BCR-ABL1 overexpression was identified when our laboratory first described in vitro 
TKI resistance mechanisms (205); in the current study it was demonstrated that genomic 
amplification is causative of gene transcript overexpression. BCR-ABL1 overexpression has 
been noted in other cell line models of TKI resistance (144, 207). However, BCR-ABL1 
amplification is not universally identified as a resistance mechanism, even with other K562 
models; a K562 line generated by Okabe et al resistant to ~15 nM dasatinib observed lower 
Bcr-Abl levels in resistant lines (289, 290). Therefore, it is hypothesised that the level of Bcr-
Abl expression in leukaemic cells is maintained with random, stochastic variance, and does 
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not consistently rise. Instead, it is selected for upon prolonged dasatinib exposure. Indeed, 
this is the case for resistance to other TKIs. A study by our laboratory generating subsequent 
ponatinib resistance from the K562 200 nM DasR cell line described here, demonstrated a 
continuing rise in BCR-ABL1 gene expression upon increasing ponatinib exposure (288, 291). 
However, in this study of dasatinib resistance, the loss of BCR-ABL1 expression was also 
identified, concurrent with the gain of the ABCG2 overexpression (Figure 6.1). The loss of BCR-
ABL1 expression with TKI treatment is normally indicative of lowered patient disease burden 
and the death of leukaemic cells, however, in this case, the loss of BCR-ABL1 expression was 
not concomitant with cell death. Instead, the reductions in BCR-ABL1 expression were 
associated with a loss of genomic BCR-ABL1 in the bulk population, which was likely due to 
expansion of cells with lower BCR-ABL1 copy numbers. This population flux was presumably 
driven by the selective advantage of ABCG2 overexpressing cells, however, the unexpected 
reduction in BCR-ABL1 expression suggests that with the gain of an alternate resistance 
mechanism, the high level expression of BCR-ABL1 does not confer a selective advantage, and 
is instead a cellular burden driving deselection. 
 
With ongoing dasatinib dose escalation, fluctuations in the expression of resistance 
mechanisms are again observed, with the loss of ABCG2 expression following the gain of the 
T315I mutation. The loss of ABC transporter expression with prolonged TKI exposure has 
previously been described (200). Indeed, a similar effect has been observed by our laboratory, 
whereby initial TKI resistance was driven by ABC transporter expression, however, expression 
was lost with the gain of alternate resistance mechanisms and prolonged TKI escalation (182). 
In this model, the de-selection of BCR-ABL1 and ABCG2 overexpressing cells concurrent with 
the gain of an alternate resistance mechanism suggests that there is a cellular expenditure 
associated with the expression of these resistance mechanisms. Indeed, there is a significant 
energy cost involved in the synthesis of a gene transcript and protein. In order for leukaemic 
cells to overcome TKI exposure by Bcr-Abl expression alone, a full length protein must be 
synthesised to ‘mop up’ each TKI molecule, making it a highly inefficient process. 
Comparatively, TKI resistance mediated by ABC transporter expression is more energy 
efficient; although the ABC transporters are ATP-dependent, following protein synthesis, a 
single transporter protein can exclude many TKI molecules from the cell. Conversely, gain of 
a mutation in the Bcr-Abl kinase domain, such as T315I, has no associated energy expenditure, 
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while rendering the TKI completely ineffective and providing the leukaemic cell a clear 
selective advantage, in the presence of TKI. However, this begs the question as to why T315I 
is not strongly selected for earlier on during dasatinib dose escalation. The lack of early 
emergence of kinase domain mutations during dasatinib dose escalation is likely due to 
decreased kinase efficiency due to T315I, which would then only be selected for in the 
presence of a TKI. Withdrawal of dasatinib from the 200 nM Das cell line, over several 
passages, has been demonstrated to coincide with the loss of T315I mutant expression 
(unpublished data). Furthermore, in CML patients T315I is rarely identified in the absence of 
prior TKI exposure, and the gatekeeper residue is highly conserved across patients and protein 
species alike (159). Thus, it seems that it is only under the selective pressure of high dasatinib 
concentrations, that T315I consistently emerges. 
 
6.3 Therapeutic implications and future prospects 
There are several therapeutic and scientific implications of the thesis here presented. This 
research aimed to investigate the evolution of resistance to TKI therapy in a cell line model of 
CML, utilising exploratory and functional methods to identify the mechanisms of resistance. 
The findings suggest that TKI resistance is not static, but dynamic, with the alterations in 
leukaemic cells possibly exposing them to therapeutic intervention. This identified several 
mechanisms of resistance to the TKI dasatinib, namely: Bcr-Abl overexpression, the T315I 
mutation, and overexpression of ABCG2. Critically, the ABCG2 inhibitor Ko143 was able to 
sensitise leukaemic cells to dasatinib treatment. While Ko143 has not been translated 
clinically, ABC transporter inhibition using other drugs may provide a therapeutic avenue. The 
exploitation of the ABC transporter-inhibiting effect of certain TKIs may prove useful. 
Concurrent treatment with low doses of several TKIs may simultaneously block transporter 
mediated resistance, while effectively inhibiting Bcr-Abl. Similarly, early treatment with a 
T315I inhibitor may prevent the spontaneous development and selective emergence of the 
mutation. Concurrent TKI treatment may also limit the side effects of the individual TKIs, 
which are linked to patient trough plasma concentrations (292). However, currently available 
T315I inhibitors have severe side effects, and the efficacy and safety of this strategy remains 
to be explored. 
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This study marks the first time the transport of ponatinib by ABCG2 has been described. 
Ponatinib is currently indicated for treatment resistant Ph+ leukaemia, particularly following 
the detection of the T315I mutation. The tolerance of ponatinib by certain K562 DasR cells, 
conferred by the same resistance mechanisms, will likely result in a lack of efficacy of 
ponatinib salvage therapy. These observations presented here suggest that when available, 
patient leukaemic material be thoroughly examined for all known resistance mechanisms, 
such that ponatinib treatment efficacy may be predicted. 
 
There is an ATP / GTP expenditure associated with certain mechanisms of drug resistance. TKI 
resistance mechanisms allows a selective advantage under TKI exposure, however, expression 
of the resistance mechanism may confer a disadvantage in the absence of TKI selective 
pressure. Thus, the addition and withdrawal of TKI results in fluctuations in cell population 
numbers and cellular traits. Studies have demonstrated that the intermittent use of 
chemotherapy cycles can allow repeated drug responses, and alleviates the strong selective 
pressure chemotherapy resistant mutations and mechanisms, which can occur over 
continuous treatment regimens (293). This also holds true for TKI treatment; if upon imatinib 
treatment withdrawal there is subsequent disease recurrence, patients typically respond to 
imatinib reintroduction (294, 295). Nevertheless, exactly how to manipulate the balance of 
leukaemic cell population, drug side effects, and the selective pressure towards TKI 
resistance, remains a case-by-case affair. 
 
The project presented here has significantly added to the understanding of therapeutic 
resistance in the treatment of Ph+ leukaemia. Exploration of the TKI resistance mechanisms 
in a CML disease model highlighted the selective advantages conferred by leukaemic cell 
expression of Bcr-Abl, ABC efflux transport, and kinase domain mutations, and emphasised 
the complexity of their interactions. For the first time, the active transport of ponatinib by 
ABCG2 has been demonstrated. Furthermore, this study underlines the exploratory power of 
transcriptome sequencing for the determination of transitory cellular adaptations which 
occur during the accrual of TKI resistance. Overall the data presented here confirm the 
complex evolution of CML and support early interrogation of resistance mechanisms in order 








(W+L! _'#,'$(! $&.(aG! +.5!,)*12# U(.(! (Z',(//&).! $(J($/! +,(! '$)%%(5! +/! +! '(,*(.%+U(! )H! %-(!
0+Z&0+$!(Z',(//&.U!$&.(/G!+.5!%-(!3SNX9!0#%+%&).!_,(5!$&.(a!&/!/-)4.!+/!+!'(,*(.%+U(!)H!)*+3
,)-.!%,+./*,&'%/O!3-(!5+/+%&.&2!91XM!_2$#(!2+,/aG!+!0+,;(,!)H!5+/+%&.&2!,(/&/%+.*(G!&/!/-)4.!).!










Figure S1: Flow diagram for the construction of the lentiviral expression vector for Ba/F3 
transduction. A vector containing the BCR-ABL1 e14a2 sequence (pLEF-p210) was purchased, 
and cloned into the pCR-XL-2-TOPO vector for site directed mutagenesis, to generate the e6a2 
and e1a2 sequences. BCR-ABL1 constructs were then cloned into the pRuf-iG2 vector for 

























































































Figure S3: Gel electrophoresis of test digest of the ~15850 bp pLEF-p210 vector using the 
restriction enzymes BamHI and EcoRI. Double digest demonstrated the presence of a ~7400 
bp band, indicative of the ~7400 bp pLEF plasmid backbone, as well as ~6300 and 2150 bp 



















































7400 bp pLEF vector backbone
6300 bp predicted BCR-ABL1 fragment
2150 bp predicted BCR-ABL1 fragment
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Figure S7: The BCR-ABL1 e14a2 PCR amplified sequence was cloned into the 3.96 kb pCR-XL-
2-TOPO vector for mutagenesis. The e6a2 mutagenised, linearised vector was 
electrophoresed alongside the original e14a2 construct, undigested (left) and digested using 
EcoRI (right). EcoRI cut sites lie on either side of the pCR-XL-2-TOPO PCR-product insert point, 
with EcoRI restriction digest releasing the BCR-ABL1 e14a2 sequence (lane 4), and the ~1.9 kb 
and ~3.3 kb bands predicted following e6a2 mutagenesis (lane 5). The mutagenised and 
















































































Predicted 3.96 kbp band 
(pCR-XL-2 TOPO vector)
Predicted 1934 bp band 
(BCR exons 1-6)
Predicted 3321 bp band 
(ABL1 exons 2-11)





































































































































































































































































K562 naïve: 359.2883 ng/µL
K562 10nM Das: 419.6428 ng/µL K562 15nM Das: 294.2954 ng/µl
K562 25nM Das: 303.2486 ng/µl K562 50nM Das: 485.726 ng/µl






Figure S14: a) Bioanalyzer electrophoresis of RNA samples used for RNA sequencing 
experiments was analysed to generate b), which demonstrated the integrity and 
concentration of samples. The two larger peaks in each sample are indicative of ribosomal 
RNA, whereas the smaller peak at ~150 nucleotides indicates fragmented mRNA used for 
sequencing. 
  
K562 200nM Das: 448.0951 ng/µL
K562 clone C10: 457.802 ng/µL K562 clone G5: 300.9391 ng/µl
K562 clone B9: 217.7998 ng/µl K562 clone E2: 258.1957 ng/µl









Figure S15: a) Quality control data from RNA sequencing experimental data demonstrated the 
accuracy of sequencing base calls. Q score (phred score) was greater than 30 (99.9% 
accuracy). b) Quality control data from RNA sequencing experimental data demonstrated an 
appropriate distribution of sequenced reads across the samples. This data was used to 

































Figure S21: Volcano plot diagram indicating genes differentially expressed in the K562 50 and 
200 nM DasR intermediates, compared with drug naïve controls. Green dots / labeled genes 




1. Bennett JH. Case of Hypertrophy of the Spleen and Liver: In which Death Took Place 
from Suppuration of the Blood: Edinburgh Med Sug J; 1845. 
2. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110(1):2-11. 
3. Piller GJ. Leukaemia – a brief historical review from ancient times to 1950. Br J 
Haematol. 2001;112(2):282-92. 
4. Union for International Cancer Control U. Medicines for treatment of the following 
cancers – review – EML and EMLc: World Health Organization; 2015 [cited 2018 11/09/2018]. 
Available from: 
http://www.who.int/selection_medicines/committees/expert/20/applications/cancer/en/. 
5. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330-40. 
6. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and Treatment of Chronic Myeloid 
Leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440-54. 
7. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, 
therapy, and monitoring. Am J Hematol. 2016;91(2):252-65. 
8. NSW CC. Chronic myeloid leukaemia (CML): Cancer Council NSW; 2016. Available 
from: https://www.cancercouncil.com.au/chronic-myeloid-leukaemia/. 
9. Tanaka K, Takechi M, Hong J, Shigeta C, Oguma N, Kamada N, et al. 9; 22 translocation 
and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb 
survivors. J Radiat Res. 1989;30(4):352-8. 
10. Radich JP. The Biology of CML blast crisis. Hematology Am Soc Hematol Educ Program. 
2007:384-91. 
11. Nowell PC. A minute chromosome n human chronic granualocytic leukemia. Science. 
1960;132:1497-501. 
12. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 
1973;243(5405):290-3. 
13. Gollin SM, editor Mechanisms leading to nonrandom, nonhomologous chromosomal 
translocations in leukemia. Semin Cancer Biol; 2007: Elsevier. 
14. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic 
cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad 
Sci USA. 1988;85(23):9312-6. 
15. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in 
mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-
30. 
16. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, et al. Efficient and rapid 
induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice 
receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92(10):3780-92. 
17. Li S, Ilaria RL, Jr., Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms 
of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice 
but have different lymphoid leukemogenic activity. J Exp Med. 1999;189(9):1399-412. 
18. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S, et al. A bcr-v-abl 
oncogene induces lymphomas in transgenic mice. Mol Cell Biol. 1989;9(7):2798-805. 
 8-199 
19. Scott S, Travis D, Whitby L, Bainbridge J, Cross NC, Barnett D. Measurement of BCR-
ABL 1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA 
Programme. Br J Haematol. 2017;177(3):414-22. 
20. Zhu Q-S, Heisterkamp N, Groffen J. Unique organization of the human BCR gene 
promoter. Nucleic Acids Res. 1990;18(23):7119-25. 
21. Shah N, Witte O, Denny C. Characterization of the BCR promoter in Philadelphia 
chromosome-positive and-negative cell lines. Mol Cell Biol. 1991;11(4):1854-60. 
22. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and 
leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 
2002;21(56):8652. 
23. Alam A, al Qawasmeh K, Kanbar J, Syed MH, Lal A, Hussain S, et al. Philadelphia Positive 
Acute Lymphoblastic Leukemia (Ph+ ALL), Tawam Experience. Blood; 2015. p. 4867. 
24. Heisterkamp N, Groffen J. Philadelphia-positive leukemia: a personal perspective. 
Oncogene. 2002;21(56):8536. 
25. Gambacorti-Passerini C, Le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, et 
al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and 
induces apoptosis. Blood Cell Mol Dis. 1997;23(3):380-94. 
26. Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the c-Abl tyrosine kinase in 
normal and cancer cells. Biology of the Cell. 2008;100(11):617-31. 
27. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural 
basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859-71. 
28. Feller SM, Knudsen B, Hanafusa H. c-Abl kinase regulates the protein binding activity 
of c-Crk. EMBO J. 1994;13(10):2341-51. 
29. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends 
Cell Biol. 1999;9(5):179-86. 
30. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in 
cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13(8):nrc3563. 
31. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell. 2002;108(2):247-59. 
32. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, et al. A 
myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 2003;112(6):845-57. 
33. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity 
within a single exon. Cell. 1991;67(3):459-68. 
34. Laurent E, Talpaz M, Wetzler M, Kurzrock R. Cytoplasmic and nuclear localization of 
the 130 and 160 kDa Bcr proteins. Leukemia. 2000;14(11):1892. 
35. Chuang T, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch G. Abr and Bcr are 
multifunctional regulators of the Rho GTP-binding protein family. P Natl Acad Sci USA. 
1995;92(22):10282-6. 
36. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: 
regulation, effectors and functions in vivo. Bioessays. 2007;29(4):356-70. 
37. Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T, et al. The c-Myc 
oncoprotein interacts with Bcr. Curr Biol. 2003;13(5):437-41. 
38. Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM. Association of the protein 
kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science. 1994;266(5182):129-33. 
39. Meng J, Jiang J-J, Atsumi T, Bando H, Okuyama Y, Sabharwal L, et al. Breakpoint Cluster 
Region–Mediated Inflammation Is Dependent on Casein Kinase II. J Immunol. 
2016;197(8):1601082. 
 8-200 
40. McWhirter JR, Galasso DL, Wang J. A coiled-coil oligomerization domain of Bcr is 
essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 
1993;13(12):7587-95. 
41. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl 
oncoprotein oligomerization domain. Nature structural biology. 2002;9(2):117-20. 
42. Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. The NH2-terminal coiled-coil 
domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in 
mice by Bcr-Abl. Mol Cell Biol. 2001;21(3):840-53. 
43. Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2011:930-637. 
44. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism 
of activation and downstream effectors. Cancer Res. 2005;65(6):2047-53. 
45. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src 
kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 1996;56(15):3589-
96. 
46. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, 
et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. 
EMBO J. 2002;21(21):5766-74. 
47. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of 
signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines 
transformed by Bcr/Abl. J Exp Med. 1996;183(3):811-20. 
48. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia—signaling 
pathways of initiation and transformation. Hematol Oncol Clin N. 2004;18(3):545-68. 
49. Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, et al. 
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in 
hematopoietic cancer. Leukemia. 2018;32:1713-26. 
50. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, Kataoka Y, et al. Functional 
cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full 
oncogenic activities of BCR/ABL in K562 cells. J Biol Chem. 2002;277(10):8076-82. 
51. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, et al. Activation of 
the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen 
species. Blood. 2005;105(4):1717-23. 
52. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid 
leukemia. Blood. 2000;96(10):3343-56. 
53. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by 
ABL oncogenes. Cell. 1992;70(6):901-10. 
54. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et 
al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-
dependent pathway. Embo J. 1997;16(20):6151-61. 
55. Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, et al. 
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Molecular 
cancer. 2015;14(1):132. 
56. Hehlmann R. How I treat CML blast crisis. Blood. 2012;120(4):737-47. 
57. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al. The BCR/ABL 
Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells. J Biol 
Chem. 2000;275(32):24273-8. 
58. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, et al. Fusion tyrosine 
kinases induce drug resistance by stimulation of homology-dependent recombination repair, 
 8-201 
prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol. 
2002;22(12):4189-201. 
59. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-
ABL in chronic myeloid leukemia. Blood. 1994;83(8):2038-44. 
60. Wilson G, Vandenberghe E, Pollitt R, Rees D, Goodeve A, Peake I, et al. Are aberrant 
BCR–ABL transcripts more common than previously thought? Br J Haematol. 
2000;111(4):1109-11. 
61. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid 
leukaemia. Acta Haematol-Basel. 2002;108(4):180-202. 
62. Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powles R, et al. A novel abl 
protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. 
Nature. 1987;325(6105):635-7. 
63. Gong Z, Medeiros L, Cortes J, Zheng L, Khoury J, Wang W, et al. Clinical and prognostic 
significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer 
J. 2017;7(7):e583. 
64. Martínez-Laperche C, Jiménez-Gámiz P, Collado R, Minguela-Puras A, Piñán-Francés 
M, Bellosillo B, et al. Chronic myeloid leukemia (CML) patients with atypical e1a2 P190 BCR-
ABL translocation show a poor response to therapy with tyrosine kinase inhibitors (TKI). Am 
Soc Hematology; 2013. 
65. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, et al. Neutrophilic-
chronic myeloid leukemia: Low levels of p230 BCR/ABL mRNA and undetectable p230 
BCR/ABL protein may predict an indolent course. Cancer: Interdisciplinary International 
Journal of the American Cancer Society. 2002;94(9):2416-25. 
66. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia 
phenotype. Blood. 1996;88(7):2375-84. 
67. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic 
potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. 
Mol Cell Biol. 1991;11(9):4710-6. 
68. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. 
BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995;86(12):4603. 
69. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, et al. A novel BCR-ABL 
fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous 
leukemia. Blood. 1996;88(6):2236-40. 
70. Dupont M, Jourdan E, Chiesa J. Identification of E6A2 BCR-ABL fusion in a Philadelphia-
positive CML. Leukemia. 2000;14(11):2011-2. 
71. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL 
transcript in chronic myeloid leukemia: is it associated with aggressive disease? 
Haematologica. 2004;89(5):611-3. 
72. Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, et al. 
Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: 
presentation of two cases. Acta Haematol. 2009;122(1):11-6. 
73. Torres F, Ivanova-Dragoeva A, Pereira M, Veiga J, Rodrigues AS, Sousa AB, et al. An 
e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial 
presentation. Leukemia Lymphoma. 2007;48(5):1034-7. 
74. Schultheis B, Wang L, Clark RE, Melo JV. BCR-ABL with an e6a2 fusion in a CML patient 
diagnosed in blast crisis. Leukemia. 2003;17(10):2054-5. 
 8-202 
75. Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C. A new case 
with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during 
imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. 
Leukemia. 2008;22(4):856-8. 
76. Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, et al. e6a2 BCR/ABL1 
fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. 
Haematologica. 2005;90(8):1139-41. 
77. Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ. E6a2 
BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive 
to Imatinib. Leukemia Lymphoma. 2005;46(9):1375-7. 
78. Langabeer SE, Crampe M, Kelly J, Fadalla K, Connaghan G, Conneally E. Nilotinib and 
allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 
BCR-ABL transcripts. Leuk Res. 2010;34(8):e204-5. 
79. Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, et al. BCR-ABL1 e6a2 
transcript in chronic myeloid leukemia: biological features and molecular monitoring by 
droplet digital PCR. Virchows Arch. 2015;467(3):357-63. 
80. Yao J, Douer D, Wang L, Arcila ME, Nafa K, Chiu A. A case of acute myeloid leukemia 
with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic 
leukemia. Leuk Res Rep. 2017;7:17-9. 
81. Ritchie DS, McBean M, Westerman DA, Kovalenko S, Seymour JF, Dobrovic A. 
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib 
then dasatinib. Blood. 2008;111(5):2896-8. 
82. Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F, et al. Identification of 
a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic 
leukemia: a case report. Leukemia. 2004;18(10):1735-6. 
83. Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical BCR-ABL 
mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007;92(12):1699-
702. 
84. Quentmeier H, Cools J, Macleod RA, Marynen P, Uphoff CC, Drexler HG. e6-a2 BCR-
ABL1 fusion in T-cell acute lymphoblastic leukemia. Leukemia. 2005;19(2):295-6. 
85. Kumar D, Panigrahi MK, Saikia KK, Kapoor G, Mehta A. Molecular analysis of childhood 
B-acute lymphoblastic leukemia: Identification and prognosis of rare breakpoints. Mol Biol. 
2015;49(6):944-8. 
86. Staal-Viliare A, Latger-Cannard V, Rault JP, Didion J, Gregoire MJ, Bologna S, et al. [A 
case of de novo acute basophilic leukaemia: diagnostic criteria and review of the literature]. 
Ann Biol Clin (Paris). 2006;64(4):361-5. 
87. Rohon P, Divoka M, Calabkova L, Mojzikova R, Katrincsakova B, Rusinakova Z, et al. 
Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: 
implications for treatment strategy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 
2011;155(2):187-90. 
88. Gregoire MJ, Latger-Cannard V, Staal A, Bologna S, Leotard B, Rault JP, et al. 
Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript. Acta 
Haematol. 2006;116(3):216-8. 
89. Beel KA, Lemmens J, Vranckx H, Maertens J, Vandenberghe P. CML with e6a2 BCR-
ABL1 transcript: an aggressive entity? Ann Hematol. 2011;90(10):1241-3. 
 8-203 
90. Branford S, Rudzki Z, Hughes T. A novel BCR–ABL transcript (e8a2) with the insertion 
of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic 
myeloid leukaemia. Brit J Haematol. 2000;109(3):635-7. 
91. Cayuela J-M, Rousselot P, Nicolini F, Espinouse D, Ollagnier C, Bui-Thi M, et al. 
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia 
patients treated with imatinib. Leukemia. 2005;19(12):2334. 
92. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, et al. e8a2 BCR–
ABL: more frequent than other atypical BCR–ABL variants? Leukemia. 2005;19(4):681. 
93. Tchirkov A, Couderc J-L, Périssel B, Goumy C, Regnier A, Uhrhammer N, et al. Major 
molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel 
form of e8a2 BCR-ABL transcript. Leukemia. 2006;20(1):167. 
94. Qin YZ, Jiang B, Jiang Q, Zhang Y, Jiang H, Li JL, et al. Imatinib mesylate resistance in a 
chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. Acta 
Haematol. 2008;120(3):146-9. 
95. Park IJ, Lim YA, Lee WG, Park JS, Kim HC, Lee H-J, et al. A case of chronic myelogenous 
leukemia with e8a2 fusion transcript. Cancer Genet Cytogenet. 2008;185(2):106-8. 
96. Mühlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, et al. Fluorescence 
in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia 
chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: A new 
strategy for remission assessment. Gene Chromosome Canc. 1998;21(2):90-100. 
97. Branford S, Hughes T, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-
time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Brit J 
Haematol. 1999;107(3):587-99. 
98. Marum JE, Branford S. Current developments in molecular monitoring in chronic 
myeloid leukemia. Ther Adv Hematol. 2016;7(5):237-51. 
99. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring 
CML patients responding to treatment with tyrosine kinase inhibitors: review and 
recommendations for harmonizing current methodology for detecting BCR-ABL transcripts 
and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. 
100. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. 
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 
2013. Blood. 2013;122(6):872-84. 
101. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical 
practice in CML. Blood. 2016;128(1):17-23. 
102. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone 
marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med. 
1986;314(4):202-7. 
103. Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin 
Hematol. 2010;47(4):354-61. 
104. Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of 
interferon-α in the treatment of chronic myeloid leukemia. Leukemia. 2013;27(4):803. 
105. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid 
leukemia and interferon-α: a study of complete cytogenetic responders. Blood. 
2001;98(10):3074-81. 
106. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a 
selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat Med. 
1996;2(5):561. 
 8-204 
107. Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U, et al. Modelling study 
of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 
52411. J Comput Aid Mol Des. 1995;9(6):465-72. 
108. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor 
CGP57148B selectively inhibits the growth of BCR-ABL–positive cells. Blood. 1997;90(9):3691-
8. 
109. Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, et al. The tyrosine 
kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-
regulating BCL-X. Clin Cancer Res. 2000;6(5):1958-68. 
110. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, et al. Results of imatinib 
mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk 
myelodysplastic syndrome, and myeloproliferative disorders. Cancer Am Cancer Soc. 
2003;97(11):2760-6. 
111. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit 
receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 
2000;96(3):925-32. 
112. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of 
major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed 
chronic myeloid leukemia. New Engl J Med. 2003;349(15):1423-32. 
113. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid 
leukaemia. Lancet Oncol. 2007;8(11):1018-29. 
114. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety 
of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J 
Med. 2001;344(14):1031-7. 
115. Lee S, Kim Y-J, Min C-K, Kim H-J, Eom K-S, Kim D-W, et al. The effect of first-line imatinib 
interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly 
diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 
2005;105(9):3449-57. 
116. Druker BJ, Guilhot F, O'brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-
year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med. 
2006;355(23):2408-17. 
117. Nicolini FE, Balsat M, Lekieffre M, Alcazer V, Labussière-wallet H, Huet S, et al. Very 
Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML 
Patients. Blood; 2015. p. 2774. 
118. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal 
structures of the kinase domain of c-Abl in complex with the small molecule inhibitors 
PD173955 and imatinib (STI-571). Cancer Res. 2002;62(15):4236-43. 
119. Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. 
Genes Cancer. 2012;3(5-6):436-46. 
120. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: 
keeping resistance in check. Expert Opin Investig Drugs. 2008;17(6):865-78. 
121. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, et al. 
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 
2005;7(2):129-41. 
122. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. 
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal 
novel kinase and nonkinase targets. Blood. 2007;110(12):4055-63. 
 8-205 
123. Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J. Important therapeutic targets in 
chronic myelogenous leukemia. Clin Cancer Res. 2007;13(4):1089-97. 
124. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'brien S, Wassmann B, et al. Nilotinib in 
imatinib-resistant CML and Philadelphia chromosome–positive ALL. New Engl J Med. 
2006;354(24):2542-51. 
125. Saglio G, Kim D-W, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus 
imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med. 2010;362(24):2251-
9. 
126. Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, et al. The structure 
of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory 
activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790-7. 
127. Shah NP, Nicoll JM, Bleickardt E, Nicaise C, Paquette RL, Sawyers CL. Potent Transient 
Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with 
Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development. 
Blood; 2006. 
128. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, et al. Comparison of 
imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-
nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations. Blood. 
2006;108(7):2332-8. 
129. Conchon M, Freitas CMBdM, Rego MAdC, Junior B, Ramos JW. Dasatinib: clinical trials 
and management of adverse events in imatinib resistant/intolerant chronic myeloid 
leukemia. Rev Bras Hematol Hemoter. 2011;33(2):131-9. 
130. Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, et al. Dasatinib increases 
endothelial permeability leading to pleural effusion. The European respiratory journal. 
2018;51(1):1701096. 
131. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in 
imatinib-resistant Philadelphia chromosome–positive leukemias. New Engl J Med. 
2006;354(24):2531-41. 
132. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus 
imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med. 
2010;362(24):2260-70. 
133. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib 
efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the 
phase 2 PACE trial. Blood. 2018;132(4):393-404. 
134. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-
BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and 
overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-12. 
135. Omar Al Ustwani M, Wetzler M. Novel Therapies for T315I-Mutant CML. Target Oncol. 
2014. 
136. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in 
refractory Philadelphia chromosome–positive leukemias. New Engl J Med. 
2012;367(22):2075-88. 
137. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A 
quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 2008;26(1):127. 
138. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 
compound mutations combining key kinase domain positions confer clinical resistance to 
ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428-42. 
 8-206 
139. Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric 
inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature. 2017;543(7647):733. 
140. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-
abl–dependent cell proliferation. Nat Chem Biol. 2006;2(2):95-102. 
141. Hughes TP, Goh Y-T, Ottmann OG, Minami H, Rea D, Lang F, et al. Expanded phase 1 
study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable 
responses in patients with CML-chronic phase with failure of prior TKI therapy. Am Soc 
Hematol; 2016. p. 625. 
142. Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor 
asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. 
Oncotarget. 2018;9(17):13423. 
143. Wylie A, Schoepfer J, Berellini G, Cai H, Caravatti G, Cotesta S, et al. ABL001, a potent 
allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered 
in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood; 
2014. p. 398. 
144. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. 
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the 
tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070-
9. 
145. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor 
STI571 in BCR/ABL–transformed hematopoietic cell lines. Blood. 2000;95(11):3498-505. 
146. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical 
resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. 
Science. 2001;293(5531):876-80. 
147. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, et al. Bcr-
Abl expression levels determine the rate of development of resistance to imatinib mesylate 
in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912-9. 
148. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes 
associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci 
USA. 2006;103(8):2794-9. 
149. Gadzicki D, von Neuhoff N, Steinemann D, Just M, Busche G, Kreipe H, et al. BCR-ABL 
gene amplification and overexpression in a patient with chronic myeloid leukemia treated 
with imatinib. Cancer Genet Cytogenet. 2005;159(2):164-7. 
150. Andrews DF, 3rd, Collins SJ. Heterogeneity in expression of the bcr-abl fusion 
transcript in CML blast crisis. Leukemia. 1987;1(10):718-24. 
151. Collins SJ, Groudine MT. Chronic myelogenous leukemia: amplification of a rearranged 
c-abl oncogene in both chronic phase and blast crisis. Blood. 1987;69(3):893-8. 
152. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL 
kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib 
(STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 
2002;2(2):117-25. 
153. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, et al. Phosphorylation of the 
ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci 
USA. 2006;103(51):19466-71. 
154. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, 
and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242-9. 
 8-207 
155. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL 
mutations in patients with CML treated with imatinib is virtually always accompanied by 
clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated 
with a poor prognosis. Blood. 2003;102(1):276-83. 
156. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of 
specificity of inhibition of the Abl kinase by STI571. J Biol Chem. 2002;277(35):32214-9. 
157. Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, et al. Crystal structure of the T315I 
mutant of AbI kinase. Chem Biol Drug Des. 2007;70(3):171-81. 
158. Soverini S, Iacobucci I, Baccarani M, Martinelli G. Targeted therapy and the T315I 
mutation in Philadelphia-positive leukemias. Haematologica; 2007. p. 437-9. 
159. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by 
mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15(10):1109. 
160. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, et al. Kinase domain 
mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate 
utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26(16):6082-93. 
161. Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, et al. Enhanced ABL-
inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism 
of altered leukemogenicity. J Cancer Res Clin. 2012;138(2):203-12. 
162. Desterke C, Aggoune D, Bonnet ML, Prade N, Chomel J-C, Delabesse E. T315I-Mutated 
BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc 
Finger (ZNF) Transcription Factors. Am Soc Hematology; 2013. p. 4899. 
163. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT-1–
mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib 
(AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 
2006;108(2):697-704. 
164. Watkins D, Hughes T, White D. OCT1 and imatinib transport in CML: is it clinically 
relevant? Leukemia. 2015;29(10):1960. 
165. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter 
superfamily. J Lipid Res. 2001;42(7):1007-17. 
166. Theodoulou FL, Kerr ID. ABC transporter research: going strong 40 years on. Biochem 
Soc Trans. 2015;43(5):1033-40. 
167. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter 
family. Hum Genomics. 2009;3(3):281-90. 
168. ter Beek J, Guskov A, Slotboom DJ. Structural diversity of ABC transporters. J Gen 
Physiol. 2014;143(4):419-35. 
169. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese 
hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152-62. 
170. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication 
and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from 
multidrug-resistant human cells. Cell. 1986;47(3):381-9. 
171. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the 
clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003;10(2):159-65. 
172. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-
dependent transporters. Nat Rev Cancer. 2002;2(1):48-58. 
173. Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and 
ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014;95(3):294-306. 
 8-208 
174. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-
27. 
175. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 
gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. 
Blood. 2003;101(6):2368-73. 
176. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M, et 
al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous 
leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18(3):401-8. 
177. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out 
of cells: implications for drug resistance. Blood. 2004;104(12):3739-45. 
178. Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, et al. 
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein 
or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. 
Pharm Res. 2008;25(4):827-35. 
179. Widmer N, Colombo S, Buclin T, Decosterd LA. Functional consequence of MDR1 
expression on imatinib intracellular concentrations. Blood. 2003;102(3):1142. 
180. Park SH, Park CJ, Kim DY, Lee BR, Kim YJ, Cho YU, et al. MRP1 and P-glycoprotein 
expression assays would be useful in the additional detection of treatment non-responders 
in CML patients without ABL1 mutation. Leuk Res. 2015;39(10):1109-16. 
181. Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, et al. The clinical 
significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-
line imatinib treatment. Leukemia. 2017;31(1):75-82. 
182. Eadie LN, Hughes TP, White DL. ABCB1 Overexpression Is a Key Initiator of Resistance 
to Tyrosine Kinase Inhibitors in CML Cell Lines. PLoS One. 2016;11(8):e0161470. 
183. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, et al. Interaction of 
nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer 
effects and pharmacological properties. Br J Pharmacol. 2009;158(4):1153-64. 
184. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, et al. Dasatinib cellular 
uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res. 
2008;14(12):3881-8. 
185. Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with 
human P-glycoprotein. J Pharmacol Exp Ther. 2003;307(2):824-8. 
186. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, et al. 
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase 
inhibitors imatinib, nilotinib and dasatinib. Drug Metab Dispos. 2010;38(8):1371-80. 
187. Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP. Dasatinib targets 
chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. 
Haematologica. 2013;98(6):896-900. 
188. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-
specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug 
resistance. Cancer Res. 1998;58(23):5337-9. 
189. Damiani D, Tiribelli M, Geromin A, Michelutti A, Cavallin M, Sperotto A, et al. ABCG2 
overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation 
outcome. Am J Hematol. 2015;90(9):784-9. 
190. Meyer zu Schwabedissen HE, Kroemer HK. In vitro and in vivo evidence for the 
importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). 
Handb Exp Pharmacol. 2011(201):325-71. 
 8-209 
191. Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. 
Expert Opin Drug Metab Toxicol. 2008;4(1):1-15. 
192. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, et al. Purification and 
3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure. 
2006;14(11):1623-32. 
193. Taylor NMI, Manolaridis I, Jackson SM, Kowal J, Stahlberg H, Locher KP. Structure of 
the human multidrug transporter ABCG2. Nature. 2017;546(7659):504-9. 
194. Jackson SM, Manolaridis I, Kowal J, Zechner M, Taylor NM, Bause M, et al. Structural 
basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat Struct Mol 
Biol. 2018;25(4):333. 
195. Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L. Overcoming ABC transporter-
mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting 
agents. Eur J Med Chem. 2017;142:271-89. 
196. Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as 
mediators of drug resistance and contributors to cancer cell biology. Drug Resist Update. 
2016;26:1-9. 
197. Hegedűs C, Szakács G, Homolya L, Orbán TI, Telbisz Á, Jani M, et al. Ins and outs of the 
ABCG2 multidrug transporter: an update on in vitro functional assays. Adv Drug Deliver Rev. 
2009;61(1):47-56. 
198. Özvegy-Laczka C, Hegedűs T, Várady G, Ujhelly O, Schuetz JD, Váradi A, et al. High-
Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter. Mol 
Pharmacol. 2004;65(6):1485-95. 
199. de Lima LT, Vivona D, Bueno CT, Hirata RD, Hirata MH, Luchessi AD, et al. Reduced 
ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in 
chronic myeloid leukemia. Med Oncol. 2014;31(3):851. 
200. Gromicho M, Dinis J, Magalhaes M, Fernandes AR, Tavares P, Laires A, et al. 
Development of imatinib and dasatinib resistance: dynamics of expression of drug 
transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leukemia Lymphoma. 
2011;52(10):1980-90. 
201. Eadie LN, Saunders VA, Hughes TP, White DL. Degree of kinase inhibition achieved in 
vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia 
Lymphoma. 2013;54(3):569-78. 
202. Kim Y-K, Lee S-S, Jeong S-H, Ahn J-S, Yang D-H, Lee J-J, et al. OCT-1, ABCB1, and ABCG2 
expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib. 
Chonnam Med J. 2014;50(3):102-11. 
203. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence 
and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance 
to STI571. Blood. 2003;101(2):690-8. 
204. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, et al. Association between 
imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN 
kinase. J Natl Cancer Inst. 2008;100(13):926-39. 
205. Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, et al. Tyrosine kinase 
inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. 
Leukemia Lymphoma. 2011;52(11):2139-47. 
206. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent 
form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. 
J Biol Chem. 2004;279(33):34227-39. 
 8-210 
207. Mahon F-X, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, et al. Evidence that 
resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 
2008;68(23):9809-16. 
208. Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, et al. BCR-ABL- and 
Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML. 
International journal of oncology. 2011;39(3):585-91. 
209. Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism 
of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 
2014;6(252):252ra121. 
210. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 
2005;44(9):879-94. 
211. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase 
inhibitors. Cancer treatment reviews. 2009;35(8):692-706. 
212. Gschwind H-P, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, et al. 
Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos. 
2005;33(10):1503-12. 
213. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 
2011;17(3):313. 
214. O’Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, 
seeking cure. Curr Opin Genetics Dev. 2006;16(1):92-9. 
215. Eiring AM, Deininger MW. Individualizing kinase-targeted cancer therapy: the 
paradigm of chronic myeloid leukemia. Genome Biol. 2014;15(9):461. 
216. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, et al. Blocking 
cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary 
CML progenitors. Leukemia. 2010;24(4):771-8. 
217. Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N, et al. BCR-ABL mutants spread 
resistance to non-mutated cells through a paracrine mechanism. Leukemia. 2008;22(4):791-
9. 
218. Zahreddine H, Borden K. Mechanisms and insights into drug resistance in cancer. Front 
Pharmacol. 2013;4:28. 
219. Foo J, Leder K, Mumenthaler SM. Cancer as a moving target: understanding the 
composition and rebound growth kinetics of recurrent tumors. Evol Appl. 2013;6(1):54-69. 
220. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144(5):646-74. 
221. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the 
cancer stem cell hypothesis. J Clin Pharmacol. 2005;45(8):872-7. 
222. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, et al. 
Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016;101(5):541-58. 
223. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia 
chromosome-positive leukemogenesis. Cancer Res. 2001;61(6):2343-55. 
224. Kamens J. Addgene: Making Materials Sharing “Science As Usual”. PLoS Biol. 
2014;12(11). 
225. Kweon SM, Cho YJ, Minoo P, Groffen J, Heisterkamp N. Activity of the Bcr GTPase-
activating domain is regulated through direct protein/protein interaction with the Rho 
guanine nucleotide dissociation inhibitor. J Biol Chem. 2008;283(6):3023-30. 
226. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F. Ba/F3 cells and their use in kinase drug 
discovery. Curr Opin Oncol. 2007;19(1):55-60. 
 8-211 
227. Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF. An improved method 
for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood 
Cell Mol Dis. 1998;24(2):167-82. 
228. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, et al. In vitro sensitivity to 
imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in 
patients with de novo CML. Blood. 2005;106(7):2520-6. 
229. Syrmis M, Moser R, Whiley D, Vaska V, Coombs G, Nissen M, et al. Comparison of a 
multiplexed MassARRAY system with real-time allele-specific PCR technology for genotyping 
of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2011;17(12):1804-10. 
230. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. 
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in 
vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 
2002;1(6):417-25. 
231. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-40. 
232. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast 
universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. 
233. Nicorici D, Satalan M, Edgren H, Kangaspeska S, Murumagi A, Kallioniemi O, et al. 
FusionCatcher-a tool for finding somatic fusion genes in paired-end RNA-sequencing data. 
BioRxiv. 2014:011650. 
234. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms 
of disease progression and management of advanced-phase chronic myeloid leukemia. 
Leukemia Lymphoma. 2014;55(7):1451-62. 
235. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX 
platform. Curr Protoc Hum Genet. 2009;Chapter 2:Unit 2 12. 
236. Magadum S, Banerjee U, Murugan P, Gangapur D, Ravikesavan R. Gene duplication as 
a major force in evolution. J Genet. 2013;92(1):155-61. 
237. Reams AB, Roth JR. Mechanisms of Gene Duplication and Amplification. CSH Perspect 
Biol. 2015;7(2):a016592. 
238. Wacker SA, Houghtaling BR, Elemento O, Kapoor TM. Using transcriptome sequencing 
to identify mechanisms of drug action and resistance. Nat Chem Biol. 2012;8(3):235-7. 
239. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and 
treatment implications. Nat Rev Clin Oncol. 2015;12(6):344-57. 
240. Giuffre A, Pabon-Pena C, Novak B, Joshi S, Ong J, Visitacion M, et al. The Agilent 
Technologies' SureSelect™ All Exon Product Portfolio: High Performance Target Enrichment 
System for Human and Mouse Exome Sequencing on Illumina and SOLiD Platforms. J Biomol 
Tech. 2011;22(Supplement):S41-S. 
241. Newman AM, Bratman SV, Stehr H, Lee LJ, Liu CL, Diehn M, et al. FACTERA: a practical 
method for the discovery of genomic rearrangements at breakpoint resolution. 
Bioinformatics. 2014;30(23):3390-3. 
242. Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, et al. SAMSN1 Is a Tumor 
Suppressor Gene in Multiple Myeloma. Neoplasia. 2014;16(7):572-85. 
243. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of 
resistance to the Abelson inhibitor STI571 in human leukemic cells through gene 
amplification. Blood. 2000;95(5):1758-66. 
244. Mayer BJ, Ren R, Clark KL, Baltimore D. A putative modular domain present in diverse 
signaling proteins. Cell. 1993;73(4):629-30. 
 8-212 
245. Haslam RJ, Koide HB, Hemmings BA. Pleckstrin domain homology. Nature. 
1993;363(6427):309-10. 
246. Lenoir M, Kufareva I, Abagyan R, Overduin M. Membrane and protein interactions of 
the pleckstrin homology domain superfamily. Membranes. 2015;5(4):646-63. 
247. Blomberg N, Baraldi E, Nilges M, Saraste M. The PH superfold: a structural scaffold for 
multiple functions. Trends Biochem Sci. 1999;24(11):441-5. 
248. Zheng Y. Dbl family guanine nucleotide exchange factors. Trends Biochem Sci. 
2001;26(12):724-32. 
249. Reckel S, Gehin C, Tardivon D, Georgeon S, Kükenshöner T, Löhr F, et al. Structural and 
functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase. Nat 
Commun. 2017;8:2101. 
250. Cutler JA, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS, et al. 
Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by 
interactome and phosphoproteome analysis. Leukemia. 2017;31(7):1513-24. 
251. Viaud J, Gaits-Iacovoni F, Payrastre B. Regulation of the DH–PH tandem of guanine 
nucleotide exchange factor for Rho GTPases by phosphoinositides. Adv Biol Regulat. 
2012;52(2):303-14. 
252. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and 
Ras transformation: the RHOad less traveled gets congested. Oncogene. 1998;17(11 
Reviews):1415-38. 
253. Adams J, Houston H, Allen J, Lints T, Harvey R. The hematopoietically expressed vav 
proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a 
yeast gene (CDC24) involved in cytoskeletal organization. Oncogene. 1992;7(4):611-8. 
254. Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV, et al. 
The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. 
Oncogene. 2007;27:2064. 
255. Kawai T, Sanjo H, Akira S. Duet is a novel serine/threonine kinase with Dbl-Homology 
(DH) and Pleckstrin-Homology (PH) domains. Gene. 1999;227(2):249-55. 
256. Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N. Differential 
interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene. 
2003;22:6445. 
257. Daubon T, Chasseriau J, El Ali A, Rivet J, Kitzis A, Constantin B, et al. Differential motility 
of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs. 
Oncogene. 2008;27(19):2673-85. 
258. Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ, et al. The function of the 
pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia. 
2010;24(1):226-9. 
259. Demehri S, O’Hare T, Wood LJ, Loriaux M, Druker BJ, Deininger MW. BCR-ABL Lacking 
the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than 
P210BCR-ABL in a Murine Model of CML. Am Soc Hematology; 2004. p. 2564. 
260. Crampe M, Haslam K, Groarke E, Kelleher E, O'Shea D, Conneally E, et al. Chronic 
Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast 
Crisis and Molecular Monitoring. Case Rep Hematol. 2017;2017:9071702. 
261. Stewart MJ, Cox G, Reifel-Miller A, Kim SY, Westbrook CA, Leibowitz DS. A novel 
transcriptional suppressor located within a downstream intron of the BCR gene. J Biol Chem. 
1994;269(14):10820-9. 
 8-213 
262. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther. 
2008;8(6):419-29. 
263. Eberth A, Ahmadian MR. In vitro GEF and GAP assays. Curr Protoc Cell Biol. 
2009;Chapter 14:Unit 14 9. 
264. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, et al. Mutations at 
amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer. 
2003;89:1971. 
265. Takara K, Yamamoto K, Matsubara M, Minegaki T, Takahashi M, Yokoyama T, et al. 
Effects of alpha-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and 
transport. PLoS One. 2012;7(2):e30697. 
266. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, et al. New 
inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther. 2007;6(12 Pt 
1):3271-8. 
267. Weidner LD, Zoghbi SS, Lu S, Shukla S, Ambudkar SV, Pike VW, et al. The Inhibitor 
Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther. 2015;354(3):384-93. 
268. White DL, Lu L, Clackson TP, Saunders VA, Hughes TP. ATP dependent efflux 
transporters ABCB1 and ABCG2 are unlikely to impact the efficacy, or mediate resistance to 
the tyrosine kinase inhibitor, ponatinib. Blood; 2011. p. 2745. 
269. Lu L, Saunders V, Leclercq T, Hughes T, White D. Ponatinib is not transported by 
ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia. 2015;29(8):1792. 
270. Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, et al. The novel BCR-ABL and 
FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette 
transporter ABCG2. Mol Cancer Ther. 2012;11(9):2033-44. 
271. Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to 
cancer therapies. J Exp Clin Cancer Res. 2015;34:159. 
272. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, et al. Imatinib 
mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug 
pump. Blood. 2004;104(9):2940-2. 
273. Shukla S, Wu C-P, Ambudkar SV. Development of inhibitors of ATP-binding cassette 
drug transporters – present status and challenges. Expert Opin Drug Metab Toxicol. 
2008;4(2):205-23. 
274. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, et al. ABCG2: a perspective. 
Adv Drug Deliv Rev. 2009;61(1):3-13. 
275. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 
(BCRP): recent findings in Abcg2 knockout mice. Adv Drug Del Rev. 2009;61(1):14-25. 
276. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, et al. Common 
defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic 
analysis in a Japanese population. Science Transl Med. 2009;1(5):5ra11. 
277. Hiwase DK, Eadie L, Saunders V, Hughes T, White DL. Proton pump inhibitors augment 
nilotinib and dasatinib mediated Bcr-Abl kinase inhibition. Am Soc Hematology; 2010. p. 3991. 
278. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. 
Oncologist. 2003;8(5):411-24. 
279. D'Cunha R, Bae S, Murry DJ, An G. TKI combination therapy: strategy to enhance 
dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharm Drug Dispos. 
2016;37(7):397-408. 
280. Selbo PK, Weyergang A, Eng MS, Bostad M, Maelandsmo GM, Hogset A, et al. Strongly 
amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and 
 8-214 
provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic 
drug. J Control Release. 2012;159(2):197-203. 
281. Wolf N, Kone A, Priestley G, Bartelmez S. In vivo and in vitro characterization of long-
term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-
rhodamine 123 FACS selection. Exp Hematol. 1993;21(5):614-22. 
282. Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu Rev 
Pharmacol Toxicol. 2006;46:381-410. 
283. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC 
transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular 
determinant of the side-population phenotype. Nat Med. 2001;7(9):1028-34. 
284. Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, et al. ABCG2 regulates self-
renewal and stem cell marker expression but not tumorigenicity or radiation resistance of 
glioma cells. Sci Rep. 2016;6:25956. 
285. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to 
dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of 
mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 
2007;92(3):401-4. 
286. Camgoz A, Gencer EB, Ural AU, Baran Y. Mechanisms responsible for nilotinib 
resistance in human chronic myeloid leukemia cells and reversal of resistance. Leukemia 
Lymphoma. 2013;54(6):1279-87. 
287. Wang Z, Chen W. A convenient cell culture model for CML acquired resistance through 
BCR-ABL mutations.  Chronic Myeloid Leukemia: Springer; 2016. p. 149-57. 
288. Lu L, Saunders V, Kok CH, Leclercq T, Hughes TP, White DL. Modeling Ponatinib 
Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and 
TKI-naïve Patients. Blood. 2014;124(21):4515. 
289. Okabe S, Tauchi T, Ohyashiki K. Characteristics of dasatinib-and imatinib-resistant 
chronic myelogenous leukemia cells. Clin Cancer Res. 2008;14(19):6181-6. 
290. Okabe S, Tauchi T, Broxmeyer HE, Ohyashiki K. Mechanism of Drug Resistance to 
Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells. Blood; 2006. 
p. 1386. 
291. Lu L, Kok CH, Saunders VA, Wang J, McLean JA, Hughes TP, et al. Modelling ponatinib 
resistance in tyrosine kinase inhibitor-naive and dasatinib resistant BCR-ABL1+ cell lines. 
Oncotarget. 2018;9(78):34735-47. 
292. Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, et al. Plasma 
concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose 
reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. 
Int J Clin Oncol. 2018;23(5):1-9. 
293. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment 
beyond progression—implications for drug resistance. Nat Rev Clin Oncol. 2013;10(10):571. 
294. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of 
imatinib in patients with chronic myeloid leukaemia who have maintained complete 
molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) 
trial. Lancet Oncol. 2010;11(11):1029-35. 
295. Goh H-G, Kim Y-J, Kim D-W, Kim H-J, Kim S-H, Jang S-E, et al. Previous best responses 
can be re-achieved by resumption after imatinib discontinuation in patients with chronic 
myeloid leukemia: implication for intermittent imatinib therapy. Leukemia Lymphoma. 
2009;50(6):944-51. 
 8-215 
296. Rudert F, Visser E, Gradl G, Grandison P, Shemshedini L, Wang Y, et al. pLEF, a novel 
vector for expression of glutathione S-transferase fusion proteins in mammalian cells. Gene. 
1996;169(2):281-2. 
 
